 
Official Title: A Phase III, Randomized, Double- Blind, Placebo- Controlled, 
Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab 
as an Induction And Maintenance Treatment For Patients With 
Moderately to Severely Active Crohn's Disease  
Study ID: [REMOVED] 
Document  Date : Protocol  Version 7: 24-April- 2019 
 
 
 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
5/Protocol GA29144, Version 74.3.[ADDRESS_1117304]/Comparator .............................................................. 72
4.3.6 Reporting of Prefilled Syringe Complaints/Events ................. [ADDRESS_1117305]- Trial Access to Etrolizumab ........................................... 73
4.4 Concomitant Therapy ............................................................ 73
4.4.1 Management of Concomitant Crohn’s Disease 
Medication in the Induction Phase ......................................... 73
4.4.2 Management of Immunosuppressants throughout 
the Study ............................................................................... 73
4.4.3 Management of Concomitant Crohn’s Disease 
Medication in the Maintenance Phase ................................... 74
4.4.4 Permitted Rescue The rapy.................................................... 74
[IP_ADDRESS] Rescue Therapy in the Induction Phase ................................ 74
[IP_ADDRESS] Rescue Therapy in the Maintenance Phase .......................... 74
4.4.5 Prohibited Therapy ................................................................ 75
4.5 Study Assessments ............................................................... 75
4.5.1 Informed Consent Forms and Screening Log ........................ 75
4.5.2 Screening .............................................................................. 76
[IP_ADDRESS] Re-Screening ......................................................................... 76
4.5.3 Study Assessments during Induction and 
Maintenance .......................................................................... 77
4.5.4 Assessments at Study Completion ........................................ 77
4.5.5 Early W ithdrawal from Study ................................................. 78
4.5.6 Assessments at Unscheduled Visits ...................................... 78
4.5.7 Description of Visit Activities .................................................. 78
[IP_ADDRESS] Medical History and Demographic Data ................................ 78
[IP_ADDRESS] Physical Examinations ........................................................... 78
[IP_ADDRESS] Fistula Examinations ............................................................. 79
[IP_ADDRESS] Vital Signs, Height, and W eight............................................. 79
[IP_ADDRESS] Crohn’s Disease Activity Assessments .................................. 79
[IP_ADDRESS] Ileocolonoscopy with Biopsies ............................................... 80
[IP_ADDRESS] Neurological Examination ...................................................... 83
[IP_ADDRESS] Progressive Multifocal Leukoencephalopathy 
Assessment ........................................................................... 83
[IP_ADDRESS] Electrocardiograms ................................................................ 84
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
6/Protocol GA29144, Version [IP_ADDRESS] Patient -Reported Outcomes .................................................. 84
[IP_ADDRESS] Study Drug and Compliance .................................................. 87
[IP_ADDRESS] Concomitant Medications ...................................................... 87
[IP_ADDRESS] Adverse Events ..................................................................... 87
[IP_ADDRESS] Tuberculosis Screening ......................................................... 87
[IP_ADDRESS] Chest X -ray............................................................................ 88
[IP_ADDRESS] Pregnancy Testing ................................................................ .88
[IP_ADDRESS] Laboratory Assessments ....................................................... 88
[IP_ADDRESS] Samples for [COMPANY_002] Clinical Repository .................................. 92
4.5.8 Safety Follow -Up Assessments ............................................. 95
4.5.9 Eligibility for Entry to Open -Label 
Extension -Safety Monitoring Study ........................................ 96
[IP_ADDRESS] Inclusion Criteria for Part 1 (OLE) of Study 
GA29145 ............................................................................... 96
[IP_ADDRESS] Exclusion Criteria for Part 1 (OLE) of Study 
GA29145 ............................................................................... 96
4.6 Patient, Treatment, Study, and Site 
Discontinuation ...................................................................... 97
4.6.1 Patient Discontinuation .......................................................... 97
[IP_ADDRESS] Withdrawal from Study ........................................................... 97
4.6.2 Discontinuation from Study Drug ........................................... 97
4.6.3 Study and Site Discontinuation .............................................. 98
5. ASSESSMENT OF SAF ETY....................................................................... 98
5.1 Safety Plan ............................................................................ 98
5.1.1 Potential Risks for Etrolizumab .............................................. 98
[IP_ADDRESS] Serious Infections .................................................................. 99
[IP_ADDRESS] Hypersensitivity Reactions ................................................... 102
[IP_ADDRESS] Hepatic Effects .................................................................... 103
[IP_ADDRESS] Local Injection -Site Reactions ............................................. 103
[IP_ADDRESS] Malignancies ........................................................................ 103
[IP_ADDRESS] Immunogenicity ................................................................... 104
[IP_ADDRESS] Decreased Effectiveness of Immunizations ......................... 104
5.1.2 Risks Associated with W orsening of Crohn’s 
Disease ................................................................................ 104
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
7/Protocol GA29144, Version 75.1.3 Data Monitoring Committee ................................................. 105
5.2 Safety Parameters and Definitions ...................................... 105
5.2.1 Adverse Events ................................................................... 105
5.2.2 Serious Adverse Events (Immediately Reportable 
to the Sponsor) .................................................................... [ADDRESS_1117306] (Immediately 
Reportable to the Sponsor) .................................................. 107
5.2.4 Methods and Timing for Capturing and 
Assessing Safety Para meters .............................................. 107
5.2.5 Adverse Event Reporting Period ......................................... 107
5.2.6 Eliciting Adverse Event Information ..................................... 108
5.2.7 Assessment of Severity of Adverse Events ......................... 108
5.2.8 Assessment of Causality of Adverse Events ....................... 109
5.2.9 Procedures for Recording Adverse Events .......................... 110
[IP_ADDRESS] Injection -Site Reactions ....................................................... 110
[IP_ADDRESS] Diagnosis Versus Signs and Symptoms .............................. 110
[IP_ADDRESS] Adverse Events That Are Secondary to Other 
Events.................................................................................. 111
[IP_ADDRESS] Persistent or Recurrent Adverse Events .............................. 111
[IP_ADDRESS] Abnormal Laboratory Values ............................................... 111
[IP_ADDRESS] Abnormal Vital Sign Values ................................................. 112
[IP_ADDRESS] Abnormal Liver Function Tests ............................................ 113
[IP_ADDRESS] Deaths ................................................................................. 113
[IP_ADDRESS] Preexisting Medical Conditions ............................................ 113
[IP_ADDRESS] Lack of Efficacy or W orsening of Crohn’s 
Disease ................................................................................ 114
[IP_ADDRESS] Hospi[INVESTIGATOR_26589] ........................ 114
[IP_ADDRESS] Adverse Events Associated with an Overdose or 
Error in Drug Administration ................................................ 114
[IP_ADDRESS] Patient -Reported Outcome Data ......................................... [ADDRESS_1117307] ................... 116
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
8/Protocol GA29144, Version [IP_ADDRESS] Events That Occur Prior to Study Drug Initiation ................. 116
[IP_ADDRESS] Events T hat Occur after Study Drug Initiation ...................... 116
5.3.3 Reporting Requirements for Pregnancies ............................ 116
[IP_ADDRESS] Pregnancies in Female Patients .......................................... 116
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients ............... 117
[IP_ADDRESS] Abortions ............................................................................. 117
[IP_ADDRESS] Congenital Anomalies/Birth Defects .................................... 117
5.3.4 Reporting Requirements for Prefilled Syringe 
Complaints/Events ............................................................... [ADDRESS_1117308] of Study .......................................... 123
6.3 Summaries of Treatment Group Comparability ................... 123
6.4 Efficacy Analyses ................................................................ 123
6.4.1 Induction Phase ................................................................... 124
[IP_ADDRESS] Cohort 1 ............................................................................... 124
[IP_ADDRESS] Cohort 2 ............................................................................... 124
[IP_ADDRESS] Cohort 3 ............................................................................... 124
6.4.2 Maintenance Phase ............................................................. 125
6.4.3 Co-Prima ry Efficacy Endpoints ............................................ 126
6.4.4 Secondary Efficacy Endpoints ............................................. 126
............................................ 127
6.5 Safety Analyses ................................................................... 127
6.5.1 Adverse Events ................................................................... 127
6.5.2 Labo ratory Tests .................................................................. 128

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
9/Protocol GA29144, Version 76.[ADDRESS_1117309] or Ethics Committee .................. 133
8.4 Confidentiality ...................................................................... 133
8.5 Financial Disclosure ............................................................ 134
9. STUDY DOCUMENTATI ON, MONITORING, AND
ADMINISTRATION ................................................................................... 134
9.1 Study Documentation .......................................................... 134
9.2 Protocol Deviations .............................................................. 134
9.3 Site Inspections ................................................................... 134
9.4 Administra tive Structure ....................................................... 135
9.5 Publication of Data and Protection of Trade 
Secrets ................................................................................ 135
9.6 Protocol Amendments ......................................................... 136
10. REFERENCES ......................................................................................... 137

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
11/Protocol GA29144, Version 7PROTOCOL AMENDMENT ACCEPTA NCE FORM
TITLE: A PHA SE III, RA NDOMI ZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, MULTICENTER STUDY 
TO EVA LUATE THE EFFI CACY AND S AFETY OF 
ETROLIZUMA B AS AN INDUCTION AND 
MAINTENA NCE TREA TMEN T FOR PA TIENTS 
WITH MODERA TELY TO S EVERELY A CTIVE 
CROHN’S DISEA SE
PROTOCOL NUMBER: GA29144
VERSION NUMBER: [ADDRESS_1117310] NUMBER: 2014 -003824 -36
IND NUMBER: [ADDRESS_1117311]: Etrolizumab (RO5490261)
MEDICA L MONITOR: , M.D., M.S.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
I agree to conduct the study  in accordance with the current protocol.
Principal Investigator’s Name  (print)
Principal Investigator’s Signature [CONTACT_33505].  Please return a copy t o 
the Sponsor Representative. 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
12/Protocol GA29144, Version 7PROTOCOL SYNOPSIS
TITLE: A PHA SE III, RA NDOMI ZED, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, MULTICEN TER STUDY TO 
EVALUATE THE EFFICA CY AND SA FETY OF 
ETROLIZUM AB AS AN INDUCTION A ND M AINTENA NCE 
TREA TMENT FOR PA TIEN TS WITH MODERA TELY T O 
SEVERELY ACTIVE CROH N’S DISEA SE
PROTOCOL NUM BER: GA29144
VERSION NUMBER: [ADDRESS_1117312] NUMBER: 2014- 003824 -36
IND NUMBER: [ADDRESS_1117313]: Etrolizumab (PRO145223)
PHASE: Phase III
INDIC ATION: Crohn's Disease
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
Objectives
Co-Primary Efficacy Objectives
The co -primary efficacy  endpoints for this study are the following:
Clinical remission, defined as a liquid/soft stool frequency ( SF)mean daily score 3 and an
abdom inal pain ( AP)mean daily score 1 with no worsening in either subscore compared to
basel ine, averaged over the 7 days prior to visit
Endoscopic improvement, defined as a 50% reduction from the baseline Simple
Endoscopic Score for Crohn’s Disease (SES-CD)
Primary efficacy  objectives for this study will be analyzed separately for the Induction and 
Maintenance Phases as outlined below.
Induction Phase :  To independently evaluate the efficacy  of etrolizumab dose regimens 
compared with placebo in inducing clinical remission and endoscopic improvement at the end of 
the Induction Phase (W eek14)
Maintenance Phase :  To independently evaluate the efficacy  of etrolizumab compared with 
placebo in achieving clinical remission and endoscopic improvement at 1 year of maintenance 
treatment (W eek66), for patients who achieved a Crohn’s Disease Acti vity Index (CDAI) 70 
response (defined as a decrease of at least 70 points from baseline CDAI) at Week14
Secondary Efficacy O bjectives
Induction Phase
To evaluate the efficacy  of etrolizumab compared with placebo in achieving clinical
remission at W eek 6
To evaluate the efficacy  of etrolizumab compared with placebo in achieving an SE S-CD ≤4
(≤2 for ileal patients), with no segment having a subcategory score (i.e., for ulceration size
and extent, affected surface, or narrowing) that is >1, at Week14
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
15/Protocol GA29144, Version 7enter an extended PML -monitoring phase Part 2 (SM) of Study GA29145 for 92 weeks.  An 
independent Data Monitoring Committee (iDMC) will monitor safety and study conduct on an 
ongoing basis.
Patients in all coh orts will be required to provide blood samples for population PK analysis and 
PD characterization.  Patients will also have an option to consent and participate in a PK/PD 
substudy.  The objective of the substudy is to determine the relationship between etrolizumab 
exposure and receptor occupancy in peripheral blood in patients with CD.  To achieve this 
objective, it is planned that approximately 150 evaluable patients will be enrolled in the substudy .  
Blood sampling for the PK/PD substudy will continue in the Maintenance Phase.
Moderate to severely active CD will be defined at baseline by [CONTACT_808388] a CDAI score between 220 and 480, as well as either an average SF ≥6 oran 
average SF 3 and average AP 1, calculated on the day of randomization using electronic 
diary (e-diary) PRO data from the 7days prior to randomization.  In conjunction, the presence of 
active inflammation, defined as a SES-CD of 7, or [ADDRESS_1117314] of patients who arerefractory  or intolerant to one or more of 
the following therapi[INVESTIGATOR_014]:  1) corticoster oid (CS), 2) immunosuppressant ( IS), or 3) anti -tumor 
necrosis factor ( TNF)(or inadequate response to anti -tumor necrosis factor [ TNF-IR]).  Patients 
who enroll on the basis of refractory  or intolerance to CS and/or IS may have been previously 
exposed to ant-TNFs or be naïve to anti -TNFs.
Approximately [ADDRESS_1117315] been on a stable dose of 
20 mg/day prednisone or equivalent or 6 mg/day oral budesonide for at least 2 weeks
immediately prior to their randomization.  Similarly, eligible patients requiring background IS
therapy (e.g., azathioprine [ AZA][or equivalent], 6- mercaptopurine [ 6-MP][or equivalent], or
methotrexate [ MTX ]) must be receiving a stable IS dose regimen for at least [ADDRESS_1117316] 9 days prior 
to randomization to allow sufficient time for a central reader scoring and determination of 
eligibility, and to avoid the ileocolonoscopy bowel preparation influencing the patient reported 
outcomes used in the determination of baseline SF, AP, and CDAI scores (i.e., abdominal pain, 
general well -being, and stool frequ ency )
Overview of Induction Phase
Eligible patients will be enrolled sequentially into one of three cohorts for the 14 -week Induction 
Phase.
Patients enrolled in Cohort 1 (double- blind, placebo -controlled, explorator y cohort; n300) will 
be randomized in a 1:2:2 ratio to receive placebo, etrolizumab 105 mg subcutaneously (SC)
every 4 weeks ( Q4W)(low dose), or etrolizumab 210 mg SC (high dose) at Weeks0, 2, 4, 8, 
and 12 within a 14 -week Induction Phase (note that patients randomize d to low -dose 
etrolizumab and patients randomized to placebo will receive oneplacebo injection at Week 2,
see below).  Patients enrolled in Cohort 2 (etrolizumab dose blind, active -treatment cohort; 
n350) will be randomized in a 1:1 ratio to receive lo w-dose or high -dose regimens of 
etrolizumab.  Patients enrolled in Cohort 3 (double -blind, placebo -controlled, pi[INVESTIGATOR_106136]; 
n500) will be randomized in a 2:3:3 ratio to receive placebo or etrolizumab low -dose or high -
dose.  Because the low dose and h igh dose of etrolizumab are in syringes of different volumes, 
in order to preserve the blind, patients in all three cohorts will receive two injections at Weeks 0, 
4, 8, and 12.  Patients randomized to low -dose etrolizumab will receive one placebo (matchin g 
high-dose prefilled s yringe) and one low -dose etrolizumab injection at each administration 
except at W eek 2, when they will receive one placebo injection.  Patients randomized to 
high-d ose etrolizumab will receive one placebo and one high-d ose etrolizumab injection at each 
administration, except at Week 2 where they will receive one high-d ose injection.  Finally, 
patients randomized to placebo will receive two placebo injecti
ons at every administration, 
except at Week 2 where they will receive one placebo injection.
The randomization in all cohorts will be stratified by [CONTACT_808389] (yes vs. no), 
concomitant IS treatment (yes vs. no), baseline CDAI  330 (yes vs. no), and prior anti-T NF 
exposure (yes vs. no).  The enrollment will be managed to ensure that the proportion of the 
TNF-e xposed patients in Cohort 3 does not exceed approximately 60% and that the proportion 
of patients with a CDAI s core between  450 and 480 does not exceed approximately 10% in 
each cohort.
During the Induc
tion Phase, patients in all cohorts should keep their dose(s) of CS and IS 
therapy stable (if requiring CS/IS at baseline).  Increase in dose of these medications will be 
considered rescue therapy.  Also, every attempt should be made to keep anti-d iarrheal  
me
dication at a fixed dose, if required.  The impact of titrating anti-d iarrheal medication on the 
placebo response rate for
 SF and AP has not been studied in a moderate to severely active CD 
population; dose adjustments may confound the data interpretation.  Changes to any 
concomitant medications must be documented in the electronic Case Report Form (eCRF).
Between and including Weeks 10 and 14, there is an optional escape to Part 1 (OLE) of Study 
GA29145, where patients can receive open-l abel etrolizumab.  This can only be exercised if a 
patient experiences disease worsening, defined as  a CDAI W eek 10 score greater than the 
patient’s baseline (W
eek 0) score.
At Week 14, patients achieving CDAI-7 0 response without the use of rescue therapy will 
continue to
 the Maintenance Phase until a sample size of approximately 480 patients enrolled 
in the Maintenance Phase has been achieved.  Patients not eligible for the Maintenance Phase 
ma
y be eligible for Part 1 (OLE) of Study GA29145.
Patients who are in the Induction Phase after closure of enrollment into the Maintenance 
Phase may enroll in Part 1 (OLE) of Study GA29145, if eligible, upon completion of the 
Induction Phase at Week 
14 or in the event of disease worsening, as specified above, between 
Weeks 10 and 14
Patients who requ
ire surgical intervention for CD at any time during the Induction Phase will 
stop study treatment, enter the Safety Follow-U p Phase, and will be asked to enter Part 2 (SM) 
of Study GA29145 for PML monitoring.  Patients who self-w ithdraw from the Induction  Phase 
and do not meet the eligibility criteria for OLE treatment will also enter the Safety Follow-Up 
Phase and be asked to enter Part 2 (SM) of Study GA29145 for PML monitoring.
Concomitant CD Therapy in the Induction Phase
Concomitant therapy includes an
y medication (e.g., prescription drugs, over-t he-counter drugs, 
herbal or homeopathic remedies, nutritional supplements) used by a patient from 4 weeks prior 
to screening to the study completion/early termination visit.  
Anti
-diarrheal medications are permitted if used to manage chronic diarrhea but every attempt 
should be made to keep the dose/regimen stable.  Any changes in the dose/regimen after 
baseline (W
eek 0) must be captured by [CONTACT_1755]/or patient. 
Occasional use of nonsteroidal anti-in flammatory  drugs (NSAIDs) or acetaminophen is 
permitted for pain relief (e.g., in the case of headache, arthritis, myalgia, etc.).  Prophylactic 
aspi[INVESTIGATOR_115075] 325 mg/day is also permitted.
Patients should not be treated for continuing signs and symptoms of CD with any medication 
that is prohibited to be taken concomitantly with etrolizumab; these include but are not limited 
to: anti-integrins, anti-a dhesion molecules (e.g., anti-M AdCAM-1), T- or B- cell-d epleting agents 
with the exception of AZA and 6-M P (or equivalent), TNF antagonists, antagonists of 
IL
-23 IL-1 2 (e.g., ustekinumab), anti-m etabolites, cyclosporine, and tacrolimus.
CS enemas/suppositories and/or topi[INVESTIGATOR_2855] (rectal) 5-am inosalicylate (5-A SA) preparations are 
also prohibited medications.  Patients taking these medications will be considered non-
responders for the purpose of any endoscopic analyses. These treatments must be 
discontinued, but patients may continue to receive etrolizumab 
and may still be eligible for 
Part 1 (OLE) of Study GA29145.
Etrolizumab—F . Hoffmann-L a [COMPANY_002] Ltd
16/Protocol GA29144, Version 7
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
18/Protocol GA29144, Version 7Management of Concomitant CD Therapy in the Maintenance Phase
During the Maintenance Phase, corticosteroid dose should be tapered starting at W eek 14 
according to the following schedule:
  20 mg/day prednisone (or equivalent):  titrated via dose reduction of 2.5 mg/week until
discontinuation
  6 mg/day oral budesonide:  titrated via dose reduction of 3 mg ever y 2-weeks until
discontinuation
If neede d, patients may increase their corticosteroid dose up to their baseline dose (i.e., dose at 
randomization), but the dose -tapering regimen should be re- initiated within 2 weeks.  
Patients who are taking concomitant IS therapy (AZA, 6 -MP, MTX) must remain o n stable doses 
throughout the study unless dose reduction or discontinuation is required because of a toxicity 
related to the medication.  
Doses of anti -diarrheal medication should also be kept stable.  
Generally accepted criteria for discontinuation of IS due to toxicity include, but are not limited to, 
acute pancreatitis, severe leukopenia, severe thrombocy topenia, or significant elevations of the 
liver-associated enzy mes from baseline, especially in the presence of an elevated total bilirubin.  
The ult imate decision to discontinue IS remains at the discretion of the Investigator. 
Rescue Therapy in the Maintenance Phase
This is defined as medication prescribed for new or worsening CD s ymptoms, and includes: 
Any new CS or IS therapy for CD
Increase in dose of IS therapy above the baseline (W eek 0) dose
Increase in the dose of CS therapy above a patient’s baseline (W eek 0) dose (applicable to
patients requiring CS at baseline)
Antibiotics, 5 -ASAs, anti -diarrheals, probiotics, herbal/ayurvedic, nutritional, and homeopathic 
supplements are not considered as rescue therapi[INVESTIGATOR_014].  
Patients who require rescue therapy during the Maintenance Phase may  be offered early 
access to the OLE (Study GA29145, Part 1), if eligible, and will be required to complete the 
Early Withdrawal visit assessment. 
Prohibited therapi[INVESTIGATOR_808347].
Study Drug A dministration
Patients will receive etrolizumab or placebo by [CONTACT_808390], as described below in “Investig ational Medicinal Products”.  Patients and study 
personnel will be blinded to study drug assignment (or the etrolizumab dose assignment for 
Cohort 2 patients in the Induction Phase) for the entire study. 
In the Induction Phase, study medication will be administered at the investigational site and 
patients will be trained to self -administer.  A health care professional (HCP) will administer the 
first two doses, with the patient or their caregiver administering subsequent doses under HCP 
supervision.  In t he Maintenance Phase after completing Week16, patients have the option to 
return to the investigational site or to self -administer/have a caregiver administer their dose 
Q4W at home within 3days of their scheduled dose unless a PK blood draw is planned , in 
which case the dose must be administered after the blood draw on the day of visit or within 
3days after the visit.
Schedule of A ssessments
A schedule of study assessments is provided in Appendix 1 and a schedule of PK and PD 
assessments is provided i n Appendix 1 and 3. 
Number of Patients
Approximately 1150 patients will be randomized into the Induction Phase of the trial via 
enrollment into one of three cohorts. 
Patients receiving etrolizumab in the Induction Phase who achieve a CDAI -70 response at 
Week 14 without the use of rescue therapy will be randomized into the Maintenance Phase of 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
20/Protocol GA29144, Version 7Meets the following surveillance colonoscopy requirements:
Surveillance was undertaken at screening or  12 months prior in patients with
colonic disease for > 10 years (regardless of any risk factors for bowel cancer ).
Surveillance was undertaken at screening or  5 years prior in patients with colonic 
disease for  [ADDRESS_1117317] risk factors for bowel cancer.
(Note local colonic s urveillance guidelines can be followed if patients have no risk 
factors and colonic disease for 10 years.)
Have experienced intolerance, refractory  disease, or no response (as defined below) to at
least one of the following therapi[INVESTIGATOR_6523] 5 years from screening:
CS Therapy
Refractory:
Has signs/sy mptoms of persistently active disease despi[INVESTIGATOR_040] a history of at least 
one 4 -week induction regimen including a dose equivalent to 30mg/day 
prednisone for 2 weeks if oral or 1 week if IV or 9 mg/day oral budesonide
Intolerance to CS therapy:
History including, but not limited to, Cushing’s syndrome, 
osteopenia/osteoporosis, hyperglycemia, insomnia, and infection 
IS Therapy
Refractory: 
Has signs/sy mptoms of persistently active disease despi[INVESTIGATOR_040] a history of at least 
one 12 -week regimen of oral AZA (or equivalent) (1.5 mg/kg) or 6 -MP (or 
equivalent) (0.75 mg/kg) or MTX ( 15mg/week)
Intolerance to 6-MP(or equivalent), AZA (or equivalent), or MTX :
History of intolerance to AZA (or equivalent) , 6-MP(or e quivalent) , and/or MTX
(including, but not limited to, infection, nausea/vomiting, abdominal pain, 
pancreatitis, liver function test abnormalities, ly mphopenia, and thiopurine 
methyltransferase genetic poly morphism)
Anti-TNF Therapy:
Inadequate primary  non-response:
Did not respond (as evidenced by [CONTACT_808391]/symptoms related to CD after 
receiving 2induction doses of either infliximab [ 5 mg/kg] or adalimumab 
[160 mg/80 mg or 80 mg/40mg] or certolizumab pegol [ 400mg])
Inadequate secondar y non-response:
Initially responded to induction therapy with infliximab ( 5 mg/kg) or adalimumab 
(40 mg) or certolizumab pegol ( 400mg), but experienced signs/sy mptoms
related to recurrence of CD during maintenance
Intolerance: 
Experienced a significant injection- site reaction , congestive heart failure, 
infection, or other condition that precluded continuing use of anti- TNF therapy at 
any time 
Patients who have not previously demonstrated inadequate response or intolerance to one 
or more anti -TNF therapi[INVESTIGATOR_808348].
Exclusion Criteria
Exclusion Criteria Related to Gastrointestinal Health
Has undergone subtotal colectom y with ileorectal anastomosis or has undergone total
colectomy
Short- bowel syndrome
Has an ileostom y or colostomy
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
21/Protocol GA29144, Version 7Has evidence of fixed stenosis or small -bowel stenosis with prestenotic dilation that
precludes adequate endoscopic assessment of the bowel
Diagnosis of UC or indeterminate colitis
Suspi[INVESTIGATOR_808349], radiation colitis, or microscopic colitis
Evidence of abdominal or perianal abscess
Sinus tract with evidence for infection (e.g., purulent discharge) in the clinical judgment of
the inv estigator.  Fistulas related to Crohn’s disease are not exclusionar y.
Expected to require surgery to manage CD -related complications during the study
A history or evidence of adenomatous colonic polyps that have not been removed
Past or present disease -related colonic mucosal dysplasia
Exclusion Criteria Related to Prior or Concomitant Therapy
Any of the following treatments for CD within 8 weeks prior to randomization:
Adalimumab
Certolizumab pegol
Infliximab
Any prior treatment with ustekinumab within 14weeks prior to randomization
Any prior treatment with etrolizumab or other anti -integrin agents (including vedolizumab,
natalizumab, and efalizumab)
Any prior treatment with anti -adhesion molecules (e.g., anti -MAdCAM -1)
Prior treatment with T cell or B cell depleting agents (e.g., rituximab, alemtuzumab, or
visilizumab) within 12months prior to randomization, with the exception of AZA and 6 -MP
(or equivalent) .
Any investigational treatment that included investigational vaccines within [ADDRESS_1117318], whichever is
greater
History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric,
human, or humanized antibodies, fusion proteins, or murine pr oteins or hypersensitivity to
etrolizumab (active drug substance) or any of the excipi[INVESTIGATOR_840] (L- histidine, L -arginine,
succinic acid, poly sorbate 20)
Treatment with corticosteroid enemas/suppositories and/or topi[INVESTIGATOR_2855] (rectal)
5-aminiosalicylate (5- ASA) preparations  2weeks prior to randomization
Continued tube feeding, defined formula diets, and/or parenteral alimentation/nutrition as
treatment for CD 3 weeks prior to randomization
Expectation of tube feeding, defined formula diets, and/or parenteral alimentation/nutrition
as treatment for CD during the study
Any live or attenuated vaccines 4 weeks prior to randomization
Use of IV steroids during screening, with the exception of a single IV steroid dose
administered in the E mergency Department
Use of cy closporine, tacrolimus, sirolimus, or my cophenolate mofetil 4weeks prior to
randomization
Chronic use of NSAIDs .  Prophylactic aspi[INVESTIGATOR_115075] 325 mg/day is permitted, as is
occasional use of NSAIDs for conditions such as headache, arthritis, myalgia , and
menstrual cramps .
If receiving oral CSs, patients will be excluded unless the dose is stable at 20mg/day
prednisone or equivalent for  2 weeks immediately prior to randomization.
If receiving ongoing treatment with oral 5-ASA, patients will be excluded if the dose is not
stable for 2 weeks immed iately prior to randomization.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
22/Protocol GA29144, Version 7If receiving ongoing treatment with probiotics (e.g., Culturelle, Saccharom yces boulardii) or
over-the-counter supplements (e.g., N -acety l glucosa mine, curcumin), patients will be
excluded if the dose is not stable for  2 weeks immediately prior to randomization.
If receiving ongoing treatment with ISs (e.g., 6 -MP, AZA, or MTX), patients will be excluded
if the dose is not stable for 8 weeks im mediately prior to randomization.
If receiving ongoing treatment with antibiotics for the treatment of CD, patients will be
excluded if the dose is not stable for 2 weeks immediately prior to randomization.
Patients may continue to receive ongoing treatment with anti -diarrheals (e.g., loperamide or 
diphenoxylate with atropi[INVESTIGATOR_050]), preferably achieving a stable dose for 2weeks prior to 
randomization.  However, if the patient and/or the treating physician decides to change the dose 
or course of anti -diarrheals at any time during screening, these patients will be allowed to 
participate in study.
Exclusion Criteria Related to Infection Risk
Congenital or acquired immune deficienc y
Patients must undergo screening for HIV and test negative for preliminary and confirmatory
tests
Positive hepatitis C virus (HCV) antibody test result, unless the patient (1) has undetectable
HCV RNA levels for 6 months after completing a successful course of HCV antiviral
treatment and an undetectable HCV RNA at screening or (2) has a known histor y of HCV
antibody positivity with history of undetectable HCV RNA and undetectable HCV RNA at
screening in the absence of histor y of HCV anti -viral treatment
In the screening hepatitis B assessment (which consists of testing for hepat itisB surface
antigen [HBsAg], hepatitis B core anti -body  [HBcAb], and if required, hepatitis B virus [HBV]
DNA), patients who test positive for HBsAg are excluded from the study.  Patients who test
positive for HBcAb but negative for HBsAg must have a confirmed negative HBV DNA test
result to be eligible for the study and will be required to undergo periodic monitoring for HBV
DNA during the study.
Positive stool test result for ova or parasites or positive stool culture for pathogens at time of
screening
Evidence of infection with and/or treatment for Clostridium difficile 
or other intestinal
pathogen treatment within 8 weeks prior to randomization.
A history of active or latent tuberculosis (TB) confirmed by [CONTACT_808392] :
Positive tuberculin (purified protein derivative -[COMPANY_003]) skin test
Or
Positive QuantiFERONTB Gold test
Patients with a documented history of BCG vaccination must have a negative 
QuantiFERON test result and negative chest radiograph (see below) to be eligible. 
Suspi [INVESTIGATOR_808350] (X -ray, posteroanterior and lateral) taken within
3months of randomization.
History of recurrent opportunistic infections and/or history of severe or disseminated viral
infections
Any serious opportunistic infections that occurred 6 months prior to screening
Any current or recent signs or sy mptoms (8 weeks before screening) of infection, except
for the following:
Minor infections (e.g., common cold) that have, in the investigator’s judgment, 
completely resolved prior to randomization
Fungal infections of the nail beds
Oral or vaginal candidiasis that has resolved with or without treatment prior to 
randomization
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
23/Protocol GA29144, Version 7Any major epi[INVESTIGATOR_808351] 8weeks prior to
screening or oral antibiotics 4weeks prior to screening.  Treatment with antibiotics as
adjunctive therapy for CD in the absence of documented infection is not exclusionary .
Exclusion Criteria Related to General Safety
Pregnancy or lactation
Lack of peripheral veno us access
Hospi[INVESTIGATOR_059] (other than for elective reasons) within 4 weeks prior to randomization
Inability to comply with study protocol, in the opi[INVESTIGATOR_871]
Significant uncontrolled comorbidity such as neurological, cardiac (e.g., moderate to severe
heart failure [LOCATION_001] Heart Association Class III/IV), pulmonary, renal, hepatic, endocrine,
or GI disorders (other than CD)
Neurological conditions or diseases that may interfere with monitoring for PML
Clinically significant abnormalities on screening neurologic examination
History of dem yelinating disease
History of major neurological disorders, including stroke, MS, brain tumor,
neurodegenerative disease, or poorly controlled epi[INVESTIGATOR_002]
History of alcohol, drug, or chemical abuse 6 months pr ior to screening
Conditions other than CD that could require treatment with 20 mg/day of prednisone
(orequivalent) during the course of the study
History of cancer, including hematologic malignancy, solid tumors, and carcinoma in situ
within 5 years bef ore screening
Non-serious basal cell or squamous cell carcinoma of the skin that has been excised 
and is considered cured is not exclusionary .
A history of chronic m yelogenous leukemia, hair y cell leukemia, melanoma, renal cell 
carcinoma, or Kaposi sarcoma is exclusionary irrespective of the duration of time 
before screening.
History of cervical smear result at any time that indicated the presence of ade nocarcinoma
in situ (AIS), high -grade squamous intraepi[INVESTIGATOR_12184] (HSIL), or cervical intraepi[INVESTIGATOR_808352] (CIN) of Grade 1
History of organ transplant or cell transplantation
Presence of metal in the body that could a pose hazard during any po tential scanning in
patients for whom a magnetic resonance imaging (MRI) scan is considered unsafe
Exclusion Criteria Related to Laboratory Values (at Screening)
Serum creatinine 2 times the upper limit of normal (ULN)
Impaired hepatic function defined by [CONTACT_080]:
Serum transaminases 3ULN
Alkaline phosphatase 3ULN
Total bilirubin 2.5ULN (excluding inherited deficiencies such as Gilbert’s disease)
Platelet count 100,000/ L
Hemoglobin  8 g/dL
Absolute neutrophil count 1500/ L
Absolute ly mphocyte count 500/L
Length of Study
The study duration, from screening to end of study participation for a given eligible patient, will 
be up to 82weeks (4 -week screening period 14-week Induction Phase 52-week Maintenance 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
27/Protocol GA29144, Version 7Secondary Efficacy Endpoints
Induc tion Phase
Proportion of patients who achieve clinical remission at Week 6
Proportion of patients who achieve SE S-CD ≤4 (≤2 for ileal patients), with no segment 
having a subcategory score (i.e., for ulceration size and extent, affected surface, or 
narrowin g) that is >1, at Week14
Changes from baseline to W eek 14 in CD -PRO/SS score
Maintenance Phase
Proportion of patients in clinical remission at W eek66 among patients who achieve clinical 
remission at W eek14
Proportion of patients who achieve corticoster oid-free clinical remission at Week66 
Proportion of patients who maintain endoscopic improvement at W eek66 among patients 
achieving endoscopic improvement at W eek14
Proportion of patients achieving SES CD ≤4 (≤2 for ile al patients), with no segment hav ing 
a subcategor y score (i.e., for ulceration size and extent, affected surface, or narrowing) that 
is >1, at Week66 
Proportion of patients achieving durable remission 
Proportion of patients achieving corticosteroid -free clinical remission for 24 weeks at 
Week66 
Change from baseline to W eek 66 in CD -PRO/SS score
Secondary endpoints for the Maintenance Phase will be assessed in the group of patients who 
were randomized into the Maintenance Phase, unless otherwise specified.
The primary  induction study endpoint -analy sis for Cohort 3 will evaluate the difference between 
each etrolizumab arm and placebo using the Cochran -Mantel -Haenszel ( CMH )test statistic 
stratified by [CONTACT_760525].  The absolute treatment difference will be 
provided along with the 95% two- sided CI estimate.
The primary  maintenance study endpoint- analysis will evaluate the difference in proportions 
between the two treatment arms using the CMH test statistic stratified by [CONTACT_808393].  The absolute treatment difference will be provided 
along with the 95% two -sided CI estimate.  Detailed specifications of the statistical methods 
used for all analyses will be described in the SAP. 
Determination of Sample Size  
Induction Phase
A total of approximately 1150 patients will be randomized into one of three induction cohorts.
The pi[INVESTIGATOR_808353] 3.  In 
this pi[INVESTIGATOR_808354], patients will be randomized to receive either placebo, etrolizumab 
105 mg or etrolizumab 210 mg in a 2:3:[ADDRESS_1117319] at the 5% significance level, where both clinical remission and endosc opy 
improvement are required to be significant.  The sample size for Cohort 3 is expected to provide 
85% power to detect a 15% difference in rates of clinical remission (SF mean daily score  3 
and AP mean daily score 1) between each etrolizumab arm and placebo under the assumption 
of a placebo remission rate of 15% and a two -sided test performed at a significance level of 
5%.   Additionally, Cohort 3 will provide 80% power to detect a 10% difference in proportions 
for each etrolizumab arm versus placebo for endoscopic improvement, under the assumption of 
placebo response rate of 5% and a two -sided test at the 5% significance level . The [ADDRESS_1117320] was 
used to confirm the power calculations.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
28/Protocol GA29144, Version 7Maintenance Phase
A total of approximately 480 patients achieving CDAI- 70 response at Week 14 will be eligible 
to enroll into the Maintenance Phase.
A co-primary  endpoint will be used for the analysis of the Maintenance Phase: clinical remission 
(SF mean daily score 3 and AP mean daily score  1) and endoscopic improv ement at 
Week66.  The maintenance co -primary  analysis will be performed on all patients re -randomized 
into the Maintenance Phase who were randomized to etrolizumab (105 mg or 210 mg) in the 
Induction Phase.  The co -primary endpoint will be tested using a CMH test at the 5% 
significance level, where both clinical remission and endoscopy improvement are required to be 
significant.  Note that to maintain the blind, patients randomized to placebo in the Induction 
Phase will undergo a sham randomization and wil l receive placebo in the Maintenance Phase.  
These patients will not form part of the pi[INVESTIGATOR_808355].
Of the approximately 480 patients projected to be enrolled in the Maintenance Phase, 
approximately 420 patients will undergo re -randomizatio n to receive either placebo or 
etrolizumab, and approximately 60 patients will undergo a sham randomization to placebo.  
These projections are based on the assumption that 50% of patients receiving etrolizumab and 
40% of patients receiving placebo during t he Induction Phase will be eligible for the 
Maintenance Phase.
Assuming a maintenance sample size of 210patients per arm using a 1:1 allocation to receive 
either placebo or etrolizumab 105 mg, the maintenance analy ses conducted at the 5% 
significance leve l will provide the following power:
Clinical remission at W eek 66 (SF m ean daily score 3 and AP mean daily score 1):  at 
least 90% power to detect a 15% treatment difference assuming a placebo Week66 
remission rate of up to 20%
Endoscopic improvement:  approximately 90% power to detect a 15% treatment difference 
assuming a placebo W eek66 im provement rate of up to 30%
Furthermore, the study is designed to provide sufficient power for the following secondary 
analyses:
Clinical remission at W eek66 among patients achieving clinical remission at W eek14:  a 
sample size of N 186 (i.e., 93per arm) will provide 80% power to detect a 20% treatment 
difference assuming a placebo rate of up to 30%.  This assumes a Week14 clinical 
remission rate of ≥22% among e trolizumab patients.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
29/Protocol GA29144, Version 7LIST OF A BBREVI ATIONS AND DEFINITIONS OF TERMS
Abbreviation Definition
5-ASA 5-aminosalicylate
6-MP 6-mercaptopurine
AIS adenocarcinoma in situ
ANCOVA analysis of covariance
AP abdom inal pain
APQ Abdominal Pain Questionnaire
ATA anti-therapeutic antibody
AUC area under the serum concentration -time curve
AZA azathioprine
CD Crohn’s disease
CDAI Crohn’s Disease Activity Index
CDEIS Crohn's Disease Endoscopic Index of Severity
CDPRO/SS Crohn’s Disease Patient -Reported Outcome Signs and 
Symptoms
CIN cervical intraepi[INVESTIGATOR_808356] -Mantel -Haenszel
Cmin minimum serum drug concentration
CS corticosteroid
CSF cerebrospi[INVESTIGATOR_808357]
e-diary electronic diary
EMA European Medicines Agency
ePRO electronic patient -reported outcome
FDA U.S. Food and Drug Administration
GI gastrointestinal
HBcAb hepatitis B core antibody
HBsAg hepatitis B surface antigen 
HBV hepatitis B virus
HCP health care professional
HCV hepatitis C virus

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
30/Protocol GA29144, Version 7Abbreviation Definition
HIPAA U.S. Health Insurance Portability and Accountability Act
HSIL high-grade squamous intraepi[INVESTIGATOR_808358] C ouncil for Harmonisation
iDCC independent data coordinating center
iDMC independent Data Monitoring Committee
IHC immunohistochemistry
IMP investigational medicinal product
IND Investigational New Drug (application)
IR inadequate responder
IRB Institutional Review Board
IS immunosuppressant
IV intravenous
IxRS interactive voice or Web-based response system
JCV John Cunningham virus
LD loading dose
mAb monoclonal antibodies
MAdCAM -1 mucosal addressin cell adhesion molecule
mITT modified intent to treat
MOA mechanism of action
MS multiple sclerosis
MRI magnetic resonance imaging
MTX methotrexate
NCI CTCAE National Cancer Institute Common Terminology Criteria for 
Adverse Events
NSAIDs nonsteroidal anti -inflammatory drugs
OLE open- label extension
PD pharmacodynamics
PFS prefilled syringe
PK pharmacokinetic
PML progressive multifocal leukoencephalopathy
[COMPANY_003] purified protein derivative
PRO patient -reported outcome
PRO2 Patient- Reported Outcome -2 
Q4W every 4 weeks

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
31/Protocol GA29144, Version 7Abbreviation Definition
QOL qualit y of life
qPCR quantitative poly merase chain reaction
RCR [COMPANY_002] Clinical Repository
SC subcutaneous
SESCD SimpleEndoscopic Score for Crohn’s Disease
SF liquid/soft stool frequency
SM safety monitoring
S[LOCATION_003]R suspected unexpected serious adverse reaction
TB Tuberculosis
TNF tumor necrosis factor
TNFIR inadequate response to anti -tumor necrosis factor
UC ulcerative colitis
ULN upper limit of normal
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
32/Protocol GA29144, Version 71. BACKGROUND
1.1 BACKGROUND ON CROHN’ S DISEA SE
Crohn’s disease (CD) is a chronic, relapsing form of inflammatory bowel disease (IBD) 
that can affect any portion of the gastrointestinal (GI) tract, with 40% 50% of  cases 
affecting the small bowel.  CD is characterized by [CONTACT_808394], transmural inflammation, 
ulcers, and granulomatous lesions that are interspersed with healthy sections of bowel 
(skip lesions).  The disease is progressive; uncontrolled inflammation develops into 
stricturing or penetrating complications such as prestenotic dilatation, obstruction
(stricturing), and intra -abdominal or perianal fistulas and abscesses (penetrating).  
Clinical signs and symptoms include chronic diarrhea, abdominal pain, cachexia, 
abdominal mass, or tenderness as well as the overt signs of fistulas. The disease 
course is variable; patients can experience a severe initial flare followed by [CONTACT_808395] 10 years (43%) or symptoms that are chronic and persistent 
(19%) or relapsing -remitting (32%) (Baumgart and Sandborn 2012 ).
The annual incidences of CD reported in Europe, Asia and the Middle East, and North 
America were 12.7, 5.0, and 20.2 per 100,000 person -years, respectively 
(Molodecky etal. 2012 ).  Current prevalence rates in North America are reported to be 
319 per 100,000 persons (Molodecky et al. 2012 ).  Disease -related mortality in CD 
accounts for approximately 30% of deaths in this population, resulting from clinical 
and/or surgical complications that occur early in the disease course or intestinal cancer 
occurring later.  The global incidence o f CD is expected to continue increasing 
substantially, affecting individuals in the most formative and productive years of life, with 
long-term costs to patients, healthcare systems, and society (Duricova etal.2010 ).
So far, there is no cure for CD.  The treatment goals for CD are to induce and maintain 
symptom improvement, induce mucosal healing, avoid surgery, and improve quality of 
life (Lichtenstein et al. 2009 ; Van Assche et al. 2010 ).
Systemic corticosteroids (CSs) have been the mainstay treatment f or inducing remission 
and are effective in approximately 80% of patients (Summers et al. 1979 ; 
Malchow etal.1984 ).  However, they are less effective as a maintenance therapy, with 
only 28% of patients achieving a prolonged response after 1 year of treatm ent and 
32% of patients becoming CS dependent (Faubion et al. 2001 ; 
Peyrin -Biroulet etal.2010 ).  Even if patients’ symptoms improve, fewer than 30% are 
expected to achieve endoscopic improvement with steroid treatment 
(Modigliani et al.1990 ).  The adver se effects of steroids are well documented and 50% 
of patients will stop their treatment because of this; long -term safety outcomes include 
osteoporosis, cataracts, and diabetes.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
33/Protocol GA29144, Version 7Immunosuppressants (ISs) (e.g., azathioprine [AZA], 6 -mercaptopurine [6-MP], or 
methotrexate [MTX]) are typi[INVESTIGATOR_808359].  Immunosuppressants are given with or without a steroid bridge , 
depending on a patient’s symptoms during the 2 4-month onset of IS efficacy.  In 
patients with ileal or ascending colonic disease, budesonide presents a less toxic, more 
tolerable bridge because of its low systemic bioavailability resulting from a rapid 
first-pass metabolism.  An earlier initiation of IS to alter the inflammatory disease course 
has been advocated over the past 20 years.  However, a decrease in the rate of 
intestinal resections and complications has not been observed during this time 
(Cosn eset al. 2005 ).  This may reflect poor adoption of this top -down treatment over 
concern for systemic toxicities including leukopenia, thromobocytopenia, and increased 
risk for lymphoma with AZA and 6- MP (Prefontaine etal.2009 ) and hepatotoxicity and 
hair loss with MTX (Hausmann et al. 2010 ).
The development of monoclonal antibodies (mAbs) against tumor necrosis factor 
(TNF) (anti-TNFs) has provided an additional treatment option.  Although anti -TNFs 
are effective in a signif icant proportion of patients, efficacy is suboptimal; remission rates 
after 4 weeks of induction therapy are lower than 35% and ,among patients who respond 
to induction therapy ,fewer than 50% have achieve dremission when assessed in 
maintenance at 20 30 w eeks (Peyrin- Biroulet et al. 2011 ).  Furthermore, 30% of patients 
are reported to be primary non -responders to anti -TNF therapy when assessed after 
4weeks of induction therapy (Targan et al. 1997 ; Sandborn et al. 2007 ), possibly 
because of an underlying pathobiology that is not TNF -driven and, as such ,may 
benefit from a different mechanistic class of drug.  It is estimated that 30% 40% of 
patients will be secondary non -responders (i.e., initially responsive) but lose response or 
become intolerant in their first year of treatment (Colombel et al. 2007 ).  Secondary 
non-response has been attributed to the development of neutralizing antibodies, 
resulting in low drug serum levels, to accelerated drug clearance, or a biological escape 
mechanism that may benef it from a therapy with a different pharmacological target.  
Anti-TNFs are also associated with significant side effects, including serious infection, 
opportunistic infection, lupus -like reactions, and an increased risk of lymphoma 
(Siegal andMelmed 2009 ).  Tolerability concerns include infusion reactions, occurring in 
9%17% of patients treated with infliximab (deVries et al. 2011 ), and injection site 
reactions, occurring in 10% o f patients receiving adalimumab
(vanderHeijde etal.2006 ).  Overall, the benefits versus risks are considered 
acceptable for this drug class, but there continues to be a need for treatments with better 
benefit -risk profiles that attenuate inflammation and the clinical sequelae and improve 
the long -term prognosis of patients wit h CD.
The anti- integrins are another class of biologics approved for the treatment of CD.  
Natalizumab is an anti -integrin approved in the U.S. only for the treatment of moderate 
to severely active CD. The use of natalizumab, which blocks both 41 and 47 has 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
34/Protocol GA29144, Version 7been limited because of concerns that inhibition of 41/VCAM -1 binding increases the 
risk of progressive multifocal leukoencephalopathy (PML) ,a rare but serious infection of 
the CNS.  Vedolizumab is the most recently approved gut -selective anti -integrin for CD, 
but this targets only the α47 integrin receptor, inhibiting T -lymphocyte binding to the 
adhesion molecule MAdCAM -1, and is administered as an intravenous (IV) infusion.  In 
the pi[INVESTIGATOR_808360] ,31% of patients had a clinical r esponse with 6 weeks 
of induction treatment; up to 39% of the vedolizumab responders achieved remission 
with 46 weeks of maintenance treatment, compared with 22% of patients given placebo 
(Sandborn et al. 2013 ).  W hile vedolizumab shows promise as a new tr eatment for CD, 
there remains a need for a more convenient therapy thatis gut selective and achieves 
bette r response and remission rates.
1.2 BACKGROUND ON ETROLI ZUMA B 
Etrolizumab, a subcutaneously administered mAb, is a novel anti -integrin which ,unlike 
vedolizumab, targets both the 47 and E[ADDRESS_1117321] ion 
(MOA), without generalized immunosuppression. 
Etrolizumab is a humanized mAb based on the IgG1 subgroup -IIIVH, subgroup -I V L 
consensus sequences and is directed specifically against the 7 subunit of the integrin 
heterodimer (Andrew et al. 1994 ).  Etrolizumab binds with high affinity to 47 
(Holzmann et al. 1989 ; Hu etal. 1992 ) and E7 (Cepek etal.1993 ).  By [CONTACT_292482], it blocks the homing and retention of leukocyte subpopulations in the 
intestinal mucosa, which occur via binding with the cell adhesion molecules (MAdCAM -1) 
and E -cadherin, respectively.  As such, it represents a novel gut mucosal selective
anti-trafficking agent whose selectivity may eliminate generalized immunosuppression by 
[CONTACT_808396] r ather than to other organs and tissues.  
Data from multiple, non -clinical, general toxicity studies of up to 6 months duration 
demonstrated that etrolizumab had no adverse effects in any organ system.  In addition, 
etrolizumab had no adverse effects in the embryo -fetal developmental toxicity studies or 
general reproductive toxicity studies (see Etrolizumab Investigator’s Brochure ).
It is important to note that ,unlike natalizumab, etrolizumab does not bind to 41 or 
inhibit the interaction of 41 and VCAM -1 and the distribution and homing of 
lymphocytes to the CNS and peripheral lymphoid tissue (see Etrolizumab Investigator’s 
Brochure ).  As such, etrolizumab is not expected to increase the risk of PML.  However, 
in any clinical trial of etrolizumab ,signs or symptoms suggestive of PML would be 
carefully monitored through regular neurological examinations.  Safety assessments for 
etrolizumab have been completed in adult Phase Iand Phase IIstudies, in which 
patients with moderate to severely active UC recei ved either single or multiple doses of 
IV or subcutaneous (SC) etrolizumab.   A total of [ADDRESS_1117322] been exposed to 
etrolizum ab in the Phase I and II studies, with no significant adverse safety signals, 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
35/Protocol GA29144, Version 7including any evidence of increased rates of se rious or opportunistic infections that might 
be associated with etrolizumab treatment.  Acknowledging that the clinical experience 
with etrolizumab is limited, no events of PML have been reported in patients treated with 
etrolizumab.
1.3 STUDY RA TIONA LE A ND BENEFIT -RISK A SSESSMEN T
The purpose of this study is to assess the efficacy and safety of etrolizumab, a novel 
anti-integrin with a unique MOA that has been shown to inhibit the trafficking and 
retention of inflammatory T -cells in the intestinal mucosa via a disruption of 
47/MAdCAM -1and E7/E-cadherin binding.
Although etrolizumab has not been studied in patients with CD, preliminary expression 
studies of the pharmacological target for etrolizumab, the integrin 7 receptor, on gut 
CD4and CD8 T cells is olated from resections of patients with UC and patients with 
CDsuggests that expression levels are similar between both diseases.  The reported 
efficacy of vedolizumab, an anti -47 mAb, in CD demonstrates a role for 47 in the 
pathobiology of this disease (Sandborn et al. 2013 ) and suggests that etrolizumab will be 
efficacious.  In addition, because E7expression is reportedly elevated in patients 
with CD (Elewaut et al. 1998 ; Oshitani et al. 2003 ) with an observed increase in 
expression from distal to proximal bowel, the dual MOA of etrolizumab may bring 
enhanced efficacy in CD without generalized immunosuppression compared with
available anti -integrin and anti -TNF therapi[INVESTIGATOR_014].  
In a global Phase II study (Study ABS4986g; EUCALYPTUS), etrolizumab was 
efficacious in treating moderate to severe UC and achieved a placebo -corrected clinical 
remission rate of 20.5% ( p0.058) and an endoscopic remission rate of 10.3% 
(p0.004) at 10 weeks after treatment initiation ( 105mgevery 4 weeks [Q4W ]) in an 
all-comers population (Vermeire et al. 2013 ).  In addition, etrolizumab had an acceptable 
safety profile with no clinically significant safety signals observed.  There is no known 
safety risk identified for etrolizumab at thi s time, but as an investigational medicinal 
product (IMP) with limited Phase IIdata, the full safety profile for etrolizumab will be 
further characterized as Phase III clinical development progresses.  A safety plan is 
provided in Section 5, describing potential risks for etrolizumab and the risk -mitigation 
strategies to minimize risks for the patients in this study.
To address potential risks to participating patients, the clinical experience with 
etrolizumab in patients with UC and informa tion on the mechanism of action was 
considered in the clinical design and safety management plan of the proposed Phase III
study to address potential risks to participating patients.  The planned induction and 
maintenance dose regimens are expected to besafe and efficacious and were selected 
based on the observed safety, pharmacokinetic (PK), and pharmacodynamic (PD) profile 
of etrolizumab in UC, with consideration given to potential diffe rences in exposure 
related to the transmural and patchy presentation of inflammation in CD.  Only patients 
who have undergone a sufficient washout of prior biological therapy for CD will be 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
36/Protocol GA29144, Version 7eligible to participate and patients with a history of moderate al lergic reactions to mAbs 
will be excluded.  As described in Section 1.2, etrolizumab is selective for intestinal 
mucosal tissue and does not impact peripheral lymphoid populations.  Consequently, the 
risk of PML is expected to be lower with etrolizumab compared with other 
non-gut-selective biologics, with no events of PML reported in the UC Phase II or OLE
studies. Patients at risk of s evere infections (including PML and opportunistic infections) 
will be excluded from this study.  The potential risk of severe infections associated with 
concomitant IS therapy has been carefully considered.  On the basis of data from the UC 
Phase II study and the recent vedolizumab Phase III program, which showed that 
concomitant IS use did not impact the infection rates, concomitant IS use will not be 
prohibited in this study (see Section 3.3.3 for a more detailed assessment of this risk).
Patient safety will be monitored throughout the study via assessment of vital signs, 
safety laboratory assessments, n eurological exams, and continuous review of adverse 
events.  Should any patients become pregnant, develop anaphylaxis, develop PML, 
specific malignancy, colonic mucosal dysplasia, or certain specific serious infections 
(see Section [IP_ADDRESS]), they will be permanently discontinued from the study treatment 
(see Section 4.6.2 ).  Patients will not be eligible to enter the Induction Phase of the study 
if requiring a CS dose 20mg/day prednisone or equivalent, or6 mg/day oral 
budesonide .  In addition, the dose must have remained stable for 2weeks prior to 
patient randomization into the Induction Phase.  During the Maintenance Phase of the 
study, patients who experience a clinical relapse in their CD status will have the option to 
enroll into an open- label study of etrolizumab.  During the In duction Phase, when 
concomitant CD treatments must remain stable, patients will not be allowed to 
participate if they require a CS dose 20mg/day prednisone or equivalent.
An independent Data Monitoring Committee (iDMC) will review all safety data twice 
yearly during the study or more frequently based on the emerging safety data.  Refer to 
Section 5for additional details. 
Given the si gnificant clinical and non -clinical data generated to date for etrolizumab, 
there is a strong rationale and a positive benefit -risk assessment for studying 
etrolizumab in a Phase III clinical trial in CD, supported by:
Studies of a n anti -47 mAb, vedolizu mab, approved for the treatment of patients 
with moderate to severe CD
Completed studies with etrolizumab in UC demonstrating clinically meaningful 
benefit, as well as a full characteriza tion of the PK/PD profile in UC and, importantly, 
an acceptable safety profile in previous etrolizumab studies
Data that implicate 47 receptors in the pathobiology of CD with the possibility that 
inhibition of the E7/E-cadherin interaction by [CONTACT_808397] b could bring enhanced 
efficacy
An acceptable safety profile in the ongoing clinical development program, and a 
carefully designed Phase III CD program with robust safety monitoring
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
37/Protocol GA29144, Version 72. OBJECTIVES
2.1 EFFICA CY OBJECTIVES
Analyses of clinical remission will be made on the basis of patient -reported values for 
liquid/soft stool freq uency (SF) and abdominal pain (AP) (derived from the 7 -day 
average scores), and centrally read, clinician -reported values for endoscopic 
improvement ,as assessed by [CONTACT_808398]’s Disease 
(SES CD), the summed score of four endoscop ic variables that are rated in 5 ileocolonic 
segments of the bowel (Daperno etal. 2004 ).
2.1.1 Co-Primary  Efficacy  Objectives 
The co -primary efficacy endpoints for this study are the following:
Clinical remission , defined as a SF mean daily score 3 and an AP mean daily 
score 1 with no worsening in either subscore compared to baseline, averaged over 
the 7 days prior to visit
Endoscopic improvement, defined as a 50% reduction from the baseline SES -CD
Primary e fficacy objectives for this study will be analyzed separately for the Induction 
and Maintenance Phases as outlined below .  
Induction Phase:  T o independently evaluate the efficacy of etrolizumab dose 
regimens compared with placebo in inducing clinical remission and endoscopic 
improvement at the e nd of the Induction Phase (W eek14) 
Maintenance Phase :  To independently evaluate the efficacy of etrolizumab 
compared with placebo in achieving clinical remission and endoscopic improvement 
at 1year of maintenance treatment ( Week66),forpatients who a chieved a Crohn’s 
Disease Activity Index (CDAI) 70 response (defined as a decrease of at least 
70points from baseline CDAI) at Week14
2.1.2 Secondary  Objectives
Induction Phase
To evaluate the efficacy of etrolizumab compared with placebo in achieving clinical 
remission at Week 6
To evaluate the efficacy of etrolizumab compared with placebo in achieving an 
SES- CD ≤4 (≤2 for ileal patients ), with no segment having a subcategory score 
(i.e., for ulceration size and extent, affected surface, or narrowing) that is >1, 
atWeek14
To evaluate the reduction in CD signs and symptoms achieved by [CONTACT_808399] W eek 14 as assessed by [CONTACT_808400]’s Disease 
Patient -Reported Outcome Signs and Symptoms (CD PRO/SS) measure
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
38/Protocol GA29144, Version 7Maintenance Phase
All secondary Maintenance endpoints are for patients who achieved CDAI -70 at 
Week14, unless otherwise stated.
To evaluate the efficacy of etrolizumab compared with placebo in maintaining 
clinical remission at Week66 forpatients who achieved clinical remission at 
Week14
To evaluate the efficacy of etrolizumab compared with placebo in achieving 
corticosteroid -free clinical remission at Week66 among patients who were receiving 
corticosteroids at baseline
To evaluate the efficacy of etrolizumab compared with placebo in maintaining 
endoscopic improvement at W eek66 forpatients who achieved endoscopic 
improvement at W eek14
To evaluate the efficacy of etrolizumab compared w ith placebo in achieving a 
SES CD ≤4 (≤2 for ileal patients), with no segment having a subcategory score 
(i.e., for ulceration size and extent, affected surface, or narrowing) that is >1, 
atWeek66 
To evaluate the efficacy of etrolizumab compared with placebo in achieving durable 
clinical remission during 1 year of maintenance therapy (i.e., at 4 of the 6 in-clinic 
assessment visits thatare conducted during the Maintenance Phase at W eeks 24, 
28, 32, 44, 56, and 66) 
To evaluate corticosteroid -free clinical remission at Week 66 (off corticosteroid for at
least 24 weeks prior to W eek 66) in patients who we re receiving corticosteroids at 
baseline
To evaluate change in CD signs and symptoms from baseline to Week66 as
assessed by [CONTACT_8671] -PRO/SS measure
 
 
 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
41/Protocol GA29144, Version 7Moderate to severely active CD will be defined at baseline by [CONTACT_808401] a CDAI score between 220 and 480, as well as either an 
average SF ≥6 oran average SF 3 and average AP1, calculated on the day of 
randomization using electronic diary (e-diary) PRO data from the7days prior to 
randomization.  In conjunction, the presence of active inflammation, defined as a 
SES- CD of 7, or [ADDRESS_1117323] of patients who arerefractory or intolerant to one or 
more of the following therapi[INVESTIGATOR_014]:  1) CS, 2) IS, or3) anti -TNFs ( orTNF-IR). Patients who 
enroll on the basis of refractory or intolerance to CS and/or IS may have been previously 
exposed to ant -TNFs or be naïve to anti -TNFs (as defined in Section 4.1.1 ).
Approximately 1150 patients will be randomized into the study from approximately 
500global investigational sites via enrollm ent into one of three cohorts 
(see Section 3.1.3 ).  The enrollment will b e sequential, first into Cohort 1, then Cohort 2, 
and lastly Cohort 3.
3.1.2 Overview  of Screening Phase
Patients will be evaluated for eligibility in the 35 -day Screening Phase (see Figure 1).  
Assessme nts for eligibility are noted in Appendix 1a.
During the Screening Phase, patients taking CS therapy must have been on a stable 
dose of 20 mg/day prednisone or equivalent or 6 mg/day oral budesonide for at least 
2weeks immediately prior to their randomization.  Similarly, eligible patients requiring 
background IS therapy (e.g., AZA [or equivalent] , 6-MP[or equivalent] ,or MTX) must 
be receiving a stable IS dose regimen for at least [ADDRESS_1117324] 
9days prior to randomization to allow sufficient time for a central reader scoring and 
determination of eligibility, and to avoid the ileocolonoscopy bowel preparation 
influencing the patient reported outcomes used in the determination of ba seline SF,AP,
and CDAI scores (i.e., abdominal pain, general well -being, and stool frequency).
Refer to Section [IP_ADDRESS] for requirements related to re -screening a patient.
3.1.3 Number of Patients
Approximately 1150 patients will be randomized into the Induction Phase of the trial via 
enrollment into one of three cohorts (see Section 3.1.3 and Table 4 for details regardi ng 
sample size for each cohort).
Patients receiving etrolizumab in the Induction Phase who achieve a CDAI-7 0  response 
at Week 14 without the use of rescue therapy will be randomized into the Maintenance 
Phase of the trial until a sample size of approximately 480 patients enrolled in the 
Maintenance Phase is achieved.  Of the approximately 480 patients enrolled in the 
Maintenance Phase, 
approximately 420 patients are estimated to be CDAI-7 0 
responders who received etrolizumab during the Induction Phase and will be 
re-randomized to either etrolizumab 105 mg SC Q4W or placebo in the Maintenance 
Phase.  The remaining approximately 60 patients are CDAI-7 0 responders who re ceived 
placebo during the Induction Phase and will undergo a sham randomization to blinded 
placebo treatment during the Maintenance Phase.
3.1.4
 Overview of Induction Phase
Eligible patients will be enrolled sequentially into one of three cohorts for the 14-w eek 
Induction Phase (see
 Appendix 1a ).
Patients enrolled in Cohort 1 (double-blind, placebo-controlled, exploratory cohort; 
n 300) will be randomized in a 1:2:2 ratio to receive placebo, etrolizumab 105 mg SC 
Q4W (low dose), or etrolizumab 210 mg SC (high dose) at  Weeks 0, 2, 4, 8, and 
12
 within a 14-w eek Induction Phase (note that patients randomized to low-d ose 
etrolizumab and patients randomized to placebo will receive one placebo injection at 
Week 2, see below).  Patients enrolled in Cohort 2 (etrolizumab dose blind, 
active-t reatment cohort; n 350) will be randomized in a 1:1 ratio to receive low-dose or 
high
-dose regimens of etrolizumab.  Patients enrolled in Cohort 3 (double-b lind, 
placebo-controlled, pi[INVESTIGATOR_106136]; n500) will be randomized in a 2:3:3 ratio to receive 
placebo or etrolizumab low-dose or high-d ose.  Because the low dose and high dose of 
etrolizumab are in syringes of different volumes, in order to preserve the blind, patients 
in all three cohorts will receive two injections at Weeks 0, 4, 8, and 12.  Patients 
randomized to low
-dose etrolizumab will receive one placebo (matching high-d ose 
pre
filled syringe) and one low-d ose etrolizumab injection at each administration except 
at Week 2, when they will receive one placebo injection.  Patients randomized to 
high-d ose etrolizumab will receive one placebo and one high-d ose etrolizumab injection 
at each administration, except at Week 2 where they will receive one high-d ose 
injection.  Finally, patients randomized to placebo will receive two placebo injections at 
every administration, except at Week 2 where they will receive one placebo injection.
The randomizat
ion in all cohorts will be stratified by [CONTACT_808389] 
(yes
 vs. no), concomitant IS treatment (yes vs. no), baseline CDAI  330 (yes vs. no), 
and prior anti-T NF exposure (yes vs. no). The enrollment will be managed to ensure that 
the proportion of the TNF-e xposed patients in Cohort 3 does not exceed approximately 
60% and that the proportion of patients with a CDAI score between
 450 and 480 does 
not exceed approximately 10% in each cohort. 
During the Induction Phase, patients in all cohorts should keep their dose(s) of CS and 
IS therapy stable (if requiring CS/IS at baseline).  Increase in dose of these medications 
Etrolizumab
—F. Hoffmann-L a [COMPANY_002] Ltd
42/Protocol GA29144, Version 7
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
45/Protocol GA29144, Version 7Figure 1 Study Schema Induction Phase
Anti-TNFanti-tumor necrosis factor ; CDCrohn’s disease ; ETRO Etrolizumab; IS immunosuppressants, 
SCsubcutaneous ; Wkweek.

Etrolizumab —F.Hoffmann -La [COMPANY_002] Ltd
46/Protocol GA29144, Version 7Figure 2Study Schema Maintenance Phase
CScorticosteroids; ETRO Etrolizumab; OLE open label extension phase; PBOplacebo; q4w every 4 weeks; Re -Rxre-randomized; W kweek.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
48/Protocol GA29144, Version 7The primary clinical endpoint isbased on previous FDA recommendations, the evolving 
global regulatory environment (new EMA new medicinal products guide line for CD 
released July 2018; CHMP 2016 ), and the results generated from the exploratory 
induction of Cohort 1 inthis study. Both FDA and EMA in its new guideline discouraged 
the use of CDAI as primary endpoint for CD registration studies due to the limitations of 
the index. Instead, co-primary endpoint composed of patient -report ed signs/symptoms 
and endoscopic measure is encouraged. 
The use of SF and AP addresses the FDA’s recommendation to use 7- day scores of SF 
and APthat correlate with CDAI remission.  Defining clinical remission and response 
that use unweighted measures of APand SFare more easily interpretable by [CONTACT_15098], 
patients, and caregivers and are more likely to represent clinically meaningful 
improvements in symptoms and disease activity for moderate to severe CD patients 
experiencing different degrees of SF and AP during a flare. 
Endoscopic improvement, defined as a change in SES -CD 50% from the baseline 
score (Ferrante etal. 2013 ), is a co-primary endpoint.
The SES CD consists of four endoscopic variables (ulcers, ulcerated surface, inflamed 
surface, and presence of narrowings) that are scored in five ileocolonic segments.  The 
SES CD was prospectively developed and validated in patients with mild to severe CD 
(according to CDAI) by [CONTACT_808402]. ( 2004 ).  This scoring system was recommended 
by [CONTACT_808403] (rather than a qualitative assessment of ulcer characteristics), 
determination of the percent ulceration in a segment (rather than determination by a 
visual analogue scale), and for better inter-rater reliability ( inter-class correlation 
coefficients were 0.83 and 0.71 for SES CD and Crohn's Dis ease Endoscopic Index of 
Severity (CDEIS) , respectively; Khanna et al. 2014 ).  Because the score does not adjust 
for the number of visible segments, only segments visualized at baseline will be included 
in the endpoint assessment.  This means any new narro wing due to inflammation that 
renders a segment not evaluable for scoring after study treatment will qualify the patient 
as not achieving endoscopic improvement for the secondary endpoint analysis.  Similarly, 
any improvement in inflammation that renders a segment evaluable for scoring after 
study treatment will not be reflected in the endpoint assessment.  The Statistical 
Analysis Plan will describe any sensitivity analysis which are planned to assess the 
impact of these missing data on the endpoint.  Given the limited experience with 
endoscopic scoring systems in general gastroenterology practice, all ileocolonoscopi[INVESTIGATOR_808361], but central readers will determine 
the SES CD.
Published studies have used multi ple endoscopic endpoints to assess efficacy, which 
appear to be arbitrarily defined.  Mucosal healing, defined qualitatively as an absence of 
mucosal ulcers, has been studied as a primary or secondary endpoint in a number of 
Phase IV studies (Rutgeerts et al. 2004 [natalizumab]; Rutgeerts et al. 2006 [infliximab]; 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
49/Protocol GA29144, Version 7Colombel et al. 2010 [infliximab and azathioprine]; Hebuterne et al. 2013 [certolizumab]; 
Rutgeerts et al. 2012 [adalimumab]).  Some studies have defined endoscopic thresholds 
that represent endos copic remission without clarity on the clinical significance of these 
scores (Hebuterne et al. 2013 [certolizumab]; Rutgeerts et al. 2012 [adalimumab]).  In 
this study, endoscopic improvement is defined as the proportion of patients 
demonstrating a 50% reduction in SES -CD versus their pretreatment baseline score.  
For induction, this endpoint will be measured at W eek [ADDRESS_1117325] hoc a nalyses of the SONIC trial which determined a 50% reduction in 
SES CD score to be predictive of CS -free CDAI remission following 50 weeks of 
treatment with biologic therapy (Ferrante et al. 2013 ).  This definition is also appropriate
when considering thelarge variability in SES CD change at the end of a 6 -week 
Induction Phase measured in a sample of 24 placebo patients (with moderate to 
severely active CD) who were participating in one of two trials of novel biologic agents 
(Ferrante et al. 2010 ).  The d ataset showed that 6patients achieved both 50% reduction 
in either SES CD or CDEIS score, and at least a 5- point r eduction in either SES CD or 
CDEIS score.
3.3.2 Rationale for Patient Population
Patients with uncontrolled, moderate to severely active CD are a t risk for developi[INVESTIGATOR_808362], as well as symptoms that are 
debilitating to quality of life.  The treatme nt goals for CD are to induce and maintain 
symptom improvement, induce mucosal healing, and improve quality of life.  However, 
for a significant proportion of patients, these goals are not met by [CONTACT_286995][INVESTIGATOR_014] 
(see Section 1.1).  As such, the study population will include patients who are refractory 
to one or more of the following therapi[INVESTIGATOR_014]: 1) CS, 2) IS , or 3) anti -TNFs ( orTNF-IR). 
Patients who enroll on the basis of refractory or intolerance to CS and/or IS may have 
been previ ously exposed to ant -TNFs or be naïve to anti -TNFs .  Data from the 
etrolizumab Studies ABS4986g and GA27927 in UC (see Etrolizumab Iinvestigator’s 
Brochure) and the vedolizumab GEMINI 2 and 3 studies (Sandborn et al. 2013 ; Sands et 
al. 2014 ) have demonstra ted the favorable efficacy of the anti-4[ADDRESS_1117326] -pass 
metabolism, the risk of accumulation in patients 65 years of age is considered low and 
is also mitigated by [CONTACT_808404].
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
50/Protocol GA29144, Version 7In line with EMA guidelines, eligible patients must have an established diagnosis of CD 
for at least [ADDRESS_1117327] a lower baseline score compared with 
patients with ileocolonic disease, regardless of whether the extent of inflammation and 
ulceration is the same in affected segments.  As such, different SES -CD entry scores 
are proposed for these subgroups of patients.  It is acknowledged that patients with 
fistulizing disease are not well served by [CONTACT_808405] .  
3.3.3 Rationale for the Design of Induction and Maintenance Phases
Patient randomization into the Induction Phase will be stratified by [CONTACT_808406] 330 or 330 (predictive of CDAI respons e and remission rates 
with biologic therapy; Sandborn et al. 2013 ; Sands etal.2014 ), CS use, IS use, and 
prior anti -TNF failure (all indicators of disease activity). These factors are considered 
sufficient to mitigate the risk of imbalance in disease se verity across treatment arms. 
Assessment of the induction of clinical remission and endoscopic improvement at 
Week14 is justified on the basis of the observation that anti -integrin therapi[INVESTIGATOR_159358] a 
slower onset of action compared with anti -TNF therapi[INVESTIGATOR_014] (Sandborn et al. 2005 , 2013 ), 
as well as the clinical consensus that the onset of endoscopic improvement is typi[INVESTIGATOR_808363] 1624weeks after induction therapy, particularly in treatment refractory 
patients (a consensus supported by [CONTACT_808407] g that Mayo Clinic Score 
remission with etroliz umab took up to 14 weeks in TNF IR patients with UC, see 
Etrolizumab Investigator’s Brochure ).  A challenge of the 14- week Induction Phase is the 
requirement to keep concomitant CD therapi[INVESTIGATOR_808364], so as not to 
confound the endpoint analysis.  This is problematic in the context of patients who 
require rescue therapy to treat a flare and patients who are responding to treatment but 
unable to taper their CS dose.  The study design addresses t his by [CONTACT_808408], in which case patients would be classified 
as non -responders for the primary analysis, and restricting the maximum baseline CS to 
20mg/day prednisone -equivalent dose.  Although not prohibited therapeutic adjustment, 
increasing the dose of anti -diarrheal drugs should be avoided.  Patients should keep 
their dose of anti -diarrheal medication stable as much as possible because the effect of 
titrating anti -diarrheal medication on the placebo -response rate on clinical remission is 
unknown .
The Induction Phase includes an exploratory cohort (Cohort 1) that is adequately sized 
to assess effect size and accuracy of statistical planning assumptions for the new 
endpoints in pi[INVESTIGATOR_106136] (Cohort 3) ,the clinical validity of the dichotomous endpoint 
definitions, and the testing hierarchy of the endpoints.  An active -treatment induction 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
51/Protocol GA29144, Version 7cohort (Cohort 2) is also included in this study to generate a sufficient number of 
remitters for assessment of endpo ints in the M aintenance Phase .  The final cohort 
(Cohort 3) is a pi[INVESTIGATOR_808365], which will generate data for the endpoint analysis 
of the induction study.
Patients achieving a CDAI -70 response at W eek14 without rescue therapy will be 
re-randomi zed into the Maintenance Phase until a sample size of approximately 
480 patients in the Maintenance Phase is achieved .  Based on expert clinical opi[INVESTIGATOR_1649], 
patients achieving clinical remission and endoscopic improvement at Week 14 are 
expected to be a subpopulation within this group.  Randomization into the Maintenance 
Phase will be stratified by [CONTACT_808409] (described for the Induction Phase, 
except CDAI -remission [score 150] at both W eeks10 and 14 will be used instead of 
CDAI 330 or 330).  In addition, the randomization will be stratified by [CONTACT_808410]-or high -dose etrolizumab (allowing an assessment of the impact of low -or high -
dose induction therapy on the maintenance endpoints).  Given the large number of strata, 
any potential imbalance in the proportion of endoscopic improvers at W eek14will be 
handled using a covariate- adjusted analysis for the W eek66endoscopic -improvement 
endpoint.
The duration of the Maintenance Phase ( 52 weeks) is considered an appropriate period 
by [CONTACT_808411] -term therapy .  During the first 
8weeks of the Maintenance Phase, patients receiving CS during the Induction Phase 
should undergo weekly dose reductions aligned with recommendations for CS tapering 
in the current American College of Gastroenterology and European Crohn’s and Colitis 
Organization guidelines and following the EMA recommendation to avoid a rapid taper.  
The tapering schedule will allow patients to be assessed for the key secondary outcome 
of achieving corticosteroid- free clinical remission at Week66 among patients who enter 
into maintenance phase .
An analysis of data from Study ABS4986g in patients with UC, which compared 
etrolizumab induction therapy with placebo (Vermeire et al. 2013 ), showed that infection 
rates were similar between etrolizuma b and placebo in the subgroups of patients taking 
concomitant IS or CS therapy and the subgroups not taking these concomitant 
treatments (see Etrolizumab Investigator’s Brochure).  Although this is a small dataset 
with limited duration of exposure, more data for a longer duration of concomitant 
exposure are available for vedolizumab .  A recent analysis of the vedolizumab 
development program demonstrated a modest increase in infection rates in patien ts 
using IS regardless of whether they rec eived vedolizumab or placebo. In addition, the 
rates of infection and serious infection in the vedolizumab treatment group were similar 
in patients who were taking concurrent IS and those who were not 
(Colombel etal.2016 ).
The risk of PML is expected to be lower with etrolizumab compared with other 
non-gut-selective biologics, with no events of PML reported in the UC Phase II or OLE 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
52/Protocol GA29144, Version 7studies.  However, the potential risk of PML and other severe infections has been
carefully considered.  Patient safety will be monitored throughout the study via 
assessment of vital signs, safety laboratory assessments, neurological exams, and 
continuous review of adverse events.  Should any patients have anaphylaxis, develop 
PML, specificmalignancy, colonic mucosal dysplasia ,or certain specific s erious 
infection s, they will be permanently discontinued from the study treatment 
(Section 4.6.2 ).  
During the Maintenance Phase of the study, patients who experience a 
clinical relapse in their CD status will have the option to enroll into an open -label study of 
etrolizumab.  
After the final visit in the treatment period , patients not participating in the OLE study will 
be assessed for safety for an additional [ADDRESS_1117328] dose of study 
drug (see Section 4.5.8 ).  This period reflects an adequate timeframe for washout of 
etrolizumab based on the estimated elimination half-life of 11 days (see Etrolizumab 
Investigator’s Brochure).  
3.3.4 Rationale for Etrolizumab Dose and Schedule
The PK profiles of several biologics are shown to be similar in UC and CD patient 
populations (Ternant etal.2008 , Fasanamde et al. 2009 , Awni et al. 2013 , 
Feagan et al.2013 ; Sandborn et al. 2013 ).  W ith these similarities, most biologic agents 
(e.g., anti -TNF or anti -integrin agents) have been successful in managing either UC or 
CD with use of the same dosing regimen (Feagan et al. 2013 , Sandborn et al. 2013 , 
Infliximab Package Insert; Adalimumab Package Insert).  Because etrolizumab has been 
evaluated in patients with moderate to severely active UC in a Phase II study 
(Study ABS4986g; Eucalyptus) in which clinically meaningful induction of disease 
remission was achieved at a nominal dose of 100 mg (0.7 mL 150 mg/mL etrolizumab 
formulation) Q4 W (three doses at W eeks 0, 4, and 8) and a nominal dose of 300mg 
Q4Wloading dose(LD [LD of 420 mg at Week0, 300 mg at Weeks 2, 4, and 8]) without 
significant safety concerns, the dose regimen (105 mg SC Q4 W) of etrolizumab is also 
proposed as one of the dos es to be test ed in this study.
[IP_ADDRESS] Rationale for Dose Ranging in the Induction Phase
In the Induction Phase, patients will be randomized to receive placebo, low -dose 
etrolizumab, or high- dose etrolizumab.  Low -dose etrolizumab (105 mg) will be 
administered Q4 W SC (W eeks 0, 4, 8, and 12). 
A low dose regimen of 105 mg SC at Q4 W is specified for dose ranging in the Induction 
Phase on the basis of the following considerations:
In the Phase II UC trial, a nominal dose of 100 mg (0.7 mL of 150 mg/mL solution 
via vial and syringe), administered Q4 W SC, showed a clinically meaningful 
induction of remission in patients with UC and had a favorable safety profile in the 
Phase II trial. 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
53/Protocol GA29144, Version 7The exposure of 100 mg, administered Q4 W SC, was shown to be sufficient for 
maximal 7-receptor occupancy in both blood and colonic tissue from all patients 
who provided evaluable samples in the Phase II trial. 
Population PK/PD modeling predicts that a dose l ower than the 100 -mgSC Q4 W 
regimen (e.g., 50 mg Q4W  SC) will result in the loss of maximal 7-receptor 
occupancy during the Q4W  dosing interval in approximately 44% of patients, and 
exposure is likely to be in the nonlinear PK range. 
In addition to the 105-mg Q4 W dose, a higher dose regimen of 210 mg SC at Weeks 0, 
2, 4, 8, and 12 is specified for dose ranging in the Induction Phase on the basis of the 
following considerations:
Despi[INVESTIGATOR_808366] , CD exhibits a more complex 
anatomical disease presentation throughout the gastrointestinal (GI)tract 
(i.e., transmural inflammation, patchy distribution, and strictures) when compared 
with UC.  A positive exposure -response relationship was reported recently for 
vedolizumab, an in -class, anti -integrin antibody, following the Induction Phase of a 
Phase III clinical trial in patients with CD.  Results showed the induction dose is 
sufficient to reach a complete receptor occupancy in all patients 
(Rosario etal.2013 ), yet an increase in c linical response/remission was observed in 
patients with higher drug concentrations (Sandborn et al. 2013 ; Rosario et al. 2014 ).  
These observations from vedolizumab studies suggest that higher etrolizumab 
exposure may have the potential to offer more clin ical benefit in this patient 
population.
In addition to Q4 W dose of 210 mg, the additional 210 -mg dose at Week 2 is 
intended to load the etrolizumab exposure upfront to allow exposure achieving 
steady state faster.  Earlier loading dose of anti -TNF agents or anti -integrins 
antibodies (Rutgeerts et al. 2004 ) were found to be effective in inducing clinical 
remission (CDAI score <150) , and such a loading dose strategy was also 
implemented in this study.
The proposed higher dose of 210 mg 5 doses SC (at W eeks 0, 2, 4, 8, and 12) in 
patients with CD will result in a 2.5 -fold total dose separation from the 105 mg 
Q4W4 dose regimen and is predicted to achieve an exposure level 30% lower 
than that from the 300 mg420mg LD cohort studied in the UC Phase II trial ,which 
had an acceptable safety/tolerability profile.
In summary, given the favorable safety profile and positive clinical outcomes observed in 
the nominal 100-mg Q4W  cohort in etrolizumab UC Phase II study, it is appropriate to 
evaluate the 105 -mg Q4W  dose, the same regimen studied in the UC Phase III trials for 
CD induction therapy.  In addition, given the complex pathophysiology of CD, an 
observed positive exposure -efficacy relationship for vedolizumab trea tment despi[INVESTIGATOR_040] a full 
receptor saturation in the blood, the available safety coverage and an acceptable safety 
profile of etrolizumab, it is scientifically sound to evaluate a higher dose regimen of 
210mg (Weeks 0, 2, 4, 8, and 12) to understand the dose -response relationship in 
patients with CD during the Induction Phase.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
54/Protocol GA29144, Version [IP_ADDRESS] Rationale for Maintenance Dose Regimen
Patients who respond to etrolizumab treatment in the Induction Phase (see Table 1 for 
definition of CDAI -70 response) will be re- randomized to receive 105 mg etrolizumab or 
placebo Q4 W in the Maintenance Phase; patients who respond to placebo in the 
Induction Phase will continue to re ceive placebo in the Maintenance Phase. 
With the assumption that the PK profiles of mAbs (anti -TNF or anti -integrins) are similar 
in UC and CD patient populations (Ternant et al. 2008 ; Fasanamde et al. 2009 ; 
Awni etal. 2013 ; Feagan et al. 2013 ; Sandborn et al. 2013 ), the lower regimen of 
105mg SC at Q4 W is specified in the Maintenance Phase on the basis the following 
considerations:
The 105 -mg Q4 W SC dose planned for the Phase III study in CD is anticipated (by 
[CONTACT_808412]) to maintain full 7receptor occupancy at all times in 85% of 
patients.  The nominal dose of 100 mg Q4 W SC administered in the UC Phase II 
study demonstrated an acceptable safety profile.
The in -class anti -integrin vedolizumab was successful in maintaining remission with 
anevery -8-week regimen that provided an average steady -state trough serum 
concentration sufficient to maintain maximal receptor occupancy 
(Rosario etal.2013 ;Sandborn et al. 2013 ).
3.3.5 Rationale for Control Group
A placebo- treated control group will be used in this study to assess the differences in 
efficacy, safety, and tolerability in patients who receive etrolizumab and background CD 
therapy compared with patients who receive placebo and background CD therapy.  The 
use of a control group is necessary give n the inherent variability in disease flares and 
the use of subjective assessments, such as the PROs.  Patients in the control group will 
undergo the same study assessments as the etrolizumab -treated patients.  The 1:1 ratio 
for etrolizumab to placebo trea ted patients is necessary to achieve a statistically 
powered comparison of primary endpoint between these treatment arms.
 
 
 
    
 
  
 
 
 
  
 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
56/Protocol GA29144, Version 73.4 OUTCOME MEA SURES
3.4.1 Efficacy  Outcome Measures
Table 1 contains definitions for the efficacy outcome measures.
[IP_ADDRESS] Co-Primary  Efficacy  Outcome Measures
Induction Phase
Clinical remission at Week 14
Endoscopic improvement at Week14
Maintenance Phase , among patients who achieve CDAI -70 response at Week 14
Clinical remission at Week 66
Endoscopic improvement at Week66 
[IP_ADDRESS] Secondary  Efficacy Outcome Measures
The secondary efficacy outcome measures for the Induction and Maintenance Phases 
are listed below.  
Induction Phase
Clinical remission at Week 6
SES CD ≤4 (≤2 for ileal patien ts), with no segment having a subcategory score 
(i.e., for ulceration size and extent, affected surface, or narrowing) that is >1, 
atWeek14
Change in CD signs and symptoms from baseline to Week14 as assessed by [CONTACT_808413]-PRO/SS measure
Maintenance Phase
Clinical remission at Week66 among patients who achieved clinical remission at 
Week14
Corticosteroid -free clinical remission at Week66 among patients who were 
receiving corticosteroids at baseline
Endoscopic improvement at Week66 among patients who achiev edendoscopic 
improvement at Week14
SES CD ≤4 (≤2 for ileal patients), with no segment having a subcategory score 
(i.e., for ulceration size and extent, affected surface, or narrowing) that is >1, 
atWeek66 
Durable clinical remission
Corticosteroid -free clinical remission for 24 weeks at W eek66 among patients who 
were receiving corticosteroids at baseline
Change in CD signs and symptoms from baseline to Week66 as assessed by [CONTACT_808413]-PRO/SS measure 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
58/Protocol GA29144, Version 7Incidence of adverse events lead ing to study drug discontinuation
Incidence of specific laboratory abnormalities
Incidence of malignancies
Incidence of ATAs to etrolizumab
3.4.4 Pharmacokinetic Outcome Measures
The PK outcome measures for this study are:
Etrolizumab serum concentrations atspecified timepoints t hroughout the Induction 
and Maintenance Phases
The PK outcome measures for the PK/PD substudy are:
Observed C maxafter the first and final doses during the Induction Phase
Time to C maxafter the first and final doses during the Induct ion Phase
Area under the serum concentration time curve (AUC) within a dose interval after 
the first and final doses during the Induction Phase
Apparent clearance
Apparent volume of distribution
Elimination half -life
 
 
 
 
 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
60/Protocol GA29144, Version 7For women who are not postmenopausal (at least 12 months of 
non therapy -induced amenorrhea) o r surgically sterile (e.g., absence of ovaries 
and/or uterus):  agreement to remain abstinent or use a highly effective method of 
contraception (e.g., combined oral contraceptive pi[INVESTIGATOR_260311], 
spermicide and barrier [condoms], intrauterine dev ice, implants for contraception, 
injections for contraception [with prolonged release], hormonal vaginal device, 
sterilization, or surgical tubal ligation for the duration of the study [i.e., during the 
treatment period and for at least [ADDRESS_1117329] dose of study drug] 
seeAppendix 4) 
Abstinence is acceptable only if it is in line with the preferred and usual lifestyle 
of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or 
postovulation methods) and withdrawal are not acceptable methods of 
contraception.
For men:  agreement to remain abstinent or use a condom , as well as not donate 
sperm during the t reatment period and for at least [ADDRESS_1117330] dose of 
study drug
Abstinence is acceptable only if it is in line with the preferred and usual lifestyle 
of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or 
postovulati on methods for the partner) and withdrawal are not acceptable 
methods of contraception.
Diagnosis of CD based on clinical, histopathological, and endoscopic evidence 
established [ADDRESS_1117331] 6 months prior to screening and a histopathology report is not available. 
The eligibility of the patient will be considered based on the weight of evidence 
supporting diagnosis and excluding other potential diagno ses.
Moderate lytoseverely active disease defined in the Screening Phase by: 
[CONTACT_808414] a CDAI score of 220 to 480 
calculated on the day of randomization, requiring a minimum of 4 days of 
e-diary PRO data from the 7 days prior to randomization AND
A mean daily SFscore ≥ 6 ORa mean daily SF>3 and a mean daily AP 
score >1 calculated on the day of randomization, requiring a minimum of 
4days of e -diary PRO data from the 7 days prior to randomization (applicable
to Cohor t3, the pi[INVESTIGATOR_106136], only) AND
The presence of active inflammation on screening ileocolonoscopy defined as 
a SES -CD of 7 or [ADDRESS_1117332] -ileocecal resection as 
determined by [CONTACT_808415]
Involvement of ileum and/or colon with at least four colonic segments traversable by 
a pediatric endoscope or three segments (colon and/or ileum) for patients who have 
undergone a bowel resection for CD
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
61/Protocol GA29144, Version 7Meets the following surveillance colonoscopy requirem ents:  
Surveillance was undertaken at screening or 12 months prior in patients with
colonic disease for >10 years (regardless of any risk factors for bowel cancer).
Surveillance was undertaken at screening or 5 years prior in patients with 
colonic di sease for [ADDRESS_1117333] risk factors for bowel cancer. 
(Note local colonic surveillance guidelines can be followed if patients have no 
risk factors and colonic disease for 10 years.) 
Have experienced intolerance, refractory disease, or no response (as defined below) 
to at least one of the following therapi[INVESTIGATOR_6523] 5 years from screening: 
CS Therapy
Refractory:
Has signs/symptoms of persistently active disease despi[INVESTIGATOR_040] a history of at 
least one 4- week induction regimen including a dose equivalent to 
30mg/day prednisone for 2 weeks if oral or 1 week if IV or 9 mg/day 
oral budesonide
Intolerance to CS therapy:
History including ,but not limited to ,Cushing’s syndrome, 
osteopenia/osteoporosis, hyperglycemia, insomnia, and infection 
IS Therapy
Refractory: 
Has signs/symptoms of persistently active disease despi[INVESTIGATOR_040] a history of at 
least one 12 -week regimen of oral AZA (or equivalent) (1.5 mg/kg) or 
6-MP (or equivalent) (0.75 mg/kg) or MTX ( 15mg/week)
Intolerance to 6 -MP(or equivalent) , AZA (or equivalent) , or MTX:
History of intolerance to AZA (or equivalent) , 6-MP(or equivalent) , and/or 
MTX(including ,but not limited to ,infection, nausea/vomiting, abdominal 
pain, pancreatitis , liver function test abnormalities, lymphopenia, and 
thiopurine methyltransferase genetic polymorphism)
Anti-TNF Therapy
Inadequate primary non- response:
Did not respond (as evidenced by [CONTACT_808391]/symptoms related to CD 
after receiving 2induction doses of either infliximab [ 5 mg/kg] or 
adalimumab [160 mg/80 mg or 80 mg/40 mg] or certolizumab pegol 
[400mg])
Inadequate secondary non- response:
Initially responded to induction therapy with infliximab ( 5 mg/kg) or 
adalimumab ( 40 mg) or certolizumab pegol ( 400mg),but experienced 
signs/symptoms related to recurrence of CD during maintenance 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
62/Protocol GA29144, Version 7Intolerance: 
Experienced a significant injection-site reaction, congestive heart failure ,
infection, or other condition that precluded continuing use of anti -TNF 
therapy at any time 
Patients who have not previously demonstrated inadequate response or intolerance 
to one or more anti -TNF therapi[INVESTIGATOR_808367].
4.1.2 Exclusion Criteria
Patients meeting any of the following criteria will be excluded from study entry.
Exclusion Criteria Related to Gastrointestinal Health
Has undergone subtotal colectomy with ileorectal anastomosis or has undergone
total colectomy
Short -bowel syndrome 
Has an ileostomy or colostomy
Hasevidence of fixed stenosis or small -bowel stenosis with prestenotic dilation that 
precludes adequate endoscopic assessm ent of the bowel
Diagnosis of UC or indeterminate colitis
Suspi[INVESTIGATOR_808349], radiation colitis, or microscopic colitis
Evidence of abdominal or perianal abscess
Sinus tract with evidence for infection (e.g., purulent discharge ) in the clinical 
judgment of the investigator.  Fistulas related to Crohn’s disease are not 
exclusionary.
Expected to require surgery to manage CD -related complications during the study
A history orevidence of adenomatous colonic polyps that have not be en removed
Past or present disease- related colonic mucosal dysplasia 
Exclusion Criteria Related to Prior or Concomitant Therapy
Any of the following treatments for CD within 8weeks prior to randomization:
Adalimumab
Certolizumab pegol
Infliximab
Any pri or treatment with ustekinumab within 14 weeks prior to randomization
Any prior treatment with etrolizumab or other anti -integrin agents (including 
vedolizumab, natalizumab, and efalizumab) 
Any prior treatment with anti -adhesion molecules (e.g., anti -MAdCA M-1)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
63/Protocol GA29144, Version 7Prior treatment with T cellor B celldepleting agents (e.g., rituximab, alemtuzumab, 
or visilizumab) within 12months prior to randomization , with the exception of AZA 
and 6 -MP(or equivalent)
Any investigational treatment that included investigational vaccines within [ADDRESS_1117334], 
whichever is greater
History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to 
chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or 
hypersensitivity to etrolizumab (active drug substance) or any of the excipi[INVESTIGATOR_840] 
(L-histidine, L- arginine, succinic acid, polysorbate 20)
Treatment with corticosteroid enemas/suppositories and/or topi [INVESTIGATOR_2855] (rectal) 
5-aminiosalicylate (5 -ASA) preparations 2weeks prior to randomization
Continued tube feeding, defined formula diets, and/or parenteral 
alimentation/nutrition as treatment for CD 3 weeks prior to randomization
Expectation of tube feeding, defined formula diets, and/or parenteral 
alimentation/nutrition as treatment for CD during the study
Any live or attenuated vaccines 4 weeks prior to randomization
Use of IV steroids during screening, with the exception of a single IV ster oid dose 
administered in the Emergency Department
Use of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil 4weeks prior 
to randomization
Chronic use of nonsteroidal anti -inflammatory drugs (NSAIDs).  Prophylactic aspi[INVESTIGATOR_808368] 325 mg/day is permitted, as is occasional use of NSAIDs for conditions 
such as headache, arthritis , myalgia,and menstrual cramps. 
If receiving oral CSs, patients will be excluded unless the dose is stable at 
20mg /day prednisone or equivalent for 2 weeks immediately prior to 
randomization.
If receiving ongoing treatment with oral 5 -ASA, patients will be excluded if the dose 
is not stable for 2weeks immediately prior to randomization.  
If receiving ongoing treatment with probiotics (e.g., Culturelle, Saccharomyces 
boulardii ) or over -the-counter supplements (e.g., N -acetyl glucosamine, curcumin), 
patients will be excluded if the dose is not stable for 2 weeks immediately prior to 
randomization.  
If receiving ongoing treatment with ISs ( e.g., 6 -MP, AZA, or MTX ), patients will be 
excluded if the dose is not stable for 8 weeks immediately prior to randomization.  
If receiving ongoing treatment with antibiotics for the treatment of CD, patients will 
be excluded if the dose is not stable for 2 weeks imm ediately prior to 
randomization.
Patients may continue to receive ongoing treatment with anti -diarrheals (e.g., loperamide 
or diphenoxylate with atropi[INVESTIGATOR_050]), preferably achieving a stable dose for 2weeks prior to 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
64/Protocol GA29144, Version 7randomization.   However, if the patient and/or the treating physician decides to change 
the dose or course of anti -diarrheals at any time during screening, these patients will be 
allowed to participate in study.
Exclusion Criteria Related to Infection Risk
Congenital or acquired immune deficiency
Patients must undergo screening for HIV and test negative for preliminary and 
confirmatory tests
Positive hepatitis C virus (HCV) antibody test result, unless the patient (1) has 
undetectable HCV RNA levels for 6months after completing a successful course 
of HCV antiviral treatment and an undetectable HCV RNA at screening or (2) has a 
known history of HCV antibody positivity with history of undetectable HCV RNA and 
undetectable HCV RNA at screening in the absence of history of HCV anti- viral 
treatment
In the screening hepatitis B assessment (which consists of testing for hepatitis B 
surface antigen [HBsAg], hepatitis B core anti -body [HBcAb], and if required, 
hepatitis B virus [HBV] DNA), patients who test positive for HBsAg ar e excluded 
from the study.  Patients who test positive for HBcAb but negative for HBsAg must 
have a confirmed negative HBV DNA test result to be eligible for the study and will 
be required to undergo periodic monitoring for HBV DNA during the study.
Positi ve stool test result for ova or parasites or positive stool culture for pathogens 
at time of screening
Evidence of infection with and/or treatment for Clostridium difficile or other intestinal 
pathogen treatment within 8 weeks prior to randomization.
A his tory of active or latent tuberculosis ( TB)confirmed by [CONTACT_808416]:
Positive tuberculin (purified protein derivative- [COMPANY_003]) skin test
Or
Positive QuantiFERONTB Gold test
Patients with a documented history of BCG vaccination must have a negative 
QuantiFERON test result and negative chest radiograph (see below) to be 
eligible. 
Suspi[INVESTIGATOR_808350] (X -ray, posteroanterior and lateral) taken 
within 3 months of randomization.
History of recurrent opportunistic infections and/or history of se vere or d issemi nated 
viral infections
Any serious opportunistic infections that occurred 6 months prior to screening
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
65/Protocol GA29144, Version 7Any current or recent signs or symptoms ( 8 weeks before screening) of infection, 
except for the following:
Minor infections (e.g., common cold) that have, in the investigator’s judgment, 
completely resolved prior to randomization
Fungal infections of the nail beds
Oral or vaginal candidiasis that has resolved with or without treatment prior to 
randomization
Any major epi[INVESTIGATOR_808351] 8weeks prior 
to screening or oral antibiotics 4weeks prior to screening. Treatment with 
antibiotics as adjunctive therapy for CD in the absence of documented infection is 
not exclusionary .
Exclusion Criteria Related to General Safety
Pregnan cy or lactation
Lack of peripheral venous access
Hospi[INVESTIGATOR_059] ( other than for elective reasons) within 4 weeks prior to 
randomization
Inability to comply with study protocol, in the opi[INVESTIGATOR_871]
Significant uncontrolled comorbidity such as neurological, cardiac (e.g., moderate to 
severe heart failure [LOCATION_001] Heart Association Class III/IV), pulmonary, renal, 
hepatic, endocrine, or GI disorders (other than CD)
Neurological conditions or diseases that may interfere with monitoring for PML
Clinically significant abnormalities on screening neurologic examination
History of demyelinating disease
History of major neurological di sorders, including stroke, MS, brain tumor, 
neurodegenerative disease, or poorly controlled epi[INVESTIGATOR_002]
History of alcohol, drug, or chemical abuse 6 months prior to screening
Conditions other than CD that could require treatment with 20 mg/day of 
prednis one (or equivalent) during the course of the study
History of cancer, including hematologic malignancy, solid tumors, and carcinoma 
insitu within 5 years before screening
Non-serious basal cell or squamous cell carcinoma of the skin that has been 
excised and is considered cured is not exclusionary .
A history of chronic myelogenous leukemia, hairy cell leukemia, melanoma, 
renal cell carcinoma, or Kaposi sarcoma is exclusiona ryirrespective of the 
duration of time before screening.
History of cervical smear result at any time that indicated the presence of 
adenocarcinoma in situ (AIS), high -grade squamous intraepi[INVESTIGATOR_12184] (HSIL), or 
cervical intraepi[INVESTIGATOR_28601] (CIN) of Grade 1
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
66/Protocol GA29144, Version 7History of organ transplant or cell transplantation
Presence of metal in the body that could a pose hazard during any potential 
scanning in patients for whom a magnetic resonance imaging (MRI) scan is 
considered unsafe
Exclusion Criteria Related to Laboratory  Values (at Screening)
Serum creatinine 2 times the upper limit of normal (ULN)
Impaired hepatic function defined by [CONTACT_080]: 
Serum transaminases 3ULN
Alkaline phosphatase 3ULN
Total bilirubin 2.5ULN (excluding inherited deficiencies such as Gilbert’s 
disease)
Platelet count 100,000/ L
Hemoglobin 8 g/dL
Absolute neutrophil count 1500/ L
Absolute lymphocyte count 500/L
4.2 METHOD OF TREA TMENT ASSIGNMENT, RA NDOMIZ ATION,
AND BLINDING
4.2.1 Induction Phase
Following completion of the screening period and after all patient eligibility requirements 
are confirmed, patients will be randomized to either placebo or etrolizumab low -dose or 
etrolizumab high -dose (Cohort 1and Cohort 3) or to etrolizumab low -dose or 
etrolizumab high -dose (Cohort 2). 
The randomization in all cohorts will be stratified by [CONTACT_808389] 
(yes vs. no), concomitant IS treatment (yes vs. no), baseline CDAI 330 (yes vs. no), 
and TNF IR patient status (yes vs. no).  A permut ed blocks randomization method will 
be used to obtain an approximately 1:2:2 ratio among the placebo, low -dose etrolizumab, 
and high -dose etrolizumab arms in Cohort 1, an approximately 1:1 ratio between the 
low-dose etrolizumab and high -dose etrolizumab ar ms in Cohort 2, and an 
approximately 2:3:3 ratio among the placebo, low -dose etrolizumab, and high -dose
etrolizumab arms in Cohort 3.
During the Induction Phase, the interactive voice or W eb-based response system (IxRS) 
will make etrolizumab low -dose, etrolizumab high -dose, or placebo study treatment kit 
assignments .  To preserve the blind to study drug assignment in the Induction Phase, all 
patients will receive injections from two separate kits at Weeks 0, 4, 8, and 12.  One kit 
will consist of a 1 -mLprefilled syringe with needle safety device (hereafter referred to as 
PFS) with a 0.7 -mL injection volume (delivering placebo or 105 mg of etrolizumab), and 
one kit will consist of a 2.25-mL PFS with a 1.4 -mL injection volume (delivering placebo 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
67/Protocol GA29144, Version 7or 210 mg of etrolizumab).  Depending on dose assignment, one PFS (patients assigned 
to active drug) or both PFSs (patients assigned to placebo) will contain placebo.  At 
Week 2, all patients will receive a study drug injection from one kit that consists of a 
2.25-mL PFS with a 1.4 -mL injection volume (delivering placebo or 210 mg of 
etrolizumab) (see Section 4.3.1 ).  The PFS will contain placebo for patients in the low -
dose etrolizumab and placebo arms and active drug for patients in the high -dose 
etrolizumab arm.  The placebo and active drug PFSs are filled and packaged to look 
identical (other than the difference in volume for the 1 -mL PFS vs. the 2.25 -mL PFS).
4.2.2 Maintenance Phase
At W eek16, patients treated with etrolizumab who achieved a CDAI -70 response at 
Week 14 without rescue therapy will undergo a second randomization into the 
Maintenance Phase in a 1:1 ratio to treatment with placebo or etrolizumab 105 mg 
SCQ4W(until napproximately 480, see Section 3.1.3 ).  The randomization will be 
stratified by [CONTACT_808417] 10 and14(yes vs. no), induction dose 
regimen (low dose vs. high dose), concomitant oral CS treatm ent (yes vs. no), and prior 
TNFIR patient (yes vs. no).
Patients who received placebo in either Cohort 1 or 3 and who are eligible for the 
Maintenance Phase willcontinue to receive blinded placebo during the Maintenance 
Phase to keep the blind and avoid any performance bias from the Induction Phase that 
confounds the Maintenance Phase.
As in the Induction Phase, during the Maintenance Phase, the IxRS will make
etrolizumab low -dose/placebo study treatment kit assignments. One treatment kit will be 
assigned for each visit.   Each kit will consist of a 1 -mL PFS w ith 0.7mLinjection volume
(delivering placebo or 105 mg of etrolizumab) .  The placebo and active drug kits are 
filled and packaged to look identical.  Patients performing study drug administration at 
home may receive two or three kits at a time beginning at Week 16 in order to allow 
sufficient supply until their next in -clinic visit.
4.2.3 Blinding/Unblinding
Patients, all study site personnel ,and the Sponsor and its agents will be blind to 
treatment assignment throughout the 14 -week induction a nd 52-week maintenance 
treatment periods of the pi[INVESTIGATOR_36491] (i.e. ,blind to the treatment assignments for 
induction Cohort 3, and for the maintenance cohort).  The IxRS service provider and 
personnel responsible for performing PK assays (in order to identify appropriate dilutions 
of PK samples to be analyzed) will be unblinded to patients’ randomized treatment 
assignm ents.  As described in Section 6, treatment assignment will be unblinded to the 
Sponsor (this does not include representatives of the Sponsor such as Site Monitors) for 
Cohort 1 at the end of the Induction Phase , or earlier ,in the event of an optional interim 
analysis as described in Section 6.7. However, patients and all study site personnel will 
remain blinded to individual treatment assignment until after the study is completed (after 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
68/Protocol GA29144, Version 7all patients have either completed the treatment and safety follow -up period or
discontinued early from the study) and the database is locked.  Because of the 
exploratory nature of active -treatment Cohort 2, the Sponsor (including personnel 
performing PK/PD  analysis )will not be blinded to dose arm assignments 
to enable performing  analyses, if required.  These personnel will 
have no involvement in the Sponsor’s oversight of the study conduct.  Patients and all 
study site personnel will remain blinded to individual dose assignment until after the 
study is completed.  The Sponsor, patients ,and all study site personnel will remain 
blind ed to individual treatment assignments for patients enrolled in the pi[INVESTIGATOR_372093] 3.
If unblinding is necessary for patient management, the investigator will be able to br eak 
the treatment code by [CONTACT_123517]. Treatment codes should not be broken 
except in emergency situations when knowledge of the study drug assignment is critical 
to the clinical management of a patient .  The Investigator must make reasonable 
attem pts to first discuss the case with the Sponsor’s representative Medical Monitor 
before breaking the treatment code.  If the investigator wishes to know the identity of the 
study drug for any other reason, he or she must contact [CONTACT_1689].  The 
investigator should document and provide an explanation for any premature unblinding 
(e.g., accidental unblinding, unblinding because of a serious adverse event as per 
Health Authority reporting requirements).  The Sponsor Safety Reporting Department 
(indepe ndent from the study team) will break the treatment code for all unexpected 
serious adverse events (see Section 5.2.2 ) considered by [CONTACT_808418].  The study team will remain blind to 
study treatment.
4.3 STUDY TRE ATMENT
4.3.1 Formulation, Packaging, and Handling
[IP_ADDRESS] Etrolizumab and Placebo
Etrolizumab will be supplied by [CONTACT_808419] a single- use PFS containing 150 mg/mL 
etrolizumab for SC administration.  To preserve the blind to study drug assignment in the 
Induction Phase, all patients will receive injections from two PFSs at Weeks 0, 4, 8, and 
12:  a 1 -mL PFS with a 0.7 -mL injection volume (delivering placebo or 105 mg of 
etrolizumab) and a 2.25-mL PFS with a 1.4 -mL injection volume (delivering placebo or 
210 mg of etrolizumab).  Depending on dose assignment, one PFS (patients assigned to 
active drug) or both PFSs (patients assigned to placebo) will contain placebo.  At 
Week2, all patients will receive a study drug injection from a 2.25 -mL PFS with a 1.4 -mL 
injection volume (delivering placebo or 210 mg of etrolizumab) .  The PFS will contain 
placebo for patients in the low -dose etrolizumab and placebo arms and active drug for 
patients in the high -dose etrolizumab arm.  In the Maintenance Phase, patients will 
receive injections from a 1- mL PFS with a 0.7 -mL injection volume (delivering placebo or 
105 mg of etrolizumab). 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
69/Protocol GA29144, Version 7Etrolizumab is formulated as 150 mg/mL in 20 mM histidine, 0.2 M arginine succinate, 
and 0.04% (weight/volume) polysorbate 20, pH 5.8.  Each PFS is for single -dose 
parenteral administration and contains no preservatives.
Drug product composition for the placebo is exactly the same as that of active drug 
product without the presence of etrolizumab.
Packaging
Study drug packaging will be overseen by [CONTACT_1034]’s Clinical Trial Supplies 
Department and will be labelled with the identification required by [CONTACT_1769], the protocol 
number, drug identification, and dosage.  The packaging and labelling of the study 
medication will be in accordance with Sponsor’s standards and local regulations.
Upon arrival of investigational products at the site, the pharmacist or medication nurse 
should check them for damage and verify proper identity, quantity, integrity of seals, and 
temperature conditions and report any deviations or product complaints to the monitor 
upon discovery .
Handling
The study drug must be stored accordi ng to the details on the product label.  The drug 
label indicates the storage temperature.  PFSs of study medication should be 
refrigerated at 2°C 8°C (35.6 F46.4F) and protected from excessive light and heat.  
PFSs should not be frozen, shaken, or store d at room temperature.
The PFS containing study drug is stable for no longer than 8 hours at room temperature 
(up to 30 C [86 F]).  If a syringe is left at room temperature for longer than this time, it 
should not be used.  In the home setting, patients sh ould be instructed to contact [CONTACT_808420] a replacement.
Used PFS with study drug will be stored at room temperature in designated sharps 
containers and returned to the site for disposal per local schedule.
Under no circumstances is the investigator to allow study medication to be used other 
than as directed by [CONTACT_760].
Details about the packaging and labeling of the study drug will be provided in the 
protocol supporting documents.
For further details, see the current Investigator's Brochure.
4.3.2 Dosage, A dministration, and Compliance
[IP_ADDRESS] Etrolizumab and Placebo
In the Induction Phase, all patients receiveone 0.7-mLinjection and one 1.4 -mL injection 
with use of a PFS at Weeks 0, 4, 8, 12 and one 1.4 -mL injection at Week 2 
(see Appendix 1a).  In the Maintenance Phase, all patients will receive one 0.7 -mL 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
70/Protocol GA29144, Version 7injection with use of a PFS Q4 W(see Appendix 1b). For the 0.7- mL injection, the device 
includes a 1- mL long glass syringe with a staked- in stainless steel needle (27G ½‘’
thin-walldesign).  For the 1.4 -mL injection, the device includes a 2.25 mL glass syringe 
with a staked- in stainless steel needle (27G ½” thin -wall design). ThePFS isastanda rd
design, and the device is fitted with a custom -designed plungerrod and an extended 
finger flange.  A part of t he needle cap of the PFS may contain natural rubber latex that 
may cause allergic reactions in latex -sensitive individuals.
Study site health care professionals (HCPs) will be trained on the use of the PFS and 
SC administration of study medication into the thigh, abdomen, or upper arm.  Patients 
will in turn be trained in the use of the device by [CONTACT_760500] “Instruction for Use” 
leaflet .  In the event that a caregiver will ultimately administer study drug to the patient in 
the home setting, the caregiver is to be trained.  The upper arm site is to be used for 
caregiver and is not a site to be used for patient self-administration of study treatment.
During the Induction Phase, study medication is to be administered under close 
supervision of the HCP in a setting where medications and resuscitation facilities are 
available.  The first two treatments (W eek 0 [Day 1] and W eek2) will be administered by 
[CONTACT_760501] (and/or caregiver).  Th e subsequent treatments in 
the Induction P hase may be administered by [CONTACT_102] (or caregiver) and observed by 
[CONTACT_760502].   Following treatment administrations, patients will be 
monitored for acute hypersensitivity reactions for at least [ADDRESS_1117335] be readily available for 
immediate use if required to treat a hypersensitivity reaction; site personnel must be able 
to detect and treat such reactions.  Patients with severe hypersensitivity reactions 
(e.g., stridor, angioedema, life -threatening change in vital signs) must be withdrawn from 
study treatment.  These patients will not be eligible to receive open -label etrolizumab in 
Part 1 (OLE) of Study GA29145 and are to enter the 12 -week safety follow -up in this 
study,followed by [CONTACT_760503] 2 (SM) of Study GA29145 .
All adverse events of systemic hypersensitivity reactions or anaphylactoid or anaphylaxis 
reactions (see Appendix 7) must be reported within [ADDRESS_1117336] be informed as soon as is practical (see the Study Manual for 
contact [CONTACT_3031]).
During the Maintenance Phase, patients will have the option to return to the 
investigational site or self -administer/have a caregiver administer their treatments at 
home, upon completion of the training for self -administration and deemed competent by 
[CONTACT_093].  Patients and/or the care giver will beprovided withcontact [CONTACT_808421]-administration between clinic visits .  Competence of the 
patient or caregiver to administer at home will be documented.  Compliance inthehome
setting is to bemonitored withuseofane-diary torecord drug administration andreturn
ofused and unused medication syringes.  Patients and/or the care giver will be provided 
with alert cards for the mselves and a partner/caregiver, which they shall carry at all 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
71/Protocol GA29144, Version 7times.  These alert cards include guidance on recognizing 
allergic/anaphylactic/anaphylactoid reactions and how to obtain emergency care in t he 
event such a reaction occurs and information regarding recognition of symptoms of PML.
If the patient cannot administer study medication on the sc heduled dosing day, then the 
patient should administer study medication within a window of [ADDRESS_1117337].  
During Weeks 0, 4, 8, and 12 of the Induction Phase when 2 injections are administered 
(0.7mL and 1.4 mL), study drug should be injected in two separate injection sites 
(e.g., middle thigh and lower abdomen). Injecting both doses of study drug in the same 
area is not r ecommended. Site personnel will inspect the injection sites at each clinic 
visit.  Record any injection -site reactions, including those following an injection in the 
home setting (see Section [IP_ADDRESS] ), as adverse events.
Guidelines for treatment interruption or discontinuation are provided in Section 4.6.
4.3.[ADDRESS_1117338] A ccountability
All IMPs required for completion of this study, etrolizumab and etrolizumab placebo, are 
provided by [CONTACT_1034] .  The study site will acknowledge receipt of IMPs with u se of 
the IxRS to confirm the shipment condition and content.  Any damaged shipments will be 
replaced.
IMPs will either be disposed of at the study site according to the study site’s institutional 
standard operating procedure or be returned to the Sponsor with the appropriate 
documentation.  The site's method of IMP destruction must be agreed to by [CONTACT_1034].  
The site must obtain written authorization from the Sponsor before any IMP is destroyed, 
and IMP destruction must be documented on the appropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of 
by [CONTACT_25729].
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
72/Protocol GA29144, Version 74.3.[ADDRESS_1117339] be clearly document ed and approved by [CONTACT_093].   
Upon study completion, the investigator will return all completed Drug Dispensing Logs 
to the Monitors.
Any unused study drug and Drug Return Records should be returned to the Monitors, 
unless alternate destruction has been authorized by [CONTACT_808422] (Section 4.3.3 ).  The investigator's copy of the Dru g Return 
Record(s) must accurately document the return of all study drug supplies to Sponsor.
4.3.[ADDRESS_1117340]/Comparator
Any used PFSs will be placed into sharps containers immediately after SC injections 
either at the site or at home.  The sharps containers should be discarded at the study 
site by [CONTACT_335558].  W ritten documentation of destruction of unused 
study drug must contain the following:
Identity (batch numbers or patient numbers) of IMP(s) destroyed
Quantity of IMP(s) destroyed
Date of destruction
Method of destruction
Name [CONTACT_335605](s)
In case of device failure or if there are any issues with the drug, the PFS should not be 
destroyed and instead should be returned to the investigator site in the packaging 
provided for this purpose.  The device is to be sent from the investigator site to the 
appropriate Sponsor clinical trial supplies department for further assessment.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
73/Protocol GA29144, Version 74.3.6 Reporti ng of Prefilled Sy ringe Complaints/Events
For reporting of PFS complaints or events, see Section 5.3.[ADDRESS_1117341] -trial access to etrolizumab, see Section 4.5.9 .
4.4 CONCOMITA NT THERA PY
Concomitant therapy includes any medication (e.g., pre scription drugs, over -the-counter 
drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from 
4 weeks prior to screening to the study completion/early withdrawal visit.  
Anti-diarrheal medications are permitted if used to manage chronic diarrhea ,but every 
attempt should be made to keep the dose/regimen stable.  Any changes in the 
dose/regimen after baseline (W eek 0) must be captured by [CONTACT_1755]/or 
patient. 
Occasional use of NSAIDs or acetaminophen is permitted for pain relief (e.g., in the case 
of headache, arthritis, myalgia, etc.).  Prophylactic aspi[INVESTIGATOR_115075] 325 mg/day is also 
permitted.
All medications used must be reported to the investigator and recorded on the 
Concomitant Medications eCR F.
4.4.1 Management of Concomitant Crohn’s Disease Medication 
inthe Induction Phase
During the Induction Phase, in all cohorts, concomitant CSs will be maintained at a 
stable dose of 20mg/day prednisone or equivalent or 6 mg/day oral budesonide.
4.4.[ADDRESS_1117342] remain on stable doses of ISs (e.g., AZA (or equivalent) , 6-MP(or 
equivalent) , MTX) throughout the study unless dose reduction or discontinuation is 
required because of a toxicity related to the m edication .  Generally accepted criteria for 
discontinuation of IS due to toxicity include, but are not limited to, acute pancreatitis, 
severe leukopenia, severe thrombocytopenia, or significant elevations of the liver -
associated enzymes from baseline, especially in the presence of an elevated total 
bilirubin.  The ultimate decision to discontinue IS remains at the discretion of the 
Investigator.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
74/Protocol GA29144, Version 74.4.3 Management of Concomitant Crohn’s Disease Medication in 
the Maintenance Phase
The CS do se should betapered start ing at Week 14 according to the following schedule:
  20 mg/day prednisone (or equivalent):  titrated via dose reduction of 2.5 mg/week 
until discontinuation
  6 mg/day oral budesonide:  titrated via dose reduction of 3 mg every 2 weeks until 
discontinuation
For patients who cannot tolerate the dose tapering without recurrence of clinical 
symptoms, the CS dose may be increased but should not exceed the baseline dose 
(i.e., dose at Week 0 of the study) ,and the dose -tapering regimen should be re-initiated 
within 2 weeks.  
Patients taking concomitant IS therapy (AZA (or equivalent) , 6-MP(or equivalent) , or 
MTX) must remain on stable doses throughout the study unless dose reduction or 
discontinuation is required because of a toxicity related to the medication.
4.4.4 Permitted Rescue Therapy
[IP_ADDRESS] Rescue Therapy  in the Induction Phase
This is defined as medication prescribed for new or worsening CD symptom sand 
includes:
Any new CS or IS therapy for CD
Any increase in dose or regimen of baseline Crohn’s medications
Antibiotics, 5 -ASAs, anti -diarrheals, probiotics, herbal/ayurvedic, nutritional and 
homeopathic supplements are not considered as rescue therapi[INVESTIGATOR_014].
Patients requiring rescue therapy during the Induction Phase will be considered 
non-responders for the primary analysis and will not be eligible for the Maintenance 
Phase.  
[IP_ADDRESS] Rescue Therapy  in the Maintenance Phase
This is defined as medication prescribed f or new or worsening CD symptoms and 
includes: 
Any new CS or IS therapy for CD
Increase in dose ofIStherapy above the baseline (W eek 0) dose
Increase in the dose of CS therapy above a patient’s baseline ( Week 0) dose 
(applicable to patients requiring CS at baseline) 
Antibiotics, 5 -ASAs, anti -diarrheals, probiotics, herbal/ayurvedic , nutritional, and
homeopathic supplements are not considered as rescue therapi[INVESTIGATOR_014].  
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
75/Protocol GA29144, Version 74.4.5 Prohibited Therapy
Patients should not be treated for continuing signs and symptoms of CD with any 
medication that is prohibited to be taken concomitantly with etrolizumab; these include,
but are not limited to ,anti-integrins, anti-adhesion molecules (e.g., anti -MAdCAM -1),
T-or B-celldepleting agents with the exception of 6 -MP and AZA (or equivalent) , 
TNF antagonist s, antagonists of IL -23IL-12(e.g., ustekinumab) , anti-metabolites, 
cyclosporine, and tacrolimus.  Any patient treated with a prohibited medication in the 
Induction or Maintenance Phase will be considered a non -responder for the purpose of 
the primary analysis.  These patients must be immediately discontinued from 
etrolizu mab; they will not be eligible for Part 1 (OLE) of Study GA29145 andmust enter 
the 12 -week safety follow -up period.  They will then be asked to enroll in an extended 
PML-monitoring phase (Part 2 [SM] of Study GA29145 ) for 92 weeks.
CS enemas/suppositories and/or topi[INVESTIGATOR_2855] (rectal) [ADDRESS_1117343] be discontinued ,but 
patients may continue t o receive etrolizumab and may still be eligible for Part 1 ( OLE) of 
Study GA29145.
4.[ADDRESS_1117344] be obtained before 
performing any study -specific screening tests or evaluations.  Informed Consent Forms 
for enrolled patients and for patients who are not subsequently enrolled (e.g., screen 
failures, eligible patients who choose not to enroll) will be maintained at the study site.
A separate informed consent is required for patients participating in the optional PK/PD 
substudy.
All screening evaluations must be completed and reviewed to confirm that patients meet 
all eligibility criteria before randomization.  The investigator will maintain a screening log 
to record details of all patients screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
76/Protocol GA29144, Version 74.5.2 Screening
The screening period should not exceed 35calendar days. 
All screening tests and evaluations (see Appendix 1afor screening tests and evaluations 
and Section 4.5.[ADDRESS_1117345] and evaluations) will be performed within 
35days prior to Day [ADDRESS_1117346] 9 days prior to the date of randomization (see Section [IP_ADDRESS] ).  
Laboratory samples should be collected from the patient early in the screening period to 
allow time for the laboratory results to be available for review by [CONTACT_335567].  
The ECG and chest X -ray can be obtained any time before Day 1 (see Sec tion4.5.7.9
and Section [IP_ADDRESS]).  All sc reening evaluations must be completed and reviewed to 
confirm that patients meet all eligibility criteria before Day 1.  The investigator will 
maintain a screening log to record details of all patients screened as described in 
Section 4.5.1 .
[IP_ADDRESS] Re-Screening
If a patient does not meet all the eligibility criteria within 35days after the original 
screening visit, re- screening is permitted.  Patients found to be ineligible for entry into 
the study may be re- screened only once (e.g., if the patient develops additional 
manifestations of CD, a worsening of existing manifestations at a later time, if patient’s 
clinical status has changed such that the abnormal laboratory value may be directly 
affected [e.g., transfusion], or if there is evidence that the central laboratory sample may 
have degraded during transport) with the exception of certain laboratory testing 
(described below ).  Each patient mu st re-consent before re -screening occurs.
Re-screening is not required for the following assessments provided the results are 
available from the initial screening , and the date of the initial screening assessment 
was6 weeks prior to the re-screening randomization visit.
HIV preliminary and confirmatory tests
Hepatitis C virus (HCV) antibody test
Hepatitis B assessment (i.e., surface antigen [HBsAg] core anti -body [HBcAb], and if 
require d, hepatitis B virus [HBV] DNA)
If, in the investigator’s judgment, the patient is deemed to have been at risk of any of the 
above infec tions (based on medical history, or geographical or social circumstance) the 
patient should be re- screened with the above tests. 
Patients who are classified as screen failures due to the presence of C. difficile may be 
re-screened 60 days after the end of successful treatment. Full re -screening will be 
required.
As described in Section [IP_ADDRESS] , if a negative TB screening test result has been 
documented w ithin [ADDRESS_1117347] is needed.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
77/Protocol GA29144, Version 7Patients who met the SES CD eligibility crit erion during their first screen do not need to
repeat the ileocolonoscopy procedures as long as date of the ileocolonoscopy during the 
initial screening assessment was [ADDRESS_1117348] been hospi[INVESTIGATOR_057] (other than elective reasons ) 5 weeks prior to the 
scheduled randomization visit after re -screen are not eligible for the study .
4.5.3 Study Assessments during Induction and Maintenance
Visits for the Induction and Maintenance Phases should occur within 3 days of the 
specified time, ex cept for CD assessment visits at W eeks 10, 14, 66, and early 
withdrawal (i.e., visits not associated with study drug administration), which may occur 
within 7days of the specified time.  
During the Induction Phase, all visits take place in the clinic; however, in the 
Maintenance Phase, patients are contact[CONTACT_5143] (a telephone visit) for the 
purpose of study assessment rather than making a clinic visit for prespecified visits 
(indicated in Appendix 1aand Appendix 1b).  Blood draws for the PK/PD substudy may 
be collected b y appropriately qualified personnel in the patient’s home or other suitable 
location away from the clinic.  If samples are not collected at the clinic, samples will be 
sent on the day of collection to a central laboratory for storage until analysis begins.
All assessments are performed on the day of the specified visit, except where a time 
window is specified.  Assessments scheduled on the day of study drug administration 
(e.g., blood draws, pregnancy tests) should be performed prior to dosing, unless 
other wise noted. 
When study drug administration in the home (or the clinic, if applicable) is required on 
the same day as clinic assessments, drug is to be administered at home afterthe clinic 
visit. 
4.5.4 Assessments at Study Completion
Patients who complete the treatment ph ase will be asked to visit the clinic for W eek66
assessments.  The end of study treatment ( Week66or the early withdrawal from 
treatment visit) is followed by a 12- week Safety Follow -Up Phase (telephone visit at 
Week6 and clinic visit at W eek 12; see Appendix 1a, Appendix 1b, and Appendix 2).  
Patients who are eligible and consent to receive ope n-label etrolizumab will enroll 
directly into Part 1 (OLE) of Study GA29145 after the Week66visit is completed; these 
patients will not enter the 12- week Safety Follow -Up Phase of the study.  Ineligible 
patients or those who choose not to enroll in Part 1 (OLE) of Study GA29145 will be 
asked to enroll in Part 2 (SM) of Study GA29145 for extended PML follow -up after 
completion of the 12 -week Safety Follow -Up Phase of the study.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
78/Protocol GA29144, Version 74.5.5 Early  Withdrawal from Study
It is critical to the integrity of this study that patients adhere to the visit schedule outlined 
in the protocol.  As such, every reasonable effort should be made to convey to the 
patients t he importance of remaining on the study.   All patients withdrawing from the 
study prior to W eek66should complete an early withdrawal visit, including those 
patients who are enrolling in Part 1 ( OLE) of Study GA29145 at the end of the Induction 
Phase or prior to completion of the Maintenance P hase.  A ssessments are specified in 
the Schedule of Assessments in Appendix 1aand Appendix 1b.
Theearly withdrawal visit should take place 4 weeks ( 7 days) after the last dose of 
study drug.  Patients who wish to withdraw from the study during the Safety Follow -Up 
Phase should also complete an early withdrawal visit.
4.5.6 Assessments at Unscheduled Visit s
An unscheduled visit may occur at any time during the study (i.e., because of relapse of 
disease or an adverse event).  Patients who are seen by [CONTACT_82295] a 
time point not required by [CONTACT_808423] -driven ass essments 
(e.g., undergo a PML assessment interview and neurological examination only if patient 
reports symptoms suspected of PML).  
See Appendix 1aand Appendix 1bforassessments that if performed in case of an 
unscheduled visit should be recorded on the eCRF. 
4.5.7 Description of Visit A ctivities
[IP_ADDRESS] Medical History  and Demographic Data
Medical history includ es clinically significant diseases, procedures, and all medication 
taken in the 4 weeks prior to screening (including prescription, over -the-counter, and 
herbal/homeopathic remedies and therapi[INVESTIGATOR_014]).  A detailed history of medication used for 
CD is required for the 5 years prior to screening. 
Demographic data, including age, sex, whether the patient is a fraternal or identical twin, 
and self -reported race/ethnicity ,will be collected during screening .
[IP_ADDRESS] Physical Examinations
A complete physical examination wil l be performed at screening and should include the 
evaluation of head, eye, ear, nose, and throat, and cardiovascular, dermatological, 
musculoskeletal, respi[INVESTIGATOR_696], GI, and neurological systems, including administration of 
the PML Subjective Checklist and the PML Objective Checklist by [CONTACT_093] 
(see Section [IP_ADDRESS] for PML assessment details and Appendix 6for PML algor ithm).  
Clinically significant findings from the physical examination should be recorded as 
medical history during screening.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
79/Protocol GA29144, Version 7Symptom -driven physical examinations will be perform ed at W eeks 14, 24, 32, 44, 56, 
and 66 (or Early W ithdrawal Visit).  New or worsened abnormalities from screening 
should be recorded as adverse events, if appropriate.  
 
 
 
 
 
 
 
[IP_ADDRESS] Vital Signs, Height, and Weight
Vital signs will include measurements of heart rate and systolic and diastolic blood 
pressure after the patient has been in a seated p osition for 5 minutes at screening and at 
Weeks 0, 4, 8, 12, 16, 24, 32, 44, 56, and 66 (or Early W ithdrawal Visit).  Record vital 
signs before study drug administration at clinic visits only.
Height should be measured at screening only.
Weight should be m easured during screening and at W eeks 0, 10, 14, 24, 28, 32, 44, 56, 
and 66 (or Early W ithdrawal Visit).
[IP_ADDRESS] Crohn’s Disease A ctivity Assessments
Collect a detailed history of CD, including date of diagnosis, disease severity, 
hospi[INVESTIGATOR_602], and extraintestinal manifestations at screening.
Disease severity will be evaluated using the CDAI, SF, AP, and SES CD.  The CDAI , 
SF, and AP are described in Appendix 9.  The SES CD is assessed through endoscopy 
and is a composite of four factors (ulcer size, percentage of ulcerated surface, 
percentage of surface affected by [CONTACT_808424], and extent of stenosis) in up to five 
ileocolonic segments. 
The CDAI ,SF, and AP scores will be calculated at Weeks 0,10, 14, 24, 28, 32, 44, 56, 
and 66 (or Early W ithdrawal Visit). SES CDassessments will take place at screening 
and W eeks 14 and 66 (or Early W ithdrawal Visit). 
Abdominal pain will be additionally assessed throughout the study with the Abdominal 
Pain Questionnaire (APQ) recorded daily on an e -diary (see Appendix 11).

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
80/Protocol GA29144, Version 7For the Week 14 and 66 visits, the ileocolono scopy should be scheduled on the day of 
the visit. If this is not possible, the ileocolonoscopy should be performed no later than 
5days after the visit.  
[IP_ADDRESS] Ileocolon oscopy  with Biopsies
The ileocolono scopy will be performed within the screening period and atleast 9 days 
prior to randomization and at Weeks14 and 66 and/or withdrawal from study 
(Early Withdrawal visit; see Appendix 1aand Appendix 1b).
Patients are to prepare their bowel prior to the ileocolonoscopy procedures.  Medications 
used for bowel preparation should be reported on the concomitant medications pages of 
eCRF.
 
.
Afull colonoscopy is required to guard against enrolling patients with colonic carcinoma 
and dysplasia. Depending on a patient’s risk factor for bowel cancer and their last 
surveillance colonoscopy, the surveillance can be done in combination with this 
screening ileocolonoscopy.  Refer t o Section 4.1.[ADDRESS_1117349] experienced in IBD who is blind to the patient’s clinical 
activity and treatment allocation.  When scoring the SES CD, please use the worst 
affected portion of each segment.
In all cases, video recordings should be performed prior to biopsy .  Technical 
instructions for making the video recording will be provided separately (these instructions 
will include how to capture the depth of insertion and how to mark bowel segments 
during the recording).
Each patient ente red into the study will have biopsy sample collections performed during 
the ileocolono scopy at Screening, Week14,and W eek66as follows:

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
81/Protocol GA29144, Version 7At Screening: a total of 9 pairs (18 biops y samples )
Two pairs of biopsies (4 biopsy samples) taken from an area that is within 20 40cm 
from the anal verge (sigmoid colon) and one pair of biopsies (2 biopsy samples) 
should be taken from the transverse colon.  The three pairs of biopsies should be 
placed in formalin at the sites.
–If the colo n segment is normal, random biopsies should be obtained and
labeled as "non -inflamed" along with the location (i.e. ,transverse colon, sigmoid 
colon) on the central laboratory requisition form.
–If the colon segment has macroscopic disea se but no discrete lesion 
(e.g., ulcers), the biopsies should be taken from the most severely affected area 
and labeled as "infl amed" along with the location (i.e. ,transverse colon, sigmoid 
colon) on the central laboratory requisition form.
–If the colon segment has discrete lesion (e.g. ,ulcers), t he biopsies should be 
taken perpend icular to the edge of the largest lesion present and labeled as 
"inflamed" along with the location (i.e. ,transverse colon, sigmoid colon) on the 
centra l laboratory requisition form.  Obtaining biopsies from the base of the 
ulcer should be avoided.
Six pai rs of biopsies ( 12 biops y samples ) preferentially from the inflamed terminal 
ileum or if necessary the inflamed ileocecal valve or another more distal inflamed 
region of the colon.
–Patients with active disease of the terminal ileum (Montreal location categ ory L1 
or L3; Silverberg et al. 2005 ) will have biopsies taken of inflamed mucosa from 
this region if it i s accessible during endoscopy.  These biopsy samples will be 
identified as ileum samples.
oFour pairs of biopsies ( 8 biops y samples ) should be placed in formalin at 
the sites .
oEach of the remaining t wo pairs of biopsies ( 4 biops y samples ) should be 
placed in separate stabilization buffer (RNAlater) and shipped to a central 
laboratory for storage a t80°C.
–Ifthe terminal ileum is not accessible in patients with L1 or L3 disease, the 
biopsies will be taken either from an inflamed region of the ileocecal valve or 
another more distal inflamed region of colon. These biopsy samples will be 
identified as colonic samples.
oFour pairs of biopsies ( [ADDRESS_1117350] es) should be placed in formalin at 
the sites .
oEach of the remaining t wo pairs of biopsies ( 4 biops y samples ) should be 
placed in separate stabilization buffer (RNAlater; one pair per tube) and 
shipped to a cent ral laboratory for storage at 80°C.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
82/Protocol GA29144, Version 7At Weeks 14 and 66 (or Early  Withdraw al Visit):  a total of 6 pairs (12 biops y 
samples ) at each timepoint
Two pairs of biopsies (4 biopsy samples) taken from an area that is within 20- 40 cm 
from the anal verge (sigmoid colon) and one pair of biopsies (2 biopsy samples) 
should be taken from the transverse colon.  The three pairs of biopsies should be 
placed in formalin at the sites.
–If the colon segment is normal, random biopsies should be obtained and 
labeled as "non -inflamed" along with the location (i.e. transverse colon, sigmoid 
colon) on the central laboratory requisition form.
–If the colon segment has macroscopic disease but no discrete lesion 
(e.g., ulcers), the biopsies should be taken from the most severely affected area 
and labeled as "inflamed" along with the location (i.e. transverse colon, sigmoid 
colon) on the central laboratory requisition form.
–If the colon segment has discrete lesion (e.g., ulcers), the biopsies should be 
taken perpendicular to the edge of the largest lesion present and labe led as 
"inflamed" along with the location (i.e. transverse colon, sigmoid colon) on the 
central laboratory requisition form.  Obtaining biopsies from the base of the 
ulcer should be avoided.
Three pairs of biopsies ( 6 biopsy samples ) preferentially from th e inflamed terminal 
ileum or if necessary the inflamed ileocecal valve or another more distal inflamed 
region of the colon.
–Patients with active disease of the terminal ileum (Montreal location category L1 
or L3; Silverberg et al. 2005 ) will have biopsies taken of inflamed mucosa from 
this region if it is accessible during endoscopy.  These biopsy samples will be 
identified as ileum samples.
oTwo pairs of biopsies ( 4 biopsy samples ) should be placed in formalin at the 
sites.
oOne pair of biopsies ( 2 biopsy sa mples ) should be placed in a stabilization 
buffer (RNAlater) and shipped to a central laboratory for storage at 80°C.
–If the terminal ileum is not accessible in patients with L1 or L3 disease, the 
biopsies will be taken either from an inflamed region of t he ileocecal valve or 
another more distal inflamed region of colon.  These biopsy samples will be 
identified as colonic samples.
oTwo pairs of biopsies ( 4 biopsy samples ) should be placed in formalin at the 
sites.
oOne pair of biopsies ( 2 biopsy samples ) should be placed in a stabilization 
buffer (RNAlater) and shipped to a central laboratory for storage at 80°C.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
83/Protocol GA29144, Version 7 
 
  Samples will be sent to the central 
laboratory to be paraffin embedded and for further storage or distribution (unless 
analysis is to be performed locally, as indicated).
[IP_ADDRESS] Neurological Examination
A neurological examination including assessments of cranial nerves, motor and sensory 
function, coordination, and mental status will be performed by a qualified HCP 
(e.g., investigator, physician assistant, nurse, nurse practitioner; a neurology 
consultation is not required) prior to any other assessment during screening and at 
Weeks 4, 14, 24, 32, 4 4, 56, and 66 (or Early W ithdrawal Visit).
Clinically significant findings from the neurological examination should be recorded as 
medical history during screening, and new clinically significant findings should be 
recorded as adverse events after the first dose of study drug.
[IP_ADDRESS] Progressive Multifocal Leukoencephalopathy Assessment
Study site personnel and patients will be educated regarding the signs and symptoms 
ofPML.
Patients will be closely monitored during the course of the study for any new symptoms 
or signs suggestive of PML through regular ne urological examinations and 
administration of the PML Subjective Checklist (symptom assessment; see Appendix 5) 
and the PML Objective Checklist (neurologic evaluation; see Appendix 5).  The PML 
assessment should be performed prior to any other as sessment along with the 
neurological examination (see Section [IP_ADDRESS] ) by a qualified HCP (e.g., investigator, 
physician assistant, nurse, nurse practitioner; a neurology consultation is not required) 
during in- clinic visits at screening and at Weeks 4, 14, 24, 32, 44, 56, and 66 (or Early 
Withdrawal Visit).
A blood sample to test for antibodies to JCV will be taken and stored for possi ble later 
assessment of how widespread the JCV infection is in the study population.  Sample 
testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for 
evaluating neurologic symptoms.  The sample may be tested if there is a strong belief 
that this information will be helpful in managing a patient's condition.
If a patient has a positive finding on the PML Subjective Checklist that is acco mpanied 
by a positive finding on the PML Objective Checklist or if there is a strong cli nical 
suspi[INVESTIGATOR_335482], the event should be reported expeditiously as an adverse event of 
special interest within 24 hours (see Section 5.2.1 and Appendix 6for the Algorithm for 
Evaluation of PML).  If PML is susp ected, dosing with study treatment for that patient 
should be suspended and the patient should be promptly referred to a neurologist to rule 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
84/Protocol GA29144, Version 7out PML.  Following formal evaluation by a neurologist, further work -upmay include 
brain MRI performed with and wi thout contrast.  If PML cannot be ruled out ,the case will
be referred to an expert PML adjudication committee.  If there remains any suspi[INVESTIGATOR_808369], the PML adjudication committee may recommend performing a lumbar puncture 
with cerebrospi[INVESTIGATOR_872] (CSF) analysis for JCV by [CONTACT_954].  If JCV is detected, the patient 
should be treated as a PML case, permanently discontinued from study drug, and 
transferred to safety follow -up. 
Dosing with study treatments can be resumed only if PML has been ruled out 
(see Appendix 6for the Algorithm for Evaluation of PML).
After completing the Maintenance Phase, patients not enrolling in Part 1 (OLE) of 
Study GA29145 to receive treatment with open -label etrolizumab will enter the 1 2-week 
Safety Follow -Up Phase (see Appendix 2).  The PML assessment interview and 
neurologic examination are to be performed at Week 12of the safety follow -up.
Following the 12 -week safety follow -up, all patients will be requested to continue 
monitoring for PML for an additional 92 weeks by [CONTACT_808425] g in Part 2 (SM) of 
Study GA29145 , giving a total of [ADDRESS_1117351] dose of study 
medication.  No study drug will be administered to patients during Part 2 (SM).
[IP_ADDRESS] Electrocardiograms
ECGs will be performed during screening or prior to r andomization at W eek 0, W eek 16, 
and Week66(or Ea rly W ithdrawal Visit).
A 12-lead ECG with formal readings should be obtained for each patient from the same 
machine whenever possible.  To minimize variability, it is important patients be in a 
resting pos ition for 10minutes prior to each ECG evaluation.  Body position should be 
consistently maintained for each ECG evaluation to prevent changes in heart rate.  
Environmental distractions (e.g., television, radio, conversation) should be avoided 
during the pre-ECG resting period and during ECG recording.  ECGs should be obtained 
prior to any scheduled vital sign measurements and blood draws.
For safety monitoring purposes, the investigator or designee must review, sign, and date 
all ECG tracings.  Paper cop ies are to be kept as part of the patient's permanent study 
file at the site.  ECG outputs are to be stored at the site.
[IP_ADDRESS] Patient -Reported Outcomes
PROs ( , APQ and the loose stool frequency, abdominal pain, 
and general well -being components of the CDAI) will be collected to help characterize 
the patient -reported clinical profile of etrolizumab.  The instruments will be translated as 
required into the local language.
PRO data are collected electronically with the use of electronic P RO (ePRO) devices 
(i.e., e-diary and tablet).  The investigator staff will provide the patient with an e -diary 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
85/Protocol GA29144, Version 7and instructions for completing the PRO questionnaires electronically for those PROs 
that need to be completed outside of the clinic.  Patients w ill also be instructed to contact 
[CONTACT_808426] e -diary during 
screening or at any time during the study.  For instances when PROs are to be 
completed at the clinic, the patient will fill them out on a ta blet.
Review electronic data captured by [CONTACT_808427].  ePRO data is collected and assessed at visits as outlined 
below and noted in the Schedule of Assessments (see Appendix 1aand Appendix 1b). 
During screening, patie nts will be instructed on how to appropriately use and complete 
questions on the e- diary.  The signs and symptoms of CD, specifically, number of liquid 
or soft stools, abdominal pain, and general well- being, must be recorded daily 
throughout the study, i ncluding the screening period.  
To ensure instrument validity and that data standards meet Health Authority 
requirements, the PROs completed at the sites ( ) must be administered 
at the investigational site prior to the completion of other non -PRO assessments and 
before the patient receives any disease -status information or study drug during that visit.  
Crohn’s Disease A ctivity Index 
The CDAI quantifies the signs and symptoms of patients with CD (see Appendix 9).  The 
CDAI consists of eight factors; each factor is summed after adjustment with a weighting 
factor (Best et al. 1979 ).  The components of the CDAI include number of liquid or soft 
stools, abdominal pain, general well- being, presence of complications, use of Lomotil
(diphenoxylate/atropi[INVESTIGATOR_050]) or other opi[INVESTIGATOR_22032], presence of an abdominal mass, 
hematocrit, and percentage deviation from standard weight .  Of the eight factors of the 
CDAI, three are patient reported (number of liquid or soft stools, abdominal pain, and 
general well-being), four are based on physician assessment (presence of complications, 
use of Lomo tilor other opi[INVESTIGATOR_22032], presence of abdominal mass, and 
percentage of deviation from standard weight, which is based on the patient’s weight at 
the visit), and one factor is based on a blood test (hematocrit).   Patients are to report 
their abdo minal pain severity, loose- stool frequency, and general well -being on the 
e-diary on a daily basis.  The weighted sum of the average scores over 7 days is 
calculated for the PRO component of the CDAI score. The Bristol Stool Scale is 
provided to patients as a reference for determining loose stools (Types 6 and 7 on the 
Bristol Stool Scale; see Appendix 8).  Because the ileocolonoscopy preparations can 
interfere with the assessment of other clinical parameters, e -diary entries used to 
calculate the complete CDAI should not correspond to day(s) of bowel preparation, 
endoscopy, or the day after endoscopy.
Stool Frequency  and A bdominal Pain
Twopatient reported factors will be evaluated:  the frequency of liquid or soft stools and 
abdominal pain.  The score is calculated using the unweighted mean number of 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
87/Protocol GA29144, Version 7 
 
 
[IP_ADDRESS] Study Drug and Compliance
During the Induction Phase, patients will receive placebo, low -dose etrolizumab, or 
high-dose etrolizumab at W eeks 0, 2, 4, 8, and 12.  
During the Maintenance Phase, patients will receive placebo or low -dose etrolizumab at 
Weeks16,20, 24, 28, 32, 36, 40, 44, 48, [ADDRESS_1117352] the option to return to the investigational site or to self -administer/have a 
caregiver administer their subsequent doses at home within 3days of their scheduled 
dose unless a PK blood draw is planned (see Appendix 1band Appendix 3), in which 
case the dose must be administered after the blood draw on the day of visit or within [ADDRESS_1117353] the location of each injection and whether the injection was 
successfully administered following each home dose a dministration.
[IP_ADDRESS] Concomitant Medications
Concomitant medications are monitored beginning at the Screening Phase and revi ewed 
at each study visit, including any unscheduled visit(s).
[IP_ADDRESS] Adverse Events
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
procedures s uch as biopsy sample collection, discontinuation of medications) should be 
reported.  All adverse events will be monitored beginning at W eek0and will be reviewed 
at each study visit including any unscheduled visit(s).  See Section 5.2.1 for more details 
about adverse events and safety reporting.
[IP_ADDRESS] Tuberculosis Screening
Patients will be evaluated for TB at screening.  The [COMPANY_003] skin test and 
QuantiFERON-TB Gold are acceptable screening assays for latent Mycobacterium TB 
infection.
If a negative TB screening test result has been documented within [ADDRESS_1117354] reaction is considered 5mm.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
88/Protocol GA29144, Version 7Patients with a history of bacille Calmette -Guérin vaccination should be screened only 
with use of the QuantiFERON-TB Gold test.  
An indeterminate QuantiFERON-TB Gold test should either be repeated or followed up 
with a [COMPANY_003] tuberculin skin test in patients who are eligible to have a [COMPANY_003] tuberculin skin 
test performed.
The patient is considered to have a positive diagnostic test for TB if at least one of 
the following circumstances applies:
Positive QuantiFERON-TB Gold test
Two successive indeterminate QuantiFERON-TB Gold tests
Positive [COMPANY_003] tuberculin skin test
The patient is considered to have a negative diagnostic test for TB if at least one of 
the following circumstances applies:
Negative QuantiFERON-TB Gold test
Negative [COMPANY_003] tuberculin skin test
If a negative TB screening test has been documented within [ADDRESS_1117355] is needed.
[IP_ADDRESS] Chest X -ray
A chest X -ray will be conducted at screening and used to detect TB.  If a ches t X-ray has 
been documented within the previous [ADDRESS_1117356] X- ray is required.
[IP_ADDRESS] Pregnancy  Testing
All women of childbearing potential (including those who have had a tubal ligation) will 
have a serum pregnancy test at screening.
Urine pregnancy tests are performed at Weeks 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 
44, 48, 52, 56, 60, and 64 (o r Early W ithdrawal visit).  A urine pregnancy test is also 
performed at W eek 12 (or Early Withdrawal visit) of the [ADDRESS_1117357].
[IP_ADDRESS] Laboratory  Assessments
Laboratory assessments are performed at Screening, Induction, and Maintenance as 
indicated on the Schedule of Assessments (see Appendix 1aand Appendix 1band 
described below ). 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
89/Protocol GA29144, Version 7Guidelines for Laboratory  Assessments
General G uidelines:
All laboratory investigations will be sent to one or more central laboratories for 
analysis. 
Laboratory sample handling and shipment are outlined in the Study Manual.
Screening Phase Guidelines
All patient laboratory samples required for screening should be collected early in the 
screening period to allow time for laboratory results to be available for review by [CONTACT_808428]. 
Patients may be re -screened for laboratory inclusion and exclusion criteria up to two 
times, with the exception of C.difficile infection.  Patients who are classified as 
screen failures because of the presence of C.difficile infection may be re -screened
[ADDRESS_1117358] time, he or she becomes a screen 
failure.
Laboratory testing repeated because of administrative or technical issues 
(e.g., breakage of a sample vial during transit to the central laboratory or 
degradation of a sample during transportation) is not considered re -screening.
Laboratory samples should be drawn prior to the initiation of bowel preparation.
Test results that are borderline or indeterminate may be repeated within the 
Screening Phase.
Induction and Maintenance Phase Guidelines
Ondays of study drug administration, take laboratory samples before the 
administration of study drug.
Laboratory  assessments include the following:
Hematology and Clinical Chemistry
Hematology (hemoglobin, hematocrit, platelet count, RBC count , WBC count, 
absolute differential count [neutrophils, eosinophils, lymphocytes, monocytes, 
basophils, other cells] ,	mean corpuscular volume, mean corpuscular hemoglobin, 
mean corpuscular hemoglobin concentration, and RBC distribution width)
Collected duri ng screening and at Weeks 0, 10 (hematocrit only), 14, 24, 28 
(hematocrit only), 32 (hematocrit only), 44, 56 (hematocrit only), and 66 (or 
Early W ithdrawal visit)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
90/Protocol GA29144, Version 7Serum chemistries including liver function test (sodium , potassium, chloride, 
bicarbonate, glucose, blood urea nitrogen, creatinine, calcium, phosphorus, 
magnesium, total and direct bilirubin, total protein, albumin, alanine 
aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline 
phosphatase, creatine phosphokinase, and uri c acid)
Collected during screening and at Weeks 0, 14, 24, 44, and 66 (or Early 
Withdrawal visit)
 
HIV, hepatitis B, and hepatitis C 
Collected during screening only
Patients who are HBV antibody positive should have HBV DNA measured at 
Weeks 14, 24, 32, 44, 56, and 66.
JCV antibodies
A blood sample to test for antibodies to JCV will be taken and stored for 
possible later assessment of how widespread the JCV infection is in the study 
population.  Sample testing for the presence of JCV antibodies is not helpful in 
predicting risk for PML or for evaluating neurologic symptoms.  The sample 
may be tested if there is a strong belief that this information will be helpful in 
managing a patient's condition.
 
 
 
 
 
 
Anti-Therapeutic Antibody Assessments
Anti-therapeutic antibody (ATA) serum samples will be collected for the detection 
and characterization of antibodies against etrolizumab in all patients.  Samples are 
analyzed using validated assays.  For ATA samples wi thout matched PK 
determinations, etrolizumab concentrations may be measured for the purpose of 
helpi[INVESTIGATOR_808370].   
. ATA samples are to be collected before dosing at W eeks 0, 4, 14, 24 , 
32, 44, 66 (or Early W ithdrawal visit) ,and unscheduled visit.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
91/Protocol GA29144, Version 7Population Pharmacokinetic Assessments
PK serum samples will be collected for determination of etrolizumab concentrations 
and are to be analyzed using a validated assay .  PK serum samples ar e to be 
collected before dosing (if specified sample collection timepoint is a dosing date) at 
Weeks0, 10, 14, 16, 24, 28, 32, 44, and 66 (or Early W ithdrawal visit).
Optional Whole-Blood DNA 
Whole-blood DNA may be collected and processed for genetic analysis from 
consenting patients at randomization.  These samples may be assayed for mRNA 
expression, genetic variation, and other biomarker(s) to predict response or toxicity 
to etrolizumab.
Optional PK/PD Substudy Assessments
The following samples will be collected only from all patients consenting to 
participate in the PK/PD substudy (see Appendix 3for additional substudy sampling 
schedule) in addition to the PK/PD samples collected from all patients in the main 
study. 
Receptor Occupancy: Whole -blood samples will be collected during screening, 
Day 1 before dosing, Days 3, 4, or 5 (only one of these days), and at W eeks 4, 
10, 14, 16, 20, 24, 28 (all predose) 
PK serum samples will be collected on Days 3, 4 , or 5 (only one of these days), 
Weeks 2, 4, 12 (all predose), D ays 3, 4, or [ADDRESS_1117359] W eek 1 2 dose (only one of 
these days), and predose on Week20 (or E arly Withdrawal visit ).
Substudy PDserum samples will be collected at D ays 3, 4 , or 5 (only one of 
these days) and at predose on Weeks 2, 4, and 20(or Early W ithdrawal visit).
Urinalysis
Collected during screening and at Week 0 (befor e the first dose of study drug)
Stool Samp les
 
 
Collected during screening and at Weeks 14, 66, and early withdrawal prior to the 
prep for the ileocolonoscopy
 
Biopsies
Collected during screening and at Weeks 14 and 66 (see Section [IP_ADDRESS] )

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
92/Protocol GA29144, Version [IP_ADDRESS] Samples for [COMPANY_002] Clinical Repository
Overview  of the [COMPANY_002] Clinical Repository
The [COMPANY_002] Clinical Repository (RCR) is a centrally administ ered group of facilities for 
the long -term storage of human biologic specimens, including body fluids, solid tissues, 
and derivatives thereof (e.g., DNA, RNA, proteins, peptides).  The collection and 
analysis of RCR specimens facilitates the rational desig n of new pharmaceutical agents 
and the development of diagnostic tests, which may allow for individualized drug therapy 
for patients in the future.
Specimens for the RCR will be collected from patients who give specific consent to 
participate in this optional research.  In addition, any residual biopsy and blood samples 
for biomarkers left over at the end of the study and analyses will be transferred to the 
RCR for consenting patients.  RCR specimens are used to achieve the following 
objectives:
To study th e association of biomarkers with efficacy, adverse events, or disease 
progression
To increase knowledge and understanding of disease biology
To study drug response, including drug effects and the processes of drug absorption 
and disposition
To develop biom arker or diagnostic assays and establish the performance 
characteristics of these assays
Approval by [CONTACT_808429]'s Institutional 
Review Board or Ethics Committee (IRB/EC) and, if applicable, an appropriate 
regulatory body.  If a site has not been granted approval for RCR sampling, this section 
of the protocol will no t be applicable at that site.
Sample Collection
Whole blood (DNA) will be collected for genetic analysis from consenting patients (RCR 
ICF).
Samples obtained  but not utilized or 
not entirely consumed ar e to be transferred to the RCR.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
93/Protocol GA29144, Version 7Specimen types include:

  
Ileum/Colon biopsy samples (formalin and stabilization buffer [such as RNAlater or a 
similar buffer]; see for specific collection timepoints)
Stool sample s
Potential applications of RCR samples include these samples being assayed for mRNA 
expression, genetic variation, histology, and other biomarker(s) that change or predict 
response or toxicity to etrolizumab.
For all samples, dates of consent should be recorded on the associated RCR page of
the eCRF.  For sampling procedures, storage conditions, and shipment instructions, see 
the Reference Manual or Laboratory Manual.
RCR specimens are destroyed no later than 15 years after the date of final closure of t he 
associated clinical database.  The RCR storage period is in accordance with the 
IRB/ECapproved Informed Consent Form and applicable laws (e.g., health authority 
requirements).
The dynamic biomarker specimens are subject to the confidentiality standards described 
in Section 8.4.  The genetic biomarker specimens undergo additional processes to 
ensure confidentiality, as described belo w.
Confidentiality
Given the sensitive nature of genetic data, [COMPANY_002] has implemented additional processes 
to ensure patient confidentiality for RCR specimens and associated data.  Upon receipt 
by [CONTACT_25736], each specimen is "double -coded" by [CONTACT_808430] a new independent number.  Data generated from the use of these 
specimens and all clinical data transferred from the clinical database and considered 
relevant are also labeled with this same independent number.  A "linking key" between 
the patient identification number and this new independent number is stored in a secure 
database system.  Access to the linking key is restricted to authorized individuals and is 
monitored by [CONTACT_25738].  Legitimate operational reasons for ac cessing the linking key are 
documented in a standard operating procedure.  Access to the linking key for any other 
reason requires written approval from the Pharma Repository Governance Committee 
and [COMPANY_002]'s Legal Department, as applicable.
Data generated from RCR specimens must be available for inspection upon request by 
[CONTACT_70145], 
representatives, and collaborators, as appropriate.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
94/Protocol GA29144, Version 7Patient medical information associated with RCR specimens i s confidential and may be 
disclosed to third parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Data derived f rom RCR specimen analysis on individual patients will generally not be 
provided to study investigators.  The aggregate results of any research conducted using 
RCR specimens will be available in accordance with the effective [COMPANY_002] policy on study 
data publi cation.
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RCR data will become and remain the exclusive and unburdened property 
of [COMPANY_002], except where agreed otherwise.
Consent to Participate in the [COMPANY_002] Clinical Repository
A separate signature [CONTACT_808443].  The 
investigator or authorized designee will explain to each patient the objectives, methods, 
and potential hazards of participation in the RCR.  Patients will be told that they are free 
to refuse to participate and may withdraw their specimens at any time, and for any 
reason, during the storage period.  A separate, specific signature [CONTACT_808444] a patient's agreement to provide optional RCR specimens .  Patients who 
decline to participate do not provide a separate signature.
The investigator should document whether the patient has given consent to participate 
by [CONTACT_26806].
In the event of an RCR participan t's death or loss of competence, the participant's 
specimens and data will continue to be used as part of the RCR research.
Withdrawal from the [COMPANY_002] Clinical Repository
Patients who give consent to provide RCR specimens have the right to withdraw their 
specimens from the RCR at any time for any reason.  If a patient wishes to withdraw 
consent to the testing of his or her specimens, the investigator must inform the Medical 
Monitor in writing of the patient's wishes with use of the RCR Subject Withdrawal For m 
and, if the trial is ongoing, must enter the date of withdrawal on the RCR Research 
Sample W ithdrawal of Informed Consent eCRF.  The patient will be provided with 
instructions on how to withdraw consent after the trial is closed.  A patient's withdrawal 
from Study GA29144 does not, by [CONTACT_5071], constitute withdrawal of specimens from the 
RCR.  Likewise, a patient's withdrawal from the RCR does not constitute withdrawal from 
Study GA29144.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
95/Protocol GA29144, Version 7Monitoring and Oversight
RCR specimens will be tracked in a manner co nsistent with Good Clinical Practice by a 
quality -controlled, auditable, and appropriately validated laboratory information 
management system to ensure compliance with data confidentiality as well as 
adherence to authorized use of specimens as specified in this protocol and in the 
Informed Consent Form.  [COMPANY_002] monitors and auditors will have direct access to 
appropriate parts of records relating to patient participation in the RCR for the purposes 
of verifying the data provided to [COMPANY_002].  The site will perm it monitoring, audits, IRB/EC 
review, and health authority inspections by [CONTACT_26807].
4.5.[ADDRESS_1117360] dose of 
study drug for patients not enrolling in Part 1 (OLE) of Study GA29145 (see Appendix 2).  
Patients are assessed at [ADDRESS_1117361] dose of study drug (i.e., the W eek6 telephone visit should take place [ADDRESS_1117362] dose of study drug).  Adverse events should be followed as 
outlined in Section 5.3.
Following the 12 -week safety monitoring period, patients will be asked to enroll in Part 2
(SM) of Study GA29145, where they are monitored for PML for an additional 92 weeks.  
Patients enrolling in Part 2 (SM) for the extended PML monitoring will NOT receive 
treatment with open- label etrolizumab.  During the extended PML follow -up period in
Part 2 (SM) , patients will have telephone visits every [ADDRESS_1117363] dose 
of study drug.
Patients who discontinue from the study will be asked to return to the clinic within 
4weeks ( 3days) af ter the last dose of study drug or last scheduled visit for an early 
withdrawal visit (see Appendix 2).
See for the Schedule of Assessments performed at the study completion/early 
withdrawal from treatment visit.
After the study completion, adverse events should be followed as outlined in 
Sections 5.4and 5.5.  See Appendix 2for the schedule of 12 -week safety follow -up 
assessments.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
97/Protocol GA29144, Version 74.[ADDRESS_1117364] the right to voluntarily 
discontinue study drug or withdraw from the study at any time for any reason.  Reasons 
for discontinuation of study drug or withdrawal from the study may include ,but are not 
limited to :
Patient withdrawal of consent at any time
Any medical condition the investigator or Sponsor det ermines may jeopardize the 
patient’s safety if he or she continues in the study
The investigator or Sponsor determines it is in the best interest of the patient
Patient non -compliance, specifically defined as missing scheduled visits or 
non-adherence with background medications
[IP_ADDRESS] Withdrawal from Study
Every effort should be made to obtain information on patients who withdraw from the 
study.  T he primary reason for withdrawal from the study should be documented on the 
appropriate eCRF.  Patients will not be f ollowed for any reason after withdrawing 
consent.  Patients who withdraw from the study will not be replaced.
4.6.[ADDRESS_1117365] discontinue study drug if they experience any of the following:
Pregnancy
Anaphylaxis or other sever e hypersensitivity reaction
Develop colonic mucosal dysplasia
Malignancy (with the exception of local , resected basal or squamous cell carcinoma 
of the skin) or cervical Pap test with AIS, HSIL, or CIN of Grade 1
Specific serious infection (see Section [IP_ADDRESS] for details on serious infection):
Any patient who experiences a de novo or reactivated serious viral infection, 
such as HBV, H CV, HIV, should discontinue study medication.
Any patient who de velops life- threatening infecti onsduring the st udy should 
discontinue study medication.
Any medication for rescue outside defined limits of the protocol (see Section 4.4.5 )
Patients who discontinue study drug prematurely for the reasons listed above will be 
asked to return to the clinic for an ear ly withdrawal visit, which should take place within 
4weeks after the last dose (see Section 4.5.4 and Section 4.5.5 ) and will continue to 
undergo safety follow -up assessments for 12 weeks within this study.  Patients should 
then enroll in Part 2 (SM) of Study GA29145 for 92 weeks of monitoring for PML 
(see Section 4.5.8 ).  The primary reason for premature study drug discontinuation 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
98/Protocol GA29144, Version 7should be documented on the appropriate eCRF.  Patients who discontinue study drug 
prematurely will not be replaced.
4.6.3 Study and Site Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not l imited to:
The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients
Patient enrollment is unsatisfactory
The Sponsor will notify the investigator if the study is placed on hold or if the Sponsor 
decides to discontinue the study or development program.
The Sponsor has the right to replace a site at any time.  Reasons for replacing a site 
may include ,but are not limited to:
Excessively slow recruitment
Poor protocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice
5. ASSESSMENT OF SA FETY
5.1 SAFETY PLA N
The safety plan for this study is designed to ensure patient safety and mitigate potenti al 
risks. The principles of the safety plan include education of investigators and patients 
regarding all identified and potential safety risks, specific eligibility criteria to screen out 
at-risk patients, monitoring to ensure timely identification and m anagement of a safety 
event, and management strategy such as guidelines for treating an event and for 
withholding or discontinuing study treatment, as appropriate.  These principles are to be 
applied for all safety risks in the clinical program.  
5.1.1 Potential Risks for Etrolizumab
Thepotential and/or hypothetical risks for etrolizumab are based on its mechanism of 
action, available nonclinical and clinical data, data from other anti -integrin drugs, and 
general risks associated with biologic agents. 
Investi gators should always refer to the Etrolizumab Investigator's Brochure (Section 6) 
for a complete summary of safety information.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
99/Protocol GA29144, Version 7Important potential risks for etrolizumab include :
Infections, in particular, serious or life- threatening infections, such as:
PML 
Other serious infections (e.g., gastrointestinal, opportunistic)
Hypersensitivity reactions, in particular:
Anaphylactic, anaphylactoid reactions 
Other systemic hypersensitivity reactions
Hepatic effects
Local injection- site reactions
Malignancies
Immunogenicity
Decreased effectiveness of immunization
[IP_ADDRESS] Serious Infections 
[IP_ADDRESS].1 Progressive Multifocal Leukoencephalopathy 
Background
PML is a potentially fatal neurological condition linked to reactivation of a polyomavirus 
(JCV) and active viral replication in the brain.  Cases of PML have been reported in 
patients with CD and multiple sclerosis who received concomitant treatment with the 
anti-4 integrin natalizumab and immunosuppressives.  Integrin 41, which is inhibited 
by [CONTACT_25763], is a pleiotropic integrin that is believed to facilitate T cell migration into 
the CNS.  Inhibition of integrin 41 is thought to reduce (CNS) immune surveillance 
and facilitate development of PML.
Etrolizumab targets cells expressing the 7 integrin ( 47 and E7 cells) and not 
41cells.  Despi[INVESTIGATOR_335487] a specific role of 
7integrins in leukocyte homing to the CNS and given the observation of PML risk with 
natalizumab, the Sponsor will continue to conduct extensive risk -monitoring procedures 
during this study.  There have been no cases of PML in patients treated with etrolizumab.
Screening, Patient Selection, and PML Education
No known interventions can reliably prevent or treat PML if it occurs; therefore, it is 
important to exclude patients with a perceived higher baseline risk for PML, such as 
patients who have received natalizumab, efalizumab, rituximab, B or T cell depleting 
agents (e.g., alemtuzumab or visilizumab), with the exception of AZA and 6- MP[or 
equivalent] ,cyclosporine, tacrolimus, sirolimus, or MMF.  Patients with a history of PML 
or neurological symptoms where suspected PML has not been ruled out are not eligible 
for this study (see Section 4.1.2 ).
A blood sample to test for antibodies to JCV will be taken and stored for possible later 
assessment of how widespread the JCV infection is in the study population.  Sample 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
100/Protocol GA29144, Version 7testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for 
evaluating neurologic symptoms.  The sample may be tested if there is a strong belief 
that this information will be helpful in managing a patient's condition.
Study site personnel and patient participants should be educated regarding the signs
and symptoms of PML.  Patients and partners/caregivers should be issued with alert 
cards to remind them of these and to advise them to contact [CONTACT_808431].
See Appendix 5for details of assessments regarding PML.
PML Monitoring
During the study, patients should be closely monitored for any signs and symptoms of 
PML via regular subjective and objective tests employing the use of checklists to assess 
the patient’s mental and neurological status.  These will comprise regular neurologic 
examinations ( including evaluation of cranial nerves, motor and sensory function, 
coordination, and mental status) as per the Schedule of Assessments 
(see Appendix 1a).  The PML Subjective Checklist (symptom assessment) and the PML 
Objective Checklist (neurologic evaluation) will be administered ( Appendix 5; Worksheet 
for the PML Neurologic Examination).
If a patient has a positive finding on the PML Subjective Checklist that is accompanied 
by a positive finding on the PML Objective Checklist or if there is strong clinical suspi[INVESTIGATOR_808371] P ML, the event should be expeditiously reported to the sponsor as adverse events of 
special interest or serious adverse events, as appropriate, within 24 hours 
(see Section [IP_ADDRESS].1 and Appendix 6for the Algorithm for Evaluation of PML).  
If PML is suspected, dosing with study drug for that patient will be suspended and the 
patient should be promptly referred to a neurologist.  Following formal evaluation by a 
neurologist, if PML cannot be ruled out, the case will be referred to an expert PML 
adjudication committee for further work -up, which may include brain MRI with and 
without contrast.  If there remains any suspi[INVESTIGATOR_335482], the PML adjudication 
committee may recommend performing a lumbar puncture with CSF analysis for JCV 
DNA by [CONTACT_954].  If JCV DNA is detected, the patient should be treated as a PML case and 
the patient should permanently discontinue study drug and enter safety follow -up.  
Dosing with study drug can only be resumed in patients where PML has been ruled out.  
Refer to Appendix 6for the Algorithm for Evaluation of PML.
PML Treatment
There is no known effective treatment for PML.  Plasmapheresis has been employed in 
some patients in an effort to promote clearance of a suspected causative agent 
(Tan etal. 2011 ).  If an event of PML occurs, subsequent management of PML will be at 
the direction of the consulting neurologist. 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
101/Protocol GA29144, Version 7Additional information for the management of this potential risk is provided in Appendix 5
(Worksheet for the PML Neurologic Examination) and Append ix6(Algorithm for the 
Evaluation of PML).
[IP_ADDRESS].[ADDRESS_1117366] not shown an increased risk of serious infections with 
etrolizumab.  In the Phase II EUCALYPTUS study, serious infections were reported in 
2.3% of patients who received placebo versus none in the etrolizumab -treated patients.  
Nonetheless, serious infections are a potential risk because of the mechanism of action 
of etrolizumab, which blocks trafficking of gut -selective lymphocytes.
Patient Selection
Patients who experienced a life -threatening infection or a de novo or reactivated serious 
viral infection, such as HBV, HCV, or HIV, are not eligible for this study 
(see Section 4.1.2 ).  
Patients who have an ongoing serious infection event should not receive study drug until 
the event has completely resolved and treatment with anti -infective medications has 
been completed.  Patients with hepatitis B infection who test positive only for core 
antibody (anti -HBc) and test negative for HBV DNA test are eligible for the study; 
however, these patients must underg o periodic monitoring for HBV DNA during the study.
Patients with active or latent TB (not including patients who have prior vaccination with 
Bacille Calmette- Guerin [BCG]) will be excluded from the study.  Any 
immunosuppressed patient with a strong suspic ion of TB exposure and no prior 
vaccination with BCG should be considered at risk for having latent TB infection.
Patients at risk for TB exposure include:
Patients who have household contact [CONTACT_4490] a person with active TB
Patients living in areas with high incidence of TB
Patients who frequently visit areas with high prevalence of active TB
Patients who meet these criteria should be evaluated per local practice to exclude 
latent TB.
Education, Monitoring, and Management
Patients should be monitored closely for serious infections during the study.  Patients 
and study staff should be informed of the possibility of increased susceptibility to 
infectious pathogens.  Investigators will be encouraged to promptly evaluate and 
aggressively treat any signs and symptoms consistent with an infection.  
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
102/Protocol GA29144, Version 7Patients who experience a serious infection event should not receive further study drug 
until the event has completely resolved and treatment with anti- infective medications has 
been completed.  All efforts should be made to identify the infectious agent.  
Patients who develop life -threatening infections, including de novo or reactivated serious 
viral infection, such as HBV, HCV, HIV, during the study should discontinue study drug.  
[IP_ADDRESS] Hypersensitivity  Reactions
Background
In completed Phase I/II clinical trials of etrolizumab in ulcerative colitis, one serious 
adverse event of hypersensitivity (Grade 2) has been reported.  No anaphylactic, 
anaphylactoid, or severe hypersensitivity reactions were observed; however, 
anaphylax is and hypersensitivity reactions will be closely monitored during the study.  
Patient Selection
Patients who have a history of moderate or severe allergic or anaphylactic/anaphylactoid 
reactions to chimeric, human, or humanized antibodies, fusion proteins, or murine 
proteins or hypersensitivity to etrolizumab (active drug substance) or any of the 
excipi[INVESTIGATOR_840] (L- histidine, L- arginine, succinic acid, polysorbate 20) are not eligible for 
thisstudy. 
Education, Monitoring, and Management
The first four injections should be administered in the clinic in order to monitor for any 
possible hypersensitivity reactions.  After each of these four injections, the patient must 
be monitored for 60 minutes.  Medicinal products for the treatment of hypersensitivity 
reactions (e.g., epi[INVESTIGATOR_238], antihistamines, and glucocorticoids) must be available for 
immediate use in the clinic for the event of an allergic reaction during administration of 
the study drug.  Resuscitation equipment should also be available.  
Patient s should be instructed to recognize the symptoms of any anaphylactic, 
anaphylactoid, or hypersensitivity reaction and to contact a HCP or seek immediate care 
in case of any such symptoms.  Patients are to be provided with alert cards to remind 
them and a c aregiver or partner of the above.
If the patient develops any systemic hypersensitivity or anaphylactic or anaphylactoid 
reaction, the event should be expeditiously reported to the Sponsor as an adverse event 
of special interest or serious adverse event, a s appropriate, within [ADDRESS_1117367] be discontinued permanently. 
Refer to Appendix 7(Clinical Criteria for Diagnosis Anaphylaxis).
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
103/Protocol GA29144, Version [IP_ADDRESS] Hepatic Effects
Background
Liver toxicity has been reported with other drugs that target 4 integrins (natalizumab) 
and 47 integrins (vedolizumab).  Therefore, this potential risk is being monitored in all 
etrolizumab studies.  In nonclinical chronic toxicology studies, no abnormalities 
indicating liver toxicity with etrolizumab were observed.  The risk in humans is currentl y 
unknown.
Patient Selection
Patients with significant liver function test abnormalities should be excluded from the 
etrolizumab clinical studies (see Section 4.1.2 ).
Education, Monitoring, and Management
Patients should receive guidance on reporting liver problems if they occur.  Liver function 
tests should continue to be monitored according to the schedule of assessments and as 
clinically indicated. Significant hepatic events should be evaluated promptly and 
managed accordingly.
[IP_ADDRESS] Local Injection -Site Reactions
Background
A local injection- site reaction is any local reaction occurring at the site of injection 
following study drug administration.  In completed Phase I/II trials, injection -site reactions 
were reported at a rate of 10%, all of which were of mild intensity.
Monitoring
In the clinic setting, patients should be monitored for signs of injection -site reactions in 
the period immediately following injections.  Patients should be given guidance on 
reporting injection- site reactions when administering drug at home or after the patient 
leaves the clinic.
[IP_ADDRESS] Malignancies
Background
There has been no evidence for increased incidence of malignancy in completed 
Phase I/II trials and nonclinical studies to date.  Nonetheless, given the elevated risk of 
malignancy in this patien t population a priori, the trial includes selection criteria and 
additional information to minimize any hypothetical risk. 
Patient Selection
Patients who have a history of cancer within 5 years prior to screening (with the 
exception of local resected basal or squamous cell carcinoma of the skin), including AIS, 
HSIL, or CIN of Grade 1 or colonic dysplasia, are to be excluded from the study. 
Monitoring and Management
Investigators should remain vigilant for signs or symptoms of cancer in scheduled study 
assessments, including those of potential lymphoma.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
104/Protocol GA29144, Version 7Any signs or symptoms that could be suggestive of malignancy should be promptly and 
aggressively evaluated and reported to the Sponsor.  Incident hematologic abnormalities 
(e.g., new or worsening neutrope nia, anemia, thrombocytopenia, macrocytosis, or 
atypi[INVESTIGATOR_335489]) should be carefully evaluated.
Patients who develop a malignancy (with the exception of local resected basal or 
squamous cell carcinoma of the skin) or who develop AIS, HSIL, or CIN of Grade [ADDRESS_1117368] not receive additional doses of study drug.
[IP_ADDRESS] Immunogenicity
Background
As with administration of any exogenous pr otein, a potential exists for the development 
of ATAs.  Such antibodies can be neutralizing with potential for reducing therapeutic 
effect of the drug and/or sensitizing, with potential for allergic reactions.  On the basis of 
the clinical experience to date, approximately 5% of patients develop ATAs to 
etrolizumab; however, this has not been correlated with any efficacy or safety sequelae.
Monitoring
To assess for the potential development of immunogenicity, antibody samples will be 
obtained at baseline, a t regular intervals during treatment, and during the Safety 
Follow -Up Period (see Appendix 1a, Appendix 1b,and Appendix 2) and stored 
appropriately for further evaluation as needed.
[IP_ADDRESS] Decreased Effectiveness of Immunizations
Background
The effect of etrolizumab upon the efficacy of vaccinations is unknown. 
Patient Selection and Risk Mitigation
Patients who received a live attenuated vaccine within [ADDRESS_1117369] 5 half-lives (approximately 12 weeks) after final study drug 
administration.
5.1.2 Risks A ssociated with Worsening of Crohn’s D isease
The worsening of CD may result in the use of rescue therapi[INVESTIGATOR_014] .  In severe cases, 
worsening of CD may lead to hospi[INVESTIGATOR_808372].
At any time during the study, patients who have worsening of their CD will be permitted 
to receive additiona l therapy with steroids (i.e., IV, oral, or topi[INVESTIGATOR_2855]).  Addition of or 
increases in doses of immunosuppressants (i.e., AZA, 6 -MP, or MTX) will also be 
allowed in the Maintenance Phase if clinically indicated in the opi[INVESTIGATOR_2511] i nvestigator.
Rescue therapy with anti -TNF agents, cyclosporine, tacrolimus, sirolimus, MMF, 
natalizumab, vedolizumab, efalizumab, rituximab, other lymphocyte depleting agents, or 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
105/Protocol GA29144, Version 7other biological or investigational therapeutics will not be allowed in conjunction with 
etrolizumab because of the level of immunosuppression anticipated with the use of these 
agents.  Patients who receive any of these prohibited rescue therapi[INVESTIGATOR_808373].
See Section 4.5.6 ,Appendix 1a,and Appendix 1bforthe schedule of assessments to be 
performed in the event of worsening of CD, which may lead to an unscheduled visit.  
5.1.3 Data Monitoring Committee
An independen t Data Monitoring Committee (iDMC) will monitor safety and study
conduct on an ongoing basis.  Members of the iDMC will be external to the Sponsor and 
will follow a charter that outlines the iDMC roles and responsibilities.  The iDMC will 
meet at a minimum every 6 months (frequency adjustable as required) to review 
unblinded safety and study conduct data prepared by [CONTACT_760491] (IDCC).  If the iDMC deems a risk -benefit assessment necessary, the iDMC may 
also review unblinded effi cacy data.  The iDMC may recommend stoppi[INVESTIGATOR_760438].  However, the iDMC may not recommend stoppi[INVESTIGATOR_760439].
5.[ADDRESS_1117370], measurement of 
protocol -specified safety laboratory assessments, measurement of protocol -specified 
vital signs, and other protocol -specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.3.
5.2.1 Adverse Events
According to the International Council for Harmonisation (ICH) guideline for Good 
Clinical Practice, an adverse event is any untoward medical occurrence in a clinical 
investigation subject administered a pharmaceutical product, regardless of causal 
attribution.  An adverse event can be any of the following:
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product
Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition), except as described in 
Sections [IP_ADDRESS] and [IP_ADDRESS]
Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
106/Protocol GA29144, Version 7Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug
Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies)
5.2.2 Serious A dverse Events (Immediately  Reportable to the 
Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:
Fatal (i.e., the adverse event actually causes or leads to death)
Life threatening (i.e., the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)
This does not include any adverse event that had it occurred in a m ore severe 
form or was allowed to continue might have caused death.
Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS])
Results in p ersistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient’s ability to conduct normal life 
functions)
Congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug
Significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)
The terms "severe" and "serious" are not synonymous.  Severity refers to t he intensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to National 
Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] criteria; 
see Section 5.2.7); the event itself may be of relatively minor medical significance (such 
as severe headache without any further findings).
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.
The investigator must report serious adverse events to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.3.2 for reporting 
instructions).
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
107/Protocol GA29144, Version 75.2.[ADDRESS_1117371] (Immediately  Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by [CONTACT_808432] (i.e., no more than 24 hours after learning of the event; 
seeSection 5.3.2 for reporting instructions).  Adverse events of special interest for this 
study include the following:
Cases of potential drug- induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined as 
defined by [CONTACT_25742]’s law (see Section [IP_ADDRESS] ). 
Suspected transmission of an infectious agent by [CONTACT_5257] , as defined below:
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent. A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal product. This term 
applies only when a contamination of the study drug is suspected.
Adverse events of special interest specific to etrolizumab:
Systemic hypersensitivity reactions and anaphylactic and ana phylactoid 
reactions (see Section [IP_ADDRESS] and Sampson’s Criteria in Appendix 7)
Neurological signs, symptoms, and adverse events that may suggest possible 
PML, on the basis of a positive finding on the PML Subjective Checklist that is 
accompanied by a positive finding o n the PML Objective Checklist or if there is 
strong clinical suspi[INVESTIGATOR_335482] (see Appendix 5and Section [IP_ADDRESS].1)
5.2.4 Methods and Timing for Capturing and A ssessing 
Safety Parameters
The investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.3, 5.4, and 5.5. 
The investigator is also responsible for reporting medical device complaints 
(see Section 5.3.4 ).
Foreach adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 forseriousness criteria), severity 
(see Section 5.2.7 ), and causality (see Section 5.2.8 ).
5.2.[ADDRESS_1117372].  All 
adverse events, whether reported by [CONTACT_25743], will be 
recorded in the patient’s medical record and on the Adverse Event eCRF.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
108/Protocol GA29144, Version 7After informed consent has been obtained but prior to initiation of study  drug , only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
procedures such as biopsy sample collections, discontinuation of medications) should be 
reported (see Section 5.3.2 for instr uctions for reporting serious adverse events).
After initiation of study drug , all adverse events, regardless of relationship to study 
drug, will be reported until the patient completes his or her last study visit (in the Safety 
Follow -Up Phase). After the Safety Follow -Up Phase, the investigator should report any 
serious adverse events that are believed to be related to prior study drug treatment 
(see Section 5.5).  In addition, the Sponsor should be notified if the investigator becomes 
aware of any post -study events of confirmed or suspected PML, regardless of 
relationship to study drug, for up to 2 years after the patient’s last dose of study drug 
(see Section 5.5).
5.2.6 Eliciting A dverse Ev ent Information
A consistent methodology of non -directive questioning should be a dopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:
"How have you felt since your last clinic visit?"
"Have you had any new or changed health problems since you we re last here?" 
5.2.7 Assessment of Severity  of A dverse Events
The adverse event severity grading scale for the NCI CTCAE (v4.0) will be used for 
assessing adverse event severity.   Table 2 will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
109/Protocol GA29144, Version 7Table 2Adverse Event Severity Grading Scale for Events Not Specifically  
Listed in NCI CTCA E
Grade Severity
1 Mild; as ymptomatic or mild sy mptoms; clinical or diagnostic observations only; 
or intervention not indicated
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily livinga
3 Severe or medically significant, but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; or 
limiting self-care activities of daily livingb,c
4 Life-threatening consequences or urgent intervention indicatedd
5 Death related to adverse eventd
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events .
Note:  Based on the most recent version of NCI CTCAE (v4.0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
aInstrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_19640], using the telephone, managing money, etc.
bExamples of self -care activities o f daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by [CONTACT_25744].
cIf an event is assessed as a "significant medical event," it must be reported as a serious
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.[ADDRESS_1117373] be reported as serious adverse events (see Section 5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2 .
5.2.8 Assessment of Causality  of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to the study drug, indicating "yes" or "no" 
accordingly.  The following guidance should be taken into consideration as well as
Table 3 .
Temporal relationship of event onset to the initiation of study drug
Course of the event, considering especially the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)
Known association of the event with the study drug or with similar treatments
Known association of the event with the disease under study
Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event
Presence of nontreatment -related factors that are known to be associated with the 
occurrence of the event
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
110/Protocol GA29144, Version 7Table 3Causal A ttribution Guidance
Is the adverse event suspected to be caused by [CONTACT_25745], evidence, 
science -base d rationales, and clinical judgment?
YES There is a plausible temporal relationship between the onset of the adverse event and 
administration of the study drug, and the adverse event cannot be readily explained by 
[CONTACT_102]'s clinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the 
adverse event follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the study drug or dose 
reduction and, if applicable, reappears upon rec hallenge.
NO An adverse event will be considered related, unless it fulfills the criteria specified below .  
Evidence exists that the adverse event has an etiology other than the study drug 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, or 
concomitant medication); and/or the adverse event has no plausible temporal 
relationship to administration of the study drug (e.g., cancer diagnosed [ADDRESS_1117374] 
dose of study drug).
5.2.[ADDRESS_1117375] medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF; use of colloquialisms and abbreviations should be 
avoided.
Only one adverse event term should be recorded in the event field on the Adver se Event 
eCRF.
[IP_ADDRESS] Injection- Site Reactions
Local cutaneous adverse events that occur at or around the injection site during or within
24 hours following study drug injection should be captured as individual signs (e.g., 
erythema, induration/swelling at injection site) or symptoms (e.g., pain, pruritus at
injection site) rather than a diagnosis of allergic reaction or injection -site reaction.
[IP_ADDRESS] Diagnosis Versus Signs and Sy mptoms
For adverse events other than injection -site reactions (see Section [IP_ADDRESS] ), adiagnosis 
(if known) should be recorded on the Adverse Event eCRF rather than individual signs 
and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, 
and elevated transaminases).  However, if a constellation of signs and/or symptoms 
cannot be medically characterized as a single diagnosis or syndrome at the time of 
reporting, each individual event should be recorded on the Adverse Event eCRF.  If a 
diagn osis is subsequently established, all previously reported adverse events based on 
signs and symptoms should be nullified and replaced by [CONTACT_319078], with a starting date that corresponds to the starting date of t he 
first symptom of the eventual diagnosis.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
111/Protocol GA29144, Version [IP_ADDRESS] Adverse Events That A re Secondary  to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the ex ception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:
If vomiting results in m ild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.
If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.
If a severe gastrointestinal hemorrhage leads t o renal failure, both events should be 
reported separately on the eCRF.
If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.
If neutropenia is accompanied by [CONTACT_25747], both events should be r eported 
separately on the eCRF.
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
[IP_ADDRESS] Persistent or Recurrent A dverse Events
A persistent adverse event is one that extends continuously, without resolution, 
between patient evaluation timepoints.  Such events should be recorded only once on 
the Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded atthe time the event is first reported. If a persistent adverse event becomes 
more severe, the most extreme severity should be recorded on the Adverse Event eCRF.  
If the event becomes serious, it should be reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning that the eve nt became serious; see Section 5.3.2 for 
reporting instructions.  The Adverse Event eCRF should be updated by [CONTACT_70156] “non- serious” to “serious,” providing the date that the event became serious 
and completing all data fields related to serious adverse events.
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded 
separately on the Adverse Event eCRF.
[IP_ADDRESS] Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the foll owing criteria:
Accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
112/Protocol GA29144, Version 7Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
ora change in concomitant therapy
Clinically significant in the investigator’s judgment 
It is the investigator’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laborat ory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 ULN associated with cholestasis), only the 
diagnosis (i.e., choles tasis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating if the t est result is above or below the normal range (e.g., "elevated 
potassium," as opposed to "abnormal potassium").  If the laboratory abnormality can be 
characterized by a precise clinical term per standard definitions, the clinical term should 
be recorded as the adverse event.  For example, an elevated serum potassium level of 
7.0mEq/L should be recorded as "hyperkalemia."
Observations of the same clinically significant laboratory abnormality from visit to visit 
should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology 
changes.  The initial severity of the event should be recorded, and the severity or 
seriousness should be updated any time the event worsens.   Refer to Section [IP_ADDRESS].
[IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it meets any of the following criteria:
Accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Clinically significant in the inv estigator’s judgment
It is the investigator’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.
If a clin ically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF.
Observations of the same clinically significant vital sign abnor mality from visit to visit 
should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
113/Protocol GA29144, Version 7changes.  The initial severity of the event should be recorded, and the severity or 
seriousness should be updated any time the event worsens .  Refer to Section [IP_ADDRESS].
[IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3ULN) in combination with either an elevated 
total bil irubin ( 2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury
(asdefined by [CONTACT_25742]’s law).   Therefore, investigators must report as an adverse event the 
occu rrence of either of the following:
Treatment -emergent ALT or AST 3ULN in combination with total bilirubin 
2ULN 
Treatment -emergent ALT or AST 3ULN in combination with clinical jaundice
The most appropriate diagnosis or if a diagnosis cannot be established, the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section [IP_ADDRESS]) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or adverse event of special interest 
(see Section 5.3.2 ).
[IP_ADDRESS] Deaths
All deaths that occur during the protocol -specified adverse event reporting period 
(see Section 5.2.5 ), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.3.2 ).  
This includes death attributed to progression of CD.
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "unexplained death" should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes availabl e (e.g., after autopsy), “unexplained death" should
be replaced by [CONTACT_25749].   The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").
If the death is attributed to progression of CD, "CD progression" should be recorde d on 
the Adverse Event eCRF.  
[IP_ADDRESS] Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  W hen 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
114/Protocol GA29144, Version 7recording such events on the Adverse Event eCRF, it is important to convey the concept 
that t he preexisting condition has changed by [CONTACT_9672] 
(e.g., "more frequent headaches").
[IP_ADDRESS] Lack of Efficacy  or Worsening of Crohn’s Disease
Medical occurrences or symptoms of deterioration that are anticipated as part of CD 
should be recorded as an adverse event if judged by [CONTACT_319080].  W hen recording an unanticipated worsening CD on the Adverse Event eCRF, 
it is important to convey the concept that the condition has changed by [CONTACT_188215] (e.g., “accelerated CD” or “worsening of CD”).
[IP_ADDRESS] Hospi[INVESTIGATOR_26663] (i.e. in -patient admission to a hospi[INVESTIGATOR_307])
or prolonged hospi[INVESTIGATOR_25676] a serious adverse 
event (per the definition of serious adverse event in Section 5.2.2 ), except as outlined 
below.  The dur ation of hospi[INVESTIGATOR_335490].
An event that leads to hospi[INVESTIGATOR_26664] a serious adverse event:
Hospi[INVESTIGATOR_25678]
Planned hospi[INVESTIGATOR_33402] (e.g., for study drug administration 
or insertion of access device for study drug administration)
Hospi[INVESTIGATOR_272] a preexisting condition, provided that a ll of the following criteria 
are met:
The hospi[INVESTIGATOR_33403].
The patient has not suffered an adv erse event.
An event that leads to hospi[INVESTIGATOR_33405] a serious adverse event, but should be reported as an adverse event 
instead:
Hospi[INVESTIGATOR_808374]
[IP_ADDRESS] Adverse Events A ssociated with an Overdose or Error in Drug 
Administration
Study drug overdose is the accidental or intentional use of the drug in an amount higher 
than the dose being st udied.  An overdose or incorrect administration of study drug is not 
an adverse event unless it results in untoward medical effects.
Any study drug overdose or incorrect administration of study drug should be noted on 
the Study Drug Administration eCRF.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
116/Protocol GA29144, Version 7To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the Quintiles and [COMPANY_002] Genentech Medical Emergency List, escalate 
emergency medical calls, provide medical translation service (if necessary), connect the 
investigator with a Quintiles Medical Monitor, and track all calls.  Th e Emergency 
Medical Call Center Help Desk will be available [ADDRESS_1117376] information will be distributed to all investigators (see "Protocol 
Administrative and Contact [CONTACT_7171] & List of Investigators").
5.3.[ADDRESS_1117377]
[IP_ADDRESS] Events That Occur Prior to Study  Drug Initiation
After informed consent has been obtained but prior to the initiation of the study drug, 
only serious adverse events caused by a protocol -mandated intervention should be 
reported.  The Serious Adverse Event/Adverse Event of Special Interest Reporting Form 
provided to investigators should be c ompleted and submitted to the Sponsor or its 
designee immediately (i.e., no more than 24 hours after learning of the event), either by 
[CONTACT_294880].
[IP_ADDRESS] Events That Occur a fter Study  Drug Initiation
After initiation of the study drug, al l serious adverse events and adverse events of 
special interest will be reported until 12weeks after the last dose of study drug (i.e. ,until 
the end of the 12 -Week Safety Follow -up Phase).  Investigators should record all case 
details that can be gathered immediately (i.e., within 24 hours after learning of the event) 
on the Adverse Event eCRF and submit the report via the electronic data capture (EDC) 
system.  A report will be gener ated and sent to the Sponsor by [CONTACT_27950].
In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse 
Event of Special Interest Reporting Form provided to investigators should be completed 
and submitted to the Sponsor or its de signee immediately (i.e., no more than 24 hours 
after learning of the event), either by [CONTACT_40880].  Once the EDC system is 
available, all information will nee d tobe entered and submitted via the EDC system.
Instructions for reporting post -study adverse events are provided in Section 5.5. 
5.3.3 Reporting Requirements for Pregnancies
[IP_ADDRESS] Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study or within [ADDRESS_1117378] 
dose of study drug.  A paper Clinical Trial Pregnancy Reporting Form should be 
completed and submitted to the Sponsor or its designee immediately (i.e., no more than 
24hours after learning of the pregnancy), either by [CONTACT_808433] —F. Hoffmann -La [COMPANY_002] Ltd
117/Protocol GA29144, Version 7the form using the fax number or email address provided to investigators. Pregnancy 
should not be recorded on the Adverse Event eCRF.  The investigator should 
discontinue study drug and counsel the patient, discussing the risks of the pregnancy 
and the possible effects on the f etus.  Monitoring of the patient should continue until 
conclusion of the pregnancy.  Any serious adverse events associated with the 
pregnancy (e.g., an event in the fetus, an event in the mother during or after the 
pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the 
Adverse Event eCRF.   Inaddition, the investigator will submit a Clinical Trial Pregnancy 
Reporting Form when updated information on the course and outcome of the pregnancy 
becomes available.
[IP_ADDRESS] Pregnancies in Fe male Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
24weeks after the last dose of study drug.  A paper Clinical Trial Pregnancy Reporting 
Form should be completed and submitted to the Sponsor or its designee immediately 
(i.e., no more than 24 hours after learning of the pregnancy), either by [CONTACT_808434].   Attempts should be made to collect and report details of the course and 
outcome of any pregnancy in the partner of a male patient exposed to study drug.  When 
permitted by [CONTACT_779], t he pregnant partner would need to sign an Authorization for Use 
and Disclosure of Pregnancy Health Information to allow for follow -up on her pregnancy.
If the authorization has been signed, the investigator should submit a Clinical Trial 
Pregnancy Reporting Form when updated information o n the course and outcome of the 
pregnancy becomes available.   An investigator who is contact[CONTACT_249179], to support an informed d ecision in cooperation with the 
treating physician and/or obst etrician.
[IP_ADDRESS] Abortions
Any therapeutic or spontaneous abortion should be classified as a serious adverse event 
(because the Sponsor considers any such abortions to be medically significant events),
recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.3.2 ).
[IP_ADDRESS] Congenital A nomalies/Birth Defects
Any congenital anomaly or birth defect in a child born to a female patient exposed to 
study drug or partner of a male patient exposed to study dru g should be classified as a 
serious adverse event, recorded on the Adverse Event eCRF, and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; 
seeSection 5.3.2 ).
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
118/Protocol GA29144, Version 75.3.4 Reporting Requirements for Prefilled Sy ringe 
Complaints/Events
In this study, the prefilled syringe is considered a medical device. The investigator must 
report all medical device complaints to the Sponsor.  The investigator must docum ent as 
much information as possible on the PD103 IMP deviation form, including product batch 
number and expi[INVESTIGATOR_320], and forward the complaint form to the Sponsor (i.e., no 
more than 24 hours) after learning of the event (refer to the pharmacy manual f or further 
details). The PD103 IMP deviation form, together with pi[INVESTIGATOR_335475], 
should be sent to [EMAIL_261].
Where possible, the investigator will retrieve the PFS unit(s) involved in the complaint 
and attempt to return it to the Sponsor for further assessment, if necessary.
If the medical device results in an adverse event to the study patient, the event must be 
reported on the Adverse Event eCRF and submitted through the EDC system .If the 
event is serious, the Adverse Event eCRF must be completed and submitted 
immediately (i.e., no more than 24 hours after learning of the event), as outlined in 
Section 5.3.[ADDRESS_1117379] to follow -up, or the patient withdraws consent.  Every effort should be made to 
follow all serious adverse events considered to be related to study drug or trial -related 
procedures until a final outcome can be reported.
During the study period, resoluti on of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient’s medical record to facilitate source data 
verification.  If, after follow -up, return to baseline status or stabilization cannot be 
established, the adverse event outcome should be updated at Study Discontinuation.
All pregnancies reported during the study should be fol lowed until pregnancy outcome.
5.4.[ADDRESS_1117380], and pregnancies, the 
Sponsor or a designee may follow up by [CONTACT_756], fax, electronic mail, and/or a 
monitoring visit to obtain additional case details and outcome information (e.g., from 
hospi[INVESTIGATOR_8838], consultant reports, autopsy reports) in order to perform 
an indepe ndent medical assessment of the reported case.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
119/Protocol GA29144, Version 75.[ADDRESS_1117381] -STUDY ADVERSE E VENTS
Patients who enter the OLE- SM study (GA29145 Parts 1 and/or 2) should follow the 
adverse event reporting requirements for that study.
Post-study, if the patient doe s not enter the OLE -SMstudy ( GA29145 Parts 1 and/or 2), 
the Sponsor should be notified if the investigator becomes aware of any serious adverse 
event that occurs after the end of the adverse event reporting period ( until [ADDRESS_1117382] dose of study drug ) if the ev ent is believed to be related to prior study drug 
treatment.  In addition, the Sponsor should be notified if the inv estigator becomes aware 
of any post -study events of confirmed or suspected PML, regardless of relationship to 
study drug, for up to 2 years after the patient’s last dose of study drug. 
The investigator should report these events directly to [COMPANY_002] or its designee either by 
[CONTACT_25752]/Adverse Event of Special 
Interest Reporting Form using the fax number or email address provided to investigators.
5.[ADDRESS_1117383] experience to identify and expeditiously 
communicate possible new safety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.
To determine reporting requirements for si ngle adverse event cases, the Sponsor will 
assess the expectedness of these events for etrolizumab using the following reference 
document:
Etrolizumab Investigator's Brochure
Within the Investigator’s Brochure, the reference safety information is 
provided in Section 6 .4(Identified Risks and Adverse Drug Reactions 
[Reference Safety Information]).
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study, with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].
All serious related (as assessed by [CONTACT_1755]/or sponsor) adverse events 
occurring in a patient administered etrolizumab at any time during the trial and assessed 
as unexpected per the reference safety information will be considered suspected 
unexpected serious adverse reactions (S[LOCATION_003]Rs) for the purpose of regulatory reporting 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
120/Protocol GA29144, Version 7to all health authorities, with the exception of the FDA.  For the FDA, S[LOCATION_003]Rs will be 
submitted as Investigational New Drug (IND) Safety Reports, in line with the FDA 
guidance “Safety Reporting Requirements for INDs and BA/BE Studies” dated 
December 2012.
The Sponsor will report all S[LOCATION_003]Rs into the EudraVigilance database in accordance 
with the “Detailed guidance on the collection, verification, and presentation of adverse 
event/reaction reports arising from clinical trials on medicinal pro ducts for human use 
(‘CT-3’)”.
To maintain the blind, investigators will be informed of all unexpected serious adverse 
events satisfying local regulatory reporting criteria but regardless of study drug 
assignment (i.e., they may also receive reports of pat ients on placebo).
6. STATISTICA L CONSIDER ATIONS AND ANAL YSIS PLAN
For the purpose of statistical analyses, the Induction and Maintenance Phases will be 
treated as independent studies.
Per the protocol, the planned analysis of induction data for Cohort [ADDRESS_1117384] data available for etrolizumab in treating Crohn’s disease, and was used to
confirm the statistical assumptions for the pi[INVESTIGATOR_808375] ( Cohort 3), to confirm 
the re -randomization rates and thus expected sample size for maintenance, and to
inform the development of the Statistical A nalysis Plan.  Only a small number of Sponsor 
personnel close to the data analysis were unblind ed and ha veknowledge of patient -level 
treatment assignment for Cohort 1.  A ll remaining Sponsor personnel (including those 
involved in oversight of study conduct) and sites remain blinded to patient -level 
treatment assignment.  The Sponsor remains blinded to maintenance data for all 
patients in the study (including cohort 1) until the maintenance database is formally 
cleaned, verified, and locked .
The open- label Cohort 2 serves as a feeder cohort to provide sufficient sample size for 
the maintenance analysis. Induction data from Cohort 2 will also be considered 
exploratory and may be analyzed to inform decision making and development of the 
Statistical Analysis P lan.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
121/Protocol GA29144, Version 76.1 DETERMINA TION OF SA MPLE SIZE
6.1.1 Induction Phase
A total of approximately 1150 patients will be randomized into one of three induction 
cohorts.  The sample size of each cohort is summarized in Table 4 and described below.
Table 4Sample Size for Each Cohort
CohortNo. of Patients
Total PlaceboLow-Dose 
(105 mg)High-Dose 
(210 mg)
Explorator y induction 
cohort 
(Cohort 1)~300 ~60 ~120 ~120
Active -treatment 
induction cohort
(Cohort 2)~350 NA ~175 ~175
Pi[INVESTIGATOR_808376] 
(Cohort 3)~496 ~124 ~186 ~186
NAnot applicable; No. number.
The sample size for Cohort 1 (see Table 4 )was determined to provide approximately 90% 
power to detect a 20% difference in PRO2 or CDAI remission rates between each 
etrolizumab arm and placebo (under the assumption of placebo remission rate of 15%, 
similar to results reported in the GEMINI 2 trial of vedolizumab i n patients with CD; 
Sandborn et al. 2013 ) and approximately 80% power to detect a 15% difference versus 
placebo in endoscopic response (under the assumption of placebo response rate of 
10%) and a two -sided 2testat the 10% significance level.
The pi[INVESTIGATOR_808377] 3 .  In this pi[INVESTIGATOR_808365], p atients will be randomized to receive either 
placebo, etrolizumab 105 mg or etrolizumab 210 mg in a 2:3:[ADDRESS_1117385] at the 5% significance level, where both clinical 
remission and endoscopy improvement are required to be significant.  The sample size 
for Cohort 3 is expected to provide 85% power to detect a 15% differen ce in rates of 
clinical remission (SF mean daily score 3 and AP mean daily score 1) between each 
etrolizumab arm and placebo under the assumption of a placebo remission rate of 15% 
and a two -sided test performed at a significance level of 5% .  Additiona lly, Cohort 3 will 
provide 80% power to detect a 10% difference in proportions for each etrolizumab arm 
versus placebo for endoscopic improvement, under the assumption of placebo response 
rate of 5% and a two -sided test at the 5% significance level .The 2test was used to 
confirm the power calculations.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
122/Protocol GA29144, Version 7Cohort 2 is sized at approximately 350 patients to achieve a sufficient number of patients 
for the Maintenance Phase analyses . 
6.1.2 Maintenance Phase
A total of approximately 480 patients achieving CDAI -70 response at Week 14 will be 
eligible to enroll into the Maintenance Phase.
A co-primary endpoint will be used for the analysis of the Maintenance Phase: clinical 
remission (SF mean daily score 3 and AP mean daily score 1) and endoscopic 
improvement at Week66.  The maintenance co -primary analysis will be performed on all 
patients re -randomized into the Maintenance Phase who were randomized to 
etrolizumab (105 mg or 210 mg) in the Induction Phase.  The co -primary endpoint will be 
tested using a CMH test at the 5% significance level, where both clinical remission and 
endoscopy improvement are required to be significant.  Note that to maintain the blind, 
patients randomized to placebo in the Induction Phase will undergo a sham 
randomization and will receive placebo in the Maintenance Phase .  These patients will 
not form part of the pi[INVESTIGATOR_808355]. 
Of the approximately 480 patients projected to be enrolled in the Maintenance Phase, 
approximately 420 patients will undergo re -randomization to receive either placebo or 
etrolizumab, and approximately 60 patients will undergo a sham randomization to 
placebo.  These projections are based on the assumption that 50% of patients receiving 
etrolizumab and 4 0% of patients receiving placebo during the Induction Phase will be 
eligible for the Maintenance Phase.
Assuming a maintenance sample size of 210 patients per arm using a 1:1 allocation to 
receive either placebo or etrolizumab 105 mg, the maintenance analy ses conducted at 
the 5% significance level will provide the following power:
Clinical remission at Week66 (SF mean daily score 3 and AP mean daily
score 1):  at least 90% power to detect a 15% treatment difference assuming a 
placebo W eek66 remission ra te of up to 20%
Endoscopic improvement: approximately 90% power to detect a 15% treatment 
difference assuming a placebo W eek66 improvement rate of up to 30%
Furthermore, the study is designed to provide sufficient power for the following 
secondary analyses:
Clinical remission at Week66 among patients achie ving clinical remission at 
Week14:  a sample size of N 186 (i.e. , 93per arm) will provide 80% power to 
detect a 20% treatment difference assuming a placebo rate of up to 30%.  This 
assumes a Week14 clinical remission rate of ≥22% among etrolizumab patients
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
123/Protocol GA29144, Version 7Table 5Power Estimates for Primary  and Key Secondary  Efficacy  
Analysis in the Pi[INVESTIGATOR_808378] ≥85% Placebo 15%
Etrolizumab 30%Placebo 124
Etrolizumab 105 mg186
Etrolizumab 210 mg186
Endoscopic 
improvement≥80% Placebo 5%
Etrolizumab 15%Placebo 124
Etrolizumab 105 mg186
Etrolizumab 210 mg186
Maintenance Clinical remission ≥90% aPlacebo ≤ 20%
Etrolizumab ≤35%Placebo 210
Etrolizumab 105 mg210
Endoscopic 
improvement~90% aPlacebo ≤30%
Etrolizumab 45%Placebo 210
Etrolizumab 105 mg210
All analyses powered using type I error, 5.0%.
aAnalysis conducted on all patients in Maintenance Phase who were randomized to 
etrolizumab in the Induction Phase .
6.[ADDRESS_1117386] OF STUDY
The number of patients randomized and re -randomized will be tabulated by [CONTACT_760523].  Patient disposition (the number of patients randomized, treated, and 
completing each study period) will be tabulated by [CONTACT_2939].  Reasons for 
premature study drug discontinuation or withdrawal from study, any eligib ility criteria 
deviations, and other major protocol deviations will be summarized by [CONTACT_2939].
6.3 SUMMA RIES OF TREA TME NT GROUP COMPA RABILITY
Demographic and baseline characteristics such as age, sex, race, region, use of
corticoster oids and immunosuppressants , anti- TNF therapy, duration of disease, extent 
of disease, average daily SF, average daily AP, CDAI, SES -CD,  and 
 will be summarized for all randomized patients by [CONTACT_808435].  Exposure to study 
drug (number of study treatments and duration of treatment) will be summarized by 
[CONTACT_2939].
6.[ADDRESS_1117387] udies.
Patients who are non -evaluable for efficacy at a specific time point, because of missing 
data, will be considered non -responders for all categorical endpoints.  In addition, 
patients requiring rescue therapy, and/ or surgical intervention for CD, and/or took 
prohibited medications (see Section 4.4.5 ), will be considered non- responders for the 

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
124/Protocol GA29144, Version 7analysis.   Non -responder definitions will be further detailed and finalized in the Statistical 
Analysis Plan for th e study.
In addition to the analyses described in Section 6.4.1 and Section 6.4.2 , the following 
analyses will be performed for the co-primary efficacy endpoint and key secondary 
efficacy endpoints. Details of these analyses will be described in the SAP:
Subgroup analyses to evaluate the consistency of results across prespecified 
subgroups (including baseline antiTNF-status , baseline CS status, baseline IS 
status, age, sex , , Region
Sensitivity analyses to evaluate the robustness of results to the pri mary analysis 
methods (e.g., handling of dropouts ,adjusting for cohort )
6.4.[ADDRESS_1117388] one do se of 
study drug (modified intent -to-treat population [mITT]).  Patients will be grouped 
according to the treatment assigned at randomization .
[IP_ADDRESS] Cohort 1
An exploratory analysis was conducted when all patients in Cohort 1 (n=300) 
completed the W eek14 visit or, discontinued early from the study.  At this point, the 
Sponsor was unblinded to patient level data and treatment assignments for patients in 
Cohort 1 Induction Phase only.  Patients, site monitors, and investigators remain blinded
to patient -spec ific treatment assignments.  The induction data from Cohort 1 was 
exploratory in natu re and was evaluated prior to the commencement of enrollment to the 
pi[INVESTIGATOR_808379] 3.  Maintenance phase data from Cohort 1 patients will 
form part of the pi[INVESTIGATOR_808380].
[IP_ADDRESS] Cohort 2
Cohort 2 is considered a “feeder” cohort to help achieve the necessary sample size for 
the maintenance study.  All primary and se condary efficacy parameters will be 
summarized descriptively for each treatment arm.  Demographic and baseline 
characteristics such as age, sex, race, region, use of corticosteroids and 
immunosuppressants, duration of disease, and CD activity scores will b e summarized for 
each treatment group by [CONTACT_808436].
[IP_ADDRESS] Cohort 3
The co-primary endpoint analysis will compare for each etrolizumab dose arm versus the 
placebo arm the proportion of patients who achieve clinical remission or endoscopic 
improvement at Week14.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
125/Protocol GA29144, Version 7The difference between each etroli zumab arm and placebo arm will be evaluated using 
the CMH test statistic stratified by [CONTACT_760525].  The absolute 
treatment difference will be provided along with the 95% two- sided CI estimate.
All categorical secondary endpoints will be analyzed using the same methodology as the 
primary endpoint.  For all efficacy endpoints, descriptive summary statistics will be 
provided for each treatment arm.
Continuo us endpoints will be analyzed using an ANCOVA model with the stratification 
variables used at randomization and the baseline value of the studied measure as a 
covariate.
The co -primary endpoints will each be tested at the 5% significance level, with both 
required to be significant for the co -primary endpoint sto be deemed significant.  The 
overall type I error rate will be maintained at 5% using a hierarchical model for testing of 
the two etrolizumab doses versus placebo and corresponding key secondary endp oints.  
The hierarchical model specifications will be detailed in the Statistical Analysis Plan 
before unblinding.  The remaining secondary endpoints  will 
be considered to provide supportive information and no adjustments for multiple
comparisons will be performed.
6.4.[ADDRESS_1117389] one 
dose of study drug (mITT populati on).  Patients will be grouped according to the 
treatment assigned at randomization into the Maintenance Phase .
For all categorical endpoints, the difference in proportions between the two treatment 
arms will be evaluated using the CMH test.  The CMH test will include important 
stratification factors such as those used to randomize patients into the Maintenance 
Phase.  The stratification factors used for re -randomization into the maintenance phase 
include sustained CDAI remission at W eeks [ADDRESS_1117390] will be performed at the two- sided 
5%significance level.  The absolute treatment difference will be provided along with the 
95% two -sided CI estimate.  All categorical secondary endpoints will be analyzed using 
the same methodology as for the primary endpoint. 
Continuous endpoints will be a nalyzed using an ANCOVA model with the stratification 
variables used at randomization and the baseline value of the studied measure as a 
covariate.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
126/Protocol GA29144, Version 7If the primary endpoint is statistically significant, key secondary endpoints will be tested 
sequentially.  Details will be specified in the Statistical Analysis Plan before unblinding.
Patients who are non -evaluable for efficacy at a specific timepoint (e.g., because of 
missing data or early enrollment into Part 1 [OLE] of Study GA29145) will be considered 
non-responders for all categorical endpoints.  
6.4.3 Co-Primary  Efficacy  Endpoint s
Induction Phase
Proportion of patients in clinical remission at W eek14
Proportion of patients achieving endoscopic improvement at W eek14
Maintenance Phase , among patients who achieve CDAI -70 response at Week 14
Proportion of patients in clinical remission at W eek66
Proportion of patients achieving endoscopic improvement at W eek66 
6.4.4 Secondary  Efficacy Endpoints
The secondary endpoints are as follows:
Induction Phase 
Proportio n of patients who achieve clinical remission at Week 6
Proportion of patients who achieve SES- CD ≤4 (≤2 for ileal patients), with no 
segment having a subcategory score (i.e., for ulceration size and extent, affected 
surface, or narrowing) that is >1, at Week14
Changes from baseline to W eek 14 in CD -PRO/SS score
Maintenance Phase 
Proportion of patients in clinical remission at Week66 among patients who achieve 
clinical remission at Week14
Proportion of patients who achieve corticosteroid -free clinical r emission at Week66 
among patients who were receiving corticosteroids at baseline
Proportion of patients who maintain endoscopic improvement at Week66 among 
patients achieving endoscopic improvement at Week 14
Proportion of patients achieving SES CD ≤4 (≤2 for ileal patients), with no segment 
having a subcategory score (i.e., for ulceration size and extent, affected surface, or 
narrowing) that is >1, at Week66 
Proportion of patients achieving durable remission 
Proportion of patients achieving co rticosteroid -free clinical remission for 24 weeks at 
Week66 among patients who were receiving corticosteroids at baseline
Change from baseline to W eek 66 in CD -PRO/SS score
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
128/Protocol GA29144, Version 7existing condition on or after the first dose of study drug.  In addition, separate 
summaries will be generated for serious adverse events, deaths, and adverse events 
leading to discontinuation of study drug.
Analyses will also be performed for:
Systemic hypersensitivity events
Specific analyses will be performed for anaphylactic reactions.
Serious infections
The frequency of serious infections, in particular GI infections, will be 
summarized for each treatment arm.
Opportunistic infections
The occurrence of o pportunistic infections will be summarized for each 
treatment arm.
Malignancies
Events of malignancy will also be summarized for each treatment arm.
Injection -site reactions
The frequency of injection -site reactions will be summarized for each treatment 
arm.
Surgery for CD
The time to onset of surgery for CD complications will be summarized for each 
treatment arm. 
6.5.[ADDRESS_1117391] deviations, and coefficients of 
variation.  Individual and mean concentration -versus -time data w ill be tabulated and 
plotted.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
129/Protocol GA29144, Version 7All drug concentration data collected from this study will be included in a model based 
analysis that uses a non -linear mixed effect model based approach to further 
characterize the PK and relevant influential factors.  The model based analysis will be 
reported separately from the main clinical study report.
 
 
 
6.[ADDRESS_1117392] an optional interim analysis and the timing of the analysis will be 
documented in the Sponsor’s trial master file prior to the conduct of the interim analysis.  
Access to treatment assi gnment information will follow the Sponsor’s standard 
procedures.
7. DATA COLLECTION A ND MANAGEMENT
7.1 DATA QUA LITY ASSURA NCE
The Sponsor, CRO, and Data Management vendor will be responsible for data 
management of this study, including quality checking of the data.  Sites will be 
responsible for data entry into the EDC system with use of eCRFs.  In the event of 
discrepant data, data queries will be issued to the sites and resolved by [CONTACT_335587].  The Sponsor will produce a data quality plan that will describe the quality 
checking to be performed on the data.  eCRFs and correction documentation will be 
maintained in the EDC system’s audit trail. 
Central laboratory data will be transferred directly to the Sponsor, with use of the 
Sponsor’s standar d procedures to handle and process the electronic transfer of these 
data.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
130/Protocol GA29144, Version 77.[ADDRESS_1117393] disc is required.
7.3 ELECTRONIC PA TIENT -REPORTED OUTCOME DA TA
Patient -reported data will be collected using a nelectronic devices provided by [CONTACT_808437].  The devices (i.e., e- diary and tablet) are designed for entry of data in a way that 
is attributable, secure, and accurate, in compliance with FDA regulations for electronic 
records (21 CFR Part 11).  The ePRO device data are available for view access only via 
secure access to a Web portal provided by [CONTACT_70170].  Only identifie d and 
trained users may view the data, and their actions become part of the audit trail.  The 
Sponsor will have view access only.  System backups for data stored by [CONTACT_808438]’s standard 
procedures.  Regular data transfers will occur from the centralized database at the 
vendor to the database at the Sponsor.
Once the study is complete, the ePRO data, audit trail, and trial and system 
documentation will be archived. The investigator will receive patient data for the site in 
both human- and machine -readable formats on an archival -quality compact disc that 
must be kept with the study records as source data.  Acknowledgement of receipt of the 
compact disc is required.  In addition, the Sponsor will receive all patient data in a 
machine- readable format on a compact disc.
Details regarding patient -reported data and the electronic devices are available in the 
Study Reference Manual.  System backups for data stored by [CONTACT_70172]’s standard procedures.
7.4 SOURCE DA TA DOCUMENT ATION
Study monitors will perform ongoing source data verification to confirm that critical 
protocol data (i.e., source data) ente red into the eCRFs by [CONTACT_26831], complete, and verifiable from source documents. 
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include ,but are not limited to ,hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, PROs, evaluation checklists, 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
131/Protocol GA29144, Version 7pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_70069], 
microfiche, photographic negatives, microfilm or magnetic media, X -rays, patient files, 
and records kept at pharmacies, laboratories, and medico- technical departments 
involved in a clinical trial.
Before study initiation, the typ es of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source dat a.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.6.
To facilitate source data verification, the investigators and institutions must provide the 
Sponsor direct access to applicable source documents and reports for trial -related 
monitoring, Sponsor audits, and IRB/EC review.  The study site must also allow 
inspection by [CONTACT_25756].
7.5 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site’s computerized medi cal 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical res earch.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are modified, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change , name [CONTACT_33508], and date of the change.
7.[ADDRESS_1117394] of this study and the distribution of 
IMP, including eCRFs, ePRO data (if applicable), Informed Consent Forms, laboratory 
test results and medication inventory records must be retained by [CONTACT_9532] [INVESTIGATOR_25653] [ADDRESS_1117395] to local 
regulations.  
No records may be disposed of without the written approval of the Sponsor.  W ritten 
notification should be provided to the Sponsor prior to transferrin g any records to 
another party or moving them to another location.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
132/Protocol GA29144, Version 78. ETHICA L CONSIDERA TIONS
8.1 COMPLIA NCE WITH LA WSAND REGULATIONS
This study will be conducted in full conformance with the International Council for
Harmonisation (ICH) E6 guideline for Good Clinical Practice and the principles of the 
Declaration of Helsinki, or the laws and regulations of the country in which the research 
is conducted, whichever affords the greater protection to the individual.  The study will 
comply with the requirements of the ICH E2A guideline (Clinical Safety Data 
Management:  Definitions and Standards for Expedited Reporting).  Studies conducted 
in the [LOCATION_002] or under an IND will comply with FDA regulations and applicable 
local, state, and federal laws.  Studies conducted in the European Union or European 
Economic Area will comply with the E.U. Clinical Trial Directive (2001/20/EC).
8.2 INFORMED CONSENT
The Sponsor’s sample Informed Consent Form (and ancillary sample Informed C onsent 
Forms such as a Child’s Assent or Caregiver's Informed Consent Form, if applicable) will 
be provided to each site.  If applicable, it will be provided in a certified translation of the 
local language.  The Sponsor or its designee must review and app rove any proposed 
deviations from the Sponsor's sample Informed Consent Forms or any alternate consent 
forms proposed by [CONTACT_779] (collectively, the "consent forms") before IRB/EC submission.  
The final IRB/EC approved consent forms must be provided to the Sponsor for health 
authority submission purposes according to local requirements.
The Informed Consent Form will contain a separate section that addresses the use of 
remaining mandatory samples for optional exploratory research.  The investigator or 
autho rized designee will explain to each patient the objectives of the exploratory 
research.  Patients will be told that they are free to refuse to participate and may 
withdraw their specimens at any time and for any reason during the storage period.  A 
separat e, specific signature [CONTACT_22862] a patient's agreement to allow 
any remaining specimens to be used for exploratory research.  Patients who decline to 
participate will not provide a separate signature.
The consent forms must be signed and dated by [CONTACT_12718]’s legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each patient shall document the informed consent process and that 
written informed consent was obtained prior to participation in the study.
The consent forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/ EC-approved consent forms must be provided to 
the Sponsor for health authority submission purposes.
Patients must be re -consented to the most current version of the consent forms (or to a 
significant new information/findings addendum in accordance with app licable laws and 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
133/Protocol GA29144, Version 7IRB/EC policy) during their participation in the study.  For any updated or revised 
consent forms, the case history or clinical records for each patient shall document the 
informed consent process and that written informed consent was obta ined using the 
updated/revised consent forms for continued participation in the study.
A copy of each signed consent form must be provided to the patient or the patient’s 
legally authorized representative.  All signed and dated consent forms must remain in
each patient’s study file or in the site file and must be available for verification by [CONTACT_33483].
For sites in the [LOCATION_002], each consent form may also include patient authorization 
to allow use and disclosure of personal health inf ormation in compliance with the U.S. 
Health Insurance Portability and Accountability Act of 1996 (HIPAA).  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of personal 
health information under the HIPAA re gulations, the review, approval, and other 
processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
8.[ADDRESS_1117396] be submitted to the IRB/EC by [CONTACT_9532] [INVESTIGATOR_25684]/EC before the study is initiated.  In 
addition, any patient recruitment materials must b e approved by [CONTACT_1201]/EC. 
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by [CONTACT_1201]/E C.  Investigators are also responsible 
for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safe ty-related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by [CONTACT_11577]/EC, and 
archived in the site’s study file. 
8.4 CONFIDENTIA LITY
The Sponsor maintains confidentiality standards by [CONTACT_77042] a unique patient identification number.  This means that 
patient names are not included in data se ts that are transmitted to any Sponsor location.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
134/Protocol GA29144, Version 7Patient medical information obtained by [CONTACT_70177] (or separate 
authorization for use and disclosure of pe rsonal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsible for the patient’s welfare, for treatment purposes.
Data generated by [CONTACT_70178], Sponsor 
monitors, representatives, and collaborators, and the IRB/EC for each study site, as 
appropriate.
8.5 FINA NCIA L DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to th e appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study (i.e., last patient last visit).
9. STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRA TION
9.[ADDRESS_1117397] of 
the study to be fully documented ,including ,but not limited to ,the protocol, protocol 
amendments, Informed Consent Forms, and doc umentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes to 
data.
9.[ADDRESS_1117398] on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB /EC 
policies and procedures .  The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to health authorities.   As per the Sponsor's standard operating procedures, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.
9.3 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833], patients’ medical records, and eCRFs.  The investigator will 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
135/Protocol GA29144, Version 7permit national and local health authorities, Sponsor monitors, representatives, and 
collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.
9.4 ADMINISTRA TIVE STRUCTURE
This trial is sponsored by F. Hoffmann La [COMPANY_002] Ltd.  Approxi mately 500global 
investigator sites will participate in this study to enroll approximately [ADDRESS_1117399] research organization will be contracted to manage the study and perform 
monitoring activities.
Centralized facilities (vendors) will be used to collect PRO data and endoscopy reading 
and interpretation; however, the investigator or a designee will also read the endoscopy 
if required for clinically indicated safety reas ons.
A central laboratory (i.e., [COMPANY_002] or a vendor) will be used for most laboratory 
assessments, including possible histologic grading of biopsies as per the laboratory 
manual.  A selected group of assessments will be performed on site or by a local 
labor atory.
The eCRF data will be recorded via a Sponsor -designated EDC system.  An IxRS will be 
used for study drug inventory management and to randomize patients to study drug.
An iDMC will be established to perform regular review of the safety data to ensure the 
ongoing safety of participating patients.  Members of the iDMC will be external to the 
Sponsor and will follow a charter that outlines the iDMC roles and responsibilities . The 
iDMC will meet approximately every 6 months (frequency adjustable as required) to 
review unblinded safety and study conduct data prepared by [CONTACT_808439] (iDCC).  If the iDMC deems a benefit riskassessment necessary, 
the iDMC may also review unblinded efficacy data .  The iDMC may recommend stoppi[INVESTIGATOR_808381].  However, the iDMC may not recommend stoppi[INVESTIGATOR_808382].
9.5 PUBLICA TION OF DATA  AND PROTECTION OF TR ADE 
SECRETS
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, both at scientific 
congresses and in peer -reviewed journals. The Sponsor will comply with all 
requirements for publication of study results.  For more information, refer to the [COMPANY_002] 
Global Policy on Sharing of Clinical Trials Data at the following W eb site:
www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
136/Protocol GA29144, Version 7manuscript reporting primary clinic al trial results within [ADDRESS_1117400] igator and the 
appropriate Sponsor personnel.
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agr eed otherwise.
9.6 PROTOCOL A MENDMENTS
Any protocol amendments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in M edical Monitor or contact [CONTACT_3031]).

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
137/Protocol GA29144, Version 710. REFERENCES
Andrew DP , Berlin C, Honda S, et al. Distinct but overlappi[INVESTIGATOR_808383] 
47-mediated adhesion to vascular cell adhesion molecule -1, mucosal adhesion 
molecule- 1, fibronectin, and lymphocyte aggregation.  J Immunol 
1994;153: 3847 -61.
Awni W , Eckert D, Sharma N, et al. Pharmacokinetics of adalimumab in adult patients 
with moderately to severely active ulcerative colitis. ECCO [abstract on the 
Internet]. 2013. Available from: https://www.ecco- ibd.eu/publications/congress -
abstract -s/abstracts -2013/item/p412 -pharmacokinetics -of-adalimumab -in-adult -
patients -with-moderately -to-severely -active -ulcerative -colitis.html.
Baumgart DC , Sandborn W J. Crohn’s disease. Lancet . 2012;380:1590- 605.
Best WR, Becktel JM, Singleton JW . Rederived values of the eight coefficients of the 
Crohn’s Disease Activity Index (CDAI). Gastroenterology 1979;77:843 -6.
Cepek KL, Parker CM, Madara JL, et al. Integrin E7mediates adhesion of 
Tlymphocytes to epi[INVESTIGATOR_1663]. J Immunol 1993;150:3459 -70.
Colombel JF, Sandborn W J, Rutgeerts P, et al. Adalimumab for maintenance of clinical 
response and remission in patients with Crohn’s disease: the CHARM trial. 
Gastroentero logy 2007;132:52 -65.
Colombel JF, Sandborn W J, Reinisch W , et al. Infliximab, azathioprine, or combination 
therapy for Crohn’s disease. N Engl J Med 2010;362:1383 -95.
Colombel JF, Sands B E, Rutgeerts, et al. The safety of vedolizumab for ulcerative colitis
and Crohn’s disease. Gut 2016;0:1 -13.
Committee for Medicinal Products for Human Use (CHMP). Guideline on the 
development of new medicinal products for the treatment of Crohn's disease 2018. 
Available from: https://www.ema.europa.eu/documents/scientific -
guideline/guideline -development -new-medicinal -products -treatment -crohns -
disease -revision -2_en.pdf
Cosnes J, Nion- Larmurier I, Beaugerie L, et al. Impact of the increasing use of 
immunusuppressants in Crohn’s disease on the need for intestinal surgery. 
Gut2005;54: 237-41.
Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, 
simplified endoscopic activity score for Crohn’s disease: the SES CD. Gastrointest 
Endosc 2004;60:505- 12.
de Vries HS, van Oijen MG, Driessen RJ, et al. Appropr iate infliximab infusion dosage 
and monitoring: results of a panel meeting of rheumatologists, dermatologists and 
gastroenterologists.  Br J Clin Pharmacol 2011;71: 7-19.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
138/Protocol GA29144, Version 7Duricova D,Pedersen N, Elkjaer M, et al. Overall and cause- specific mortality in Crohn’s 
disease:  a meta -analysis of population -based studies.  Inflamm Bowel Dis
2010;16: 347-53.
Elewaut D, Van Damme N, De Keyser F, et al. Altered expression of E7 integrin on 
intra-epi[INVESTIGATOR_808384]’s di sease.  
Acta Gastroenterol Belg 1998;61:288 -94.
Gasink C, Friedman J, Gao LL et al. Evaluation of an interim Crohn's disease outcome 
measure (PRO -2) based on two patient -reported components (stool frequency, 
abdominal pain) of the Crohn's Disease Activity Index (CDAI) in the ustekinumab 
CERTIFI Study. Poster P164 at ECCO Conference 2015.
Fasanamde AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of 
infliximab in patients with ulc erative colitis. Eur J Clin Pharmacol 2009;65: 1211 -28.
Faubi on W A, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid 
therapy for inflammatory bowel disease: a population -based study. 
Gastroenterology 2001;121:255- 60.
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance 
therapy for ulcerative colitis.  N Engl J Med 2013;369:699- 710.
Ferrante et al. Evolution of Endoscopic Activity Scores Under Place bo Therapy in 
Crohn’s Disease. Gastroenterology 2010; 138, Issue 5, Supplement 1, S -358.
Ferrante M, Colombel JF, Sandborn W J, et al. Validation of endoscopic activity scores in 
patients with Crohn’s disease based on a post hoc analysis of data from SONIC. 
Gastroenterology 2013;145:978- 86.
Gasink C, Friedman J, Gao L, et al. Evaluation of an interim Crohn’s disease o utcome 
measure (PRO2) based on 2 patient -reported components (stool frequency, 
abdominal pain) of the Crohn’s disease activity index (CDAI) in the Ustekinumab 
CERTIFI study [abstract]. ACG Annual Meeting 2014.
GREAT2 W orkshop [ADDRESS_1117401]-22nd2013. g reat2.org. Available from: 
http://www.fda.gov/drugs/newsevents/ucm362766.htm .
Guyatt G, Deyo R, Charlson M, et al. Responsiveness and validity in health status 
measurement:  a clarification.  J Clin Epi[INVESTIGATOR_5541] 1989;42(5):403 -408.
Hausmann J, Zabel K, Herrmann E, et al. Methotrexate for maintenance of remission in 
chronic active Crohn’s disease: long -term single- center experience and meta -
analysis of observational studies.  Inflamm Bowel Dis 2010;16: 1195 -202. 
Hebuterne X, Lemann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions 
in patients with moderate to severe ileocolonic Crohn’s disease following treatment 
with certolizumab pegol. Gut 2013;62:201 -8.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
139/Protocol GA29144, Version 7Henao MP, Bewtra M, Osterman MT, et al. Measurement of inflammatory bowel disease 
symptoms:  reliability of an abbreviated approach to data collection. Inflamm Bowel 
Dis 2015;21:2262 -2271.
Holzmann B, McIntyre BW , Weissman IL. Identification of a murine Peyer’s 
patch specific lymphocyte homing receptor as an integrin molecule with an 
-chain homologous to human VLA -4-α. Cell 1989;56:37 -46.
Hu M, Crowe DT, W eissman IL, et al. Cloning and expression of mouse integrin p(7): 
a functional role in Peyer's patch– specific lymphocyte homing. Proc Natl Acad Sci 
[LOCATION_003] 1992;89:8254 -8.
Irvine EJ.  Develo pment and subsequent refinement of the inflammatory bowel disease 
questionnaire: a quality -of-life instrument for adult patients with inflammatory bowel 
disease.  J Pediatr Gastroenterol Nutr 1999;28:S23 –7.
Khanna R, Zou G, D’Haens G.D, et al. A retrospective analysis: the development of 
patient reported outcome measures for the assessment of Crohn’s disease activity. 
Aliment Pharmacol Ther [ADDRESS_1117402] 27; doi: 10.1111/apt.[ZIP_CODE]. [Epub ahead of 
print]
KimY, Mulberg AE, Lee JJ , et al .Can Crohn’s disease activity index differentiate clinical 
remission induced by [CONTACT_808440] b iologics treatment?- Analysis of six clinical 
trials of crohn’s disease. Gastroenterology 2014 ;146;supplement 1.S -368.
Korzenik JR, Dieckgraefe BK, Valentine JF, et al.Sargramostim for active Crohn's 
disease. N Engl J Med 2005;352:2193 -201.
Lewis SJ and Heaton KW.Stool form scale as a useful guide to intestinal transit time.  
Scandi JGastroenterol 1997; 32:920-4.
Lichtenstein GR, Hanauer SB, Sandborn W J, et al. Management of Crohn’s disease in 
adults.  Am J Gastroenterol 2009;104:465 -83.
Malchow H, Ewe K, Brandes JW , et al. European cooperative crohn’s disease study 
(ECCDS): results of drug treatment.  Gastroenterology 1984;86: 249-66.
Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic pi[INVESTIGATOR_808385]’s disease.  Evolution on prednisolone.  Groupe d’Etudes 
Thérapeutiques des Affections Inflammatories du Tube Digestif (GETAID).  
Gastroenterology 1990;98: 811-8.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the 
inflammatory bowel diseases with time, based on systematic review. 
Gastroenterology 2012;142:46- 54.
Oshitani N, Watanabe K, Maeda K, et al. Differential expression of homing receptor 
CD103 on lamina propria lympho cytes and association of CD103 with epi[INVESTIGATOR_808386].  Int J Mol Med 2003;12:715- 9.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
140/Protocol GA29144, Version 7Peyrin -Biroulet L, Lof tus EV Jr, Colombel JF, et al. The natural history of adult Crohn's 
disease in population -based cohorts .  Am J Gastroenterol 2010;105:289 -97.
Peyrin -Biroulet L, and Lémann M. Review article: remission rates achievable by [CONTACT_471319][INVESTIGATOR_471275].  Aliment Pharmacol Ther 2011;33: 870-9.
Prefontaine E, Macdonald JK, Sutherland LR, et al. Azathioprine or 6- mercaptopurine for 
induction of remission in Crohn's disease.  Cochrane Database Syst Rev 
2009;(4):CD000545.
Rabin R, de Charro F. EQ -5D: a measure of health status from the EuroQol Group. Enn 
Med 2001;33:337 -43.
Rosario M, Fox I, Milch C , et al. Pharmacokinetic/pharmacodynamics relationship and 
immunogenicity of vedolizumab in adults with inflammatory bowel disease:  
additional results from GEMINI 1 and 2 (abstract).  Crohn’s and Colitis Foundation 
of America, Advances in Inflammatory Bow el Diseases 2013. Abstract P -140.
Rosario M, French J, Dirks, N, et al. Exposure -response relationship during vedolizumab 
induction therapy in adults with ulcerative colitis (abstract).  European Crohn’s and 
Colitis Organisation Congress 2014; abstract P48 9.
Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with 
infliximab is superior to epi[INVESTIGATOR_808387]’s disease.  Gastrointest Endosc 2006;63:433 -42.
Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains 
mucosal healing in patients with Crohn's disease: data from the EXTEND trial.  
Gastroenterology 2012;142(5):1047 -9.
Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti -TNF treatment in infl ammatory 
bowel disease. Gastro 2004;126:1593 -610.
Sands and Jin Ooi A survey of methodological Variation in the crohn’s disease activity 
index.  Inflammatory Bowel disease 2005; 11:133 8.
Sands BE, Feagan BG, Rutgeerts P, et al. Effects of Vedolizumab Indu ction Therapy for 
Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist 
Treatment Had Failed. Gastroenterology 2014;147:618 -27.
Sandborn W J, Colombel JF, Enns R, etal. Natalizumab induction and maintenance 
therapy for Crohn's disease.  N Engl J Med 2005;353:1912 -25.
Sandborn W J, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn 
disease previously treated with infliximab: a randomized trial.  Ann Intern Med 
2007:19;146: 829-38. Epub 2007 Apr 30.
Sandborn W J, Colombel JF, D’H aens G, et al. One -year maintenance outcomes among 
patients with moderately -to-severely active ulcerative colitis who responded to 
induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment 
Pharmacol Ther 2013;37:204- 13.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
141/Protocol GA29144, Version 7Sandler RS, Jordan MC, Kupper LL. Development of a Crohn’s index for survey 
research. J Clin Epi[INVESTIGATOR_5541] 1988;41:451 -8.
Siegal CA, Melmed GY. Predicting response to anti -TNF agents for the treatment of 
Crohn’s disease.  Therap Adv Gastroenterol 2009;2:[ADDRESS_1117403] an integrated clinical, molecular and 
serological classification of inflammatory bowel disease: report of a working party 
of the 2005 Montreal W orld Congress of Gastroenterology. Can J Gastroenterol 
2005;[ADDRESS_1117404] A:5A -36A.
Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative crohn’s disease 
study:  results of drug treatment.  Gastroenterology 1979;77: 84769.
Tan IL, McArthur JC, Clifford DB, et al. Immune re constitution inflammatory syndrome in 
natalizumab -associated PML. Neurology 2011;77:1061 -7.
Targan SR, Hanau
er SB, van Deventer SJ, et al. A short -term study of chimeric 
monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease.  
Crohn’s Disease cA2 Study Group.  N Engl J Med 1997;337: 1029 -35.
Ternant D, Aubourg A,  Magdelaine -Beuzelin C, et al. Infliximab pharmacokinetics in 
inflammatory bowel disease patients. Ther Drug Monit 2008 30: 523-9.
Thia K, Faubion WA Jr, Loftus EV Jr, et al. Short CDAI: development and validation of 
shortened and simplified Crohn’s disease activity index.  Inflamm Bowel Dis
2011;17(1):105 -11.
Van Assche G, Dignass A, Reinisch W , et al. The second European evidence- based 
Consensus on the diagnosis and managemen t of Crohn's disease: Special 
situations. J Crohns Colitis. 2010;4: 63-101.
van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in 
patients with ankylosing spondylitis: results of a multicenter, randomized, 
double -blind, placebo -controlled trial. Arthritis Rheum. 2006;54:2136- 46.
Vermeire S, O’By[CONTACT_7943] S, W illiams M, et al. Differentiation between etrolizumab (rhumab 
Beta7) and placebo in the EUCALYPTUS Phase II randomized double -blind 
placebo -controlled induction study to ev aluate efficacy and safety in patients with 
refractory moderate -to-severely active ulcerative colitis. Gastroenterology 
2013;144,S1:S -36.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
142/Protocol GA29144, Version 7Appendix 1a
Schedule of Assessments:  Screening and Induction Phase
Assessment 
Category AssessmentsScreening Daya
35to1Study Week (3 days for W eeks 2, 4, 8, 
and 12; 7 day s for Weeks 10 and 14 ) UVcEarly WD
(7 day s)
0b2 [ADDRESS_1117405] x
Plasma sample ( Storage for
JCV antibody testing )1 x
Study Drug Initial randomization x
Study drug administrationfx x x x x
Appendix 1a
Schedule of A ssessments:  Screening and Induction Phase (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
143/Protocol GA29144, Version 7Assessment 
Category AssessmentsScreening Daya
35to1Study Week (3 days for W eeks 2, 4, 8, 
and 12; 7 day s for Weeks 10 and 14 ) UVcEarly WD
(7 day s)
0b2 4 8 10 12 14
Assessments at 
Screening and 
InductionReview eligibility criteria x x g
Concomitant medications x x x x x x x x x x
Adverse eventshx x x x x x x x x x
e-Diary checkix x x x x x x x x x
Pregnancy testjx x gx x x x x
CDAI assessment x x kx x x x l
Weight x x x x x x
PML assessment interviewmx x x x x
Neurological examinationmx x x x x
Vital signs (BP and pulse) x x gx x x x
Physical examinationnx x x
Fistula examinationox x x
ECG x x px
qx x x
 qx x
Stool sample x r, sx sx s, t
Ileocolonoscopy ux x x x t, v
Ileum /colon biopsies 
(formalin) x wx xx t, v, x
Ileum /colon biopsies 
(RNAlater )x wx xx t, v, x

Appendix 1a
Schedule of A ssessments:  Screening and Induction Phase (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
145/Protocol GA29144, Version 7aAll assessments must be performed afte r obtaining informed consent.
bDay 1 of Week 0. Visit window of  [ADDRESS_1117406] to be performed at an unscheduled visit; assessments should be sy mptom-driven (e.g., perform PML 
assessment interview and neurological ex amination only if patient reports sy mptoms suspected of PML).  Assessments 
corresponding to items noted in this column should be recorded on the eCRF.
dNot required if normal chest X –ray result within 3 months prior to screening.
e The following tests ar e acceptable screening assay s for latent TB in this study:  [COMPANY_003] (a tuberculin skin test reaction; e.g., Mantoux 
test), INF -based test (e.g., QuantiFERON-TB Gold).  Only one of these screening assays is required. 
fAll patients will receive one 0.7 -mL injection and one 1.4 -mL injection of Weeks 0, 4, 8, and 12. On W eek 2, all patients will receive 
one 1.4 -mLinjection. 
gPerform prior to randomization.
hAfter informed consent has been obtained but prior to the initiation of study drug, only serious adv erse events cause by a protocol -
mandated intervention (e.g., invasive procedure such as biops y sam ple collections, discontinuation of medications) should be 
reported. After initiation of study drug, all adverse events, regardless of relationship to study drug, will be reported until the patient 
completes his or her last visit.
iPatients are to complete the e -diary daily for frequency of loose/liquid stools , abdominal pain (including the APQ) , and general well -
being.  Patients will complete the CD PRO/SS m easure for at least 9 consecutive days around each visit as programmed in the e -
diary. In order to allow for the visit window to account for early or delayed visit s, patients may  complete the CD PRO/SS up to 12 
days, except for the W eek0 visit in which pa tients are to complete the CD- PRO /SS on a daily basis for the [ADDRESS_1117407] for all females except those who are 1-year postmenopausal or surgically sterile; perform a urine test at 
other visits.  If urine test result is positive, perform confirmatory serum test. Patients must be instructed at screening an d reminded 
throughout the study that in case of positive pregnan cy test result they must call the site immediately.  Do not administer etrolizumab 
unless the serum test result is negative.
kThe patient will complete the PRO components of the CDAI on the e -diary daily during the screening phase. The blood draw for the 
hematocrit component can occur at any time during screening and the screening hematocrit value will be used for the W eek 0 CD AI 
calculation. The physician assessment components of the CDAI score will be assessed at the W eek 0 visit. The CDAI score for 
eligibility will be calculated at the Week 0 visit prior to randomization.
Appendix 1a
Schedule of A ssessments:  Screening and Induction Phase (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
147/Protocol GA29144, Version 7zEnrolled patients wh o are HBV core antibody positive should have HBV DNA measured at Week 14.
ccAt all timepoints indicated and whenever serum sickness or a clinically significant allergic drug reaction is suspected.   
1A blood sample to test for antibodies to JCV will be taken and stored for possible later assessment of how widespread the JCV 
infection is in the study population.  Sample testing for the presence of JCV antibodies is not helpful in predicting risk fo rPML or for 
evaluating neurologic sy mptoms.  The sample may  be tested if there is a strong belief that this information will be helpful i n 
managing a patient's condition.

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
152/Protocol GA29144, Version 7Appendix 2Schedule of A ssessment sfor 12 -Week Safety  
Follo w-Up
AssessmentWeek (3days)Unscheduled 
Visitc6a12/Early Withdrawalb
PML assessment interviewdx x e
Neurological examinationdx x e
Anti-therapeutic antibody sample (serum)fx
Urine pregnancy testgx
Medication changes x x x
Adverse events x x x
ATAanti-therapeutic antibody sample; PML progressive multifocal leukoencephalopathy .
aWeek [ADDRESS_1117408].

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
153/Protocol GA29144, Version 7Appendix 3Schedule of A ssessments: All Optional PK/PD Substudy  Samples
AssessmentsScreening 
Day a
35to1Study Week (3 day s)
Unscheduled 
VisitEarly 
Withdrawal 0b2 4 8 10 12 14 16 20 c24283236c40c4448c52c5660c64c66
Substudy PK 
sample d, e  
(Serum)x f
Baseline 
not 
required. 
Sample to 
be taken 
on one of 
Days 3/ 4/[ADDRESS_1117409] -visitx xx e, f 
At visit 
AND 
one of 
Days 
3/4/[ADDRESS_1117410] 
visitx x
Substudy PD 
sample d, e  
(whole blood, 
FACS tube)xxf 
Baseline 
AND one 
of Days 
3/4/[ADDRESS_1117411] 
visitx x x x x x x
Substudy PD 
sample d, e
(serum)x f 
Baseline 
not 
required. 
Sample to 
be taken 
on one of 
Days 3/4/[ADDRESS_1117412]-visitx x x x
Appendix 3Schedul e of Assessments:  A ll Optional PK/ PD Substudy  Samples
(cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
154/Protocol GA29144, Version 7FACS fluorescence -activated cell sorting; PDpharmacodynamics; PK pharmacokinetic.
These samples are to be collected only in those patient s who consent for the PK/PD substudy, in addition to the samples collected for the main 
study (see Appendix 1). 
Samples for PK/PD sub -study  will be collected in approximately 150 evaluable patients participating in the PK/PD substudy (see footnote f, 
below)
aAll assessments must be performed after obtaining informed consent.  
bDay 1 of Week 0.
cTelephone visit:  Blood draws may be collected by [CONTACT_808441]’s home or other suitable location away from 
the clinic. If samples are not collected at the clinic, samples will be sent on the day of collection to a central laborator yforstorage until 
analysis begins.
dOnly for patients who consent to participate in PK/PD substudy. 
eSamples are to be collected prior to dose administration (if specified sample collection timepoint is a dosing date .
fFor patients participating in the PK /PD substudy, an additional blood draw will be required; this can take place 3, 4, or [ADDRESS_1117413] dose and after the dose on Week 12visit.  The additional blood draws should be collected by [CONTACT_808442]’s home or other suitable location away from the clinic.  If samples are not collected at the clinic, samples 
should be sent on the day of collection to a central laboratory for storage until analysis begins.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
155/Protocol GA29144, Version 7Appendix 4Childbearing Potential, Pregnancy  Testing, and 
Contraception
All women of childbearing potential (including those who have had a t ubal ligation) will 
have a serum pregnancy test at screening and a urine pregnancy test prior to 
administration of study drug at subsequent visits.  If a urine pregnancy test result is 
positive, study drug will not be administered until pregnancy is ruled out.  The result 
must be confirmed by a serum pregnancy test (conducted by [CONTACT_2237]).  
Refer to Section 5.3.3 of the pr otocol for management of a patient with a confirmed 
pregnancy.
A woman is considered to be of childbearing potential if she is postmenarcheal, has not 
reached a postmenopausal state ( 12months of amenorrhea with no identified cause 
other than menopause), and has not undergone surgical sterilization (removal of ovaries 
and/or uterus).
For female patients of reproductive or childbearing potential who are unwilling to use a 
highly effective method of contraception or remain abstinent during the treatment period 
and for at least [ADDRESS_1117414] dose of study drug will be excluded from study 
participation.
Examples of highly effective contraception include the following:
Combined oral contraceptive pi[INVESTIGATOR_4382]
Contraceptive transdermal patch
Intrauterine d evice
Implants for contraception
Injections for contraception (with prolonged release)
Hormonal vaginal device
Sterilization, surgical tubal ligation
Sole sexual partner consisting of surgically sterilized male partner with appropriate 
postsurgical verific ation of the absence of spermatozoa in the ejaculate
Double -barrier methods:  condom and occlusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/suppository (Note:  a female condom 
and male condom should not be used together b ecause friction between the two 
can result in either product failing)
Patients may provide verbal confirmation that the partner completed appropriate 
follow -up after vasectomy.  Sites are not required to obtain partner medical records
For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or use 
contraceptive measures and agreement to refrain from donating sperm, as defined 
below:
Appendix 4Childbearing Potential, Pregnancy  Testing, and 
Contraception (cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
156/Protocol GA29144, Version 7With female partners of childbearing potential or pregnant female partners, men 
must remain abstinent or use a condom during the treatment period and for at 
least [ADDRESS_1117415] refrain from 
donating sperm during this same period.
For men and women: The reliability of sexual abstinence should be evaluated in relation 
to the duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) 
and withdrawal are not acceptable methods of contraception
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
157/Protocol GA29144, Version 7Appendix 5Worksheet for the PML Neurologic E xamination
PML SUBJ ECTIVE A NDOBJECTIVE CHECK LISTS OFNEURO LOGIC
ASSESSMENT S TO MONIT ORFORPRO GRE SSIVE MULTIFOCAL
LE[LOCATION_006]OENCEPHALOPAT HY(PML)IN THEETROLIZUMAB PHASE III STUDIES
PML usually manif estswith su bacut e,progressiveneurologic deficits i ncluding:
Neurologic Domain Signs/Sympt omsReleva nt PML
Subjectiv e/Objective
Checklist Questi on
Altered menta l status Can encompa ssa variety of pres entin g signs
andsymptoms including cogniti ve changes
(confusion, difficult y concentrating, memory lo ss) 
and altere d behavior (including persona lity
change s)Q2, Q5, Q6
Higher cortical dysf unction Im paired comprehension and/o r formulation of
language (ap hasia), lo ssof ability to reco gnize
object s,person s, sounds, shape s,or smells
(agnosia)Q2, Q5, Q6
Visual chan ges Loss of visual fields (homonymou s 
hemianopsia), do uble vision (diplopia)Q1
Moto r deficits Weakne ss(hemiparesis o r mono paresis) , 
seizures (ge neralized or partial), difficultie s with
speech (d ysarthria ) or swallowing (dysphagia)Q2,Q3
Sensory deficits Sensory lo ss(i.e. paresthesia s) Q7
Coordi nation Difficulty walking and maintaining balance 
(ataxia), la ckof voluntary coordi nation o f limb
movement(limbataxia)Q4
To m onitor patients for PML, a n eurologic exa m (including evaluation of cranial nerves , 
motor and s ensory f unction, coordinati on, and menta l statu s) will beperfo rmed as per
the sche dule of assessments (see Appendix 1). This n eurologic exam will consist of
administration of the PM L Subjective Che cklist and the PML Objective Check list.
A
t scr eening, the PML S ubjectiveCheck list and the PML Objecti veChecklist(including
the components listed as optio na l, e.g. mu scle group strength testing, recal l of 3 objects
in 1 minute , and sensory testing ) should be perfo rmed.
At all other visits , the PML S ubjecti veChecklistand the PML Objecti veChecklist
(bolded items ) should be perfo rmed, and th e optio nal items should only b e perfo rmed 
when there is an abno rmal finding on the co rresponding PML S ubjective C heck list(i.e.
complaints of foca l weakness or focal s ensory change would prompt a more detailed
objecti veneurol ogic evaluati on).
Appendix 5 Worksheet for the PML Neurologic examination 
(cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
158/Protocol GA29144, Version 7PML Subjective Che cklist
Symptoms“Compare d to
how y ou u sually
feel, have y ou 
had asignifi cant 
change i n any of
the following?”If theanswer is “Yes ”,
obtain a descripti on of
the symptom(s ) with 
examplesAppli cable Obj ective
Test(s): Docume ntresul t 
on PML Objectiv e 
Checklist W orksheet
YES NO
1. Ha veyou bee n 
experi encing an y persistent
difficulty with your v ision su ch
as lo ss of vision o r doubl e 
vision? Have you bee n having
trouble with reading?Testvisual fields an d 
ocula r motility
2. Ha veyou bee n 
experi encing an y persistent
difficult y speaking or having
your speechunderstood b y 
other s?Casua l observation o f 
spee choutput fo r 
dysarthria o r aphasia.
3. Ha veyou bee n 
experi encing an y persistent
weakne ssin an ar m or a leg?Testfor pronato r drift 
(Barre maneuve r).
Assessg ait.
Testmuscle strength
(
only if indicated).
4. Ha veyou notice d yourself
regularl y bumpi[INVESTIGATOR_335493]?Observe tan dem gait
and finge r to nose.
5. Ha veyou regularl y been
experiencin g difficulty
understa nding other s?Testability to fo llow 
seria l commands.
6. Ha veyou ha d persist ent
problems with your memory or
thinking?Recall of 3 objects ove r 
1 minute with distractio n 
(only if i ndicated).
7. Ha veyou bee n 
experi encing an y persistent
numbne ssor other lossof
sensation?Testsensation side to 
side with eithe r pi[INVESTIGATOR_335494](only if
indicated).
Appendix 5 Worksheet for the PML Neurologic examination 
(cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
159/Protocol GA29144, Version 7PML O bjective Check list
Neurologic functi on 
being assessedInstructions
(bold text indicates parts of exam
required at each visit, as specified in
Schedule of A ssessments)Abnormal
exam?If theanswer is
“Yes ”,descri bethe 
abnormal obj ectiv e 
exam findi ng
YES NO
1. Visualfields a nd 
ocular motilityVisual Fiel d Testi ng 
Ocular Motility Testi ng
2. Sp eech Observe the patient’s speech 
outpu t fordysarthriaoraphasia.
3. Stre ngth Pron atordrift tes t (Barre 
maneuver)
Gait testing (normal , heeland 
toewalk)
ONLYif thepatie nt has any 
subjectivecomplaints o f weakness,
test muscle strength o f therelevan t 
4.Coordi nation Observe tandemgait and finger 
to no se
5.Comprehe nsion Test ability t o follow serial 
commands
“Take a pi[INVESTIGATOR_335495] , fold it in half, and p ut it on 
the floor.”
6.Memory a nd thinkingONLYif thepatie nt has subjective 
complaints abou t their memory or 
thinking,test theability o f the 
patientto recall 3 objectsover 1 
minute with distraction
7. Se nsation ONLYif thepatie nt has subjective 
sensory complaint s,evaluate 
relevantareasbasedonpatient’ s 
subjectivecomplaints by [CONTACT_335599]. right side sen sation to cold
(e.g. alcohol swabor co ld
stethoscope ) or p inprick(e.g. 
broken Q-ti p)
Appendix 5 Worksheet for the PML Neurologic examination 
(cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
160/Protocol GA29144, Version 7Please refer t o the PML Algorith m in theProtocolAppendix f ordetails.
If there is an ab normal findingon thePML Subjecti veChecklist, this should be
appropriatel y documente d on the workshe etand in t heeCRF.
If there is an ab normal findingon thePML Obj ectiveChecklist, t his sh ould be
appropriatel y documente d on the workshe et and in t heeCRF.
If there are a nyabnorm alitiesfound on the PML S ubjecti veCheck list thatare
accomp anied by [CONTACT_335600] t hePML Obj ectiveCheck list,ori f
there is hi ghclinical susp i cion for PML (in the opi[INVESTIGATOR_335496]):
This mus t bereported as an adverse eve ntofspecial interes t (AESI ) within 
24 hours
An urg entreferral to a ne urologist shoul d be made.
Dosingwith studydrug willbesuspende d until PM L can be ruled out.
Further evaluati on willproceed acc ording to thePML Algorithm i n the 
Protocol Appendix.
Any confirme d diagnosis ofPML shoul d be reporte d as a serious advers e 
event(SAE).
Please complete t hePML e CRF.
Was t hePML Subjective Check list administere d? (Yes/No)
If yes, date ofadmi nistration of PML Subj ective Che cklist (Date)
If yes, we rethereanyabnormalitieson thePML Subj ective Check list? (Yes/N o) 
Was t hePML Objective Check list administere d? (Yes/No)
If yes, we rethereanyabnormalitiesonthePML Objective Check list? (Yes/N o) 
Is PM L suspecte d? (Yes/No)
More detailed instructions for the PML Objective Checklist Neurologic Evaluations 
(please refer to the PML Neurologic Exam Video for more information):
1. Visual fiel dsand o cular mot ility
Visual Field Testi ng:
Position y oursel f approximately 3 f eetawayfromthepatient , witheyes atthe same
level.
Keepi[INVESTIGATOR_335497],askthepatie ntto cov erone eye and askif all parts of y our
face a nd headare cl earto them. Askthem to rep eat, coveringthe oth er eye.
Appendix 5 Worksheet for the PML Neurologic examination 
(cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
161/Protocol GA29144, Version 7Havethe patie ntcover oneeye a ndstare at your nose,and then askthem how
many fin gers you areholding up, testi ng eachof the 4 vis ualquadrants. Repe at with
theothereyecovere d.
Ocular Mot ility Testing:
Evaluate t hepatie ntfor conjugate eye movement.
Startingabou t 3feetfrom center , movein a big “H” , pausingat thecenter andat 
l
ateral gaze, and finishing with co nvergence(finger to theirnose). Watch f or
nystagmusin later al gaze, smooth pursuits,and p upi[INVESTIGATOR_335498] g ence.Note:a couple of b eats o f nystagm usupon extreme later al gaze is
considered no rmal.
2. Speech
Observe thepatient’s spe echoutputfordysarthria or aphasia.
Dysarthria is a mot or speech disorder . Findingscaninclude“slurred” speech, 
decreased volume , slow rate o f speech,limitedtongue,lip,andjaw movement,
abnorm al rhythm when sp eaking, chang esinvocalquality,and droo ling o r poor 
contr olo f sa liva.
Aphasia is a disor derthat results fr omdamagetoparts o f the brain th at contr ol 
language , and can lead to pr oblems with a nyor all of thefollowin g: speaking, 
listening,reading or writing.
3. Strength
Pronator drift test (Ba rre m aneuve r):
Ask t hepatie nt to sta ndwith their fe et toget herand exte ndtheir armsoutin frontof 
them at90 degrees(parallel to floor) with palms faci ngupwar dstoward the ce iling.
Askthepatie nt to closetheir eyesand ke eptheir a rmsextended f or 15 seconds.
If eitherarm drifts downward, upwar d,or starts to pronate (i. e.thumb tur nsup), this
is consi dered anabnorm al exam.
Gait testing:
Ask the patient to walk across the r oom (~10 f eet).  The patient sh ould ha vea
norma l gait, wit h their left ar m swinging forward when the right foot l eads,and vice
versa.   Be certain to not e whether there is symmetric ar m swinging, because a
slight decrease in ar m swingi ng may be a n indicator of up per extremity weakne ss.
Ask the patient to walk on t heir heels across the r oom (~10 feet). Carefu lly obser ve
whether they ha veany di fficulty maintaining thei r toes off the ground o r loss of
balance.
Ask the patient to walk on t heir toes acro ssthe roo m (~10 f eet). Carefu llyobser veif
they ha ve any difficulty maintaining t heir heels off the gr ound o r loss of balance.
Appendix 5 Worksheet for the PML Neurologic examination 
(cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
162/Protocol GA29144, Version 7Addition al strength testing ( ONLY if thepatienthasanysubjecti vec omplaints o f 
weakn ess):
Test muscle strength of the relev ant muscle groups based on the patient’s
subjectivecomplaints.
General guidelines fo r abasic muscle strength exam:
Upper
extremit y:
o Finger grip strength
o Flexion at elbow
o Extension at el bow
oDeltoid strength:   Maintai n bent arms up ( perpendicula r to floor) and
resist wh ile investi gator pushesdown
o Shoulde r shrug against resistance
Lower extremit y:(examine wh ile patient is si tting down)
oRaise thigh (wh ile bent)
oStraight enleg
oFlexleg
oFlexfoot
oExtendfoot
4. Coordination
Tandem gait:
As the patient is l ooking at his feet, a skthem to walk 8 steps withone f oot touching
in front o f the ot her (demonstrate for the m).
Finger to nose:
Hold y ourfinger out so th eyneed to reach o utand lea n.Start nearthe c enter, and
move y our finger slowly so tha t theyreach acrosstheir body. Makesure th ey
alternate touching y our finger andtheir noseata goodspee d.Inab ility to perfor m 
thisaccurately is c onsidered an abnorm al test.
5. Com prehensi on
Test ability to fo llow seria l commands
“Takea pi[INVESTIGATOR_462020] r in your h and, fold it in half, and put it on the floor.”
Appendix 5 Worksheet for the PML Neurologic examination 
(cont.)
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
163/Protocol GA29144, Version 76. Memory a nd Thinki ng
(ONLY if the patient has s ubjecti vecomplaints abou t thei r memory o r thinki ng) test
theability o f the patient to recall 3 objects over 1 minute wit h distraction.
7. Sensati on
(ONLYif thepatien t hassubjectivesensory com plaints) evaluate rel evant areas
basedon the pa tient’s subj ective complaints by[CONTACT_335601]. rightside
sensation to cold (e.g . alcohol swabor co ld stet hoscope) or pi[INVESTIGATOR_335500](e.g.broken
Q-tip). Confir m that thepatie nt is able t o feelthe s ensation sy mmetrica lly.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
165/Protocol GA29144, Version 7Appendix 7Clinical Criteria for Diagnosing A naphy laxis
These criteria are taken from a summary report from the second symposium on the 
definition and management of anaphylaxis, conducted by [CONTACT_260509]/Food Allergy and Anaphylaxis Network.1  Anaphylaxis is highly 
likely when any one of the following three criteria is fulfilled: 
1.Acute onset of an illness (minutes to sever al hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen 
lips-tongue -uvula) 
AND AT LEAST ONE OF THE FOLLO WING: 
Respi[INVESTIGATOR_7798] (e.g., dyspnea, wheeze -bronchospasm, stridor, reduced 
peak expi[INVESTIGATOR_10229], hypoxemia) 
Reduced blood pressure or associated symptoms of end -organ dysfunction 
(e.g., hypotonia, syncope, incontinence) 
Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for 
that patient (minutes to several hours): 
Involvement of the skin- mucosal tissue (e.g., generalized hives, itch -flush, 
swollen lips -tongue -uvula) 
Respi[INVESTIGATOR_7798] (e.g., dyspnea, wheeze -bronchospasm, stridor, reduced 
peak expi[INVESTIGATOR_10229], hypoxemia) 
Reduced blood pressure or associated symptoms (e.g., hypotonia, syncope, 
incontinence) 
Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting) 
2.Reduced blood pressure after exposure to known allergen for that patient (minutes 
to sever al hours): 
Infants and children: low systolic blood pressure (age specific)2or greater than 30% 
decrease in systolic blood pressure 
Adults: systolic blood pressure of less than 90 mmHg or greater than 30% decrease 
from that person’s baseline 
                                           
1Sampson HA, Muñoz -Furlong A, Campbell RL, et al. Second sy mposium on the definition and 
managem ent of anaphylaxis: summary report —second National In stitute of Allergy and Infectious 
Disease/Food Allergy and Anaphylaxis Network sy mposium. J Allergy Clin Immunol 
2006;117:391 –7.
2Low s ystolic blood pressure for children is defined as less than 70 mmHg from 1 month to 
1year, less than (70 mmH g[2 x age]) from 1 to 10 years, and less than 90 mmHg from 11 to 
17years.  
Etrolizumab —F.Hoffmann -La [COMPANY_002] Ltd
166/Protocol GA29144, Version 7Appendix 8Bristol Stool Form Scale

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
167/Protocol GA29144, Version 7Appendix 9 Crohn’s Disease A ctivity  Index (CDA I)

Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
168/Protocol GA29144, Version 7Appendix 10 Simple Endo scopic Score for Crohn’s Disease 
(SES CD)
Table 1 Definitions of Simple Endoscopic Score for Crohn’s Disease
Simple Endoscopic Score for Crohn’s Disease values
Variable 0 1 2 3
Size of ulcers None Aphthous ulcers 
(Ø 0.1 to 0.5 cm)Large ulcers 
(Ø 0.5 to 2 cm)Very large ulcers 
(Ø > 2 cm)
Ulcerated 
surfaceNone <10% 10-30% >30%
Affected surface Unaffected 
segment<50% 50-75% >75%
Presence of 
narrowingsNone Single, can be 
passedMultiple, can be 
passedCannot be 
passed
Ø, Diameter.
Table 2Example of SES CD scoring form
Ileum Right 
colonTransverse 
colonLeft 
colonRectum Total
Presence and size of ulcers 
(0-3)
Extent of ulcerated surface 
(0-3)
Extent of affected surface 
(0-3)
Presence and type of 
narrowings (0 -3)
SES-CD =
Adapted from: Daperno M, D’Haens G, Van Assche G, et al. Development and 
validation of a new, simplified endoscopic activity sco re for Crohn’s disease: the 
SES CD. Gastrointestinal Endoscopy 2004; 60:505- 512.
Etrolizumab —F. Hoffmann -La [COMPANY_002] Ltd
185/Protocol GA29144, Version 7
